



**Scientific Committee on Health, Environmental and Emerging Risks
SCHEER**

**Opinion on
Additives used in tobacco products
(Opinion 2)
Tobacco Additives II**



The SCHEER approved this Opinion by written procedure on 16 December 2016.

About the Scientific Committees (2016-2021)

Two independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat.

They are: the Scientific Committee on Consumer Safety (SCCS) and the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER). The Scientific Committees review and evaluate relevant scientific data and assess potential risks. Each Committee has top independent scientists from all over the world who are committed to work in the public interest.

In addition, the Commission relies upon the work of other Union bodies, such as the European Food Safety Authority (EFSA), the European Medicines Agency (EMA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

SCHEER

This Committee, on request of Commission services, provides Opinions on questions concerning health, environmental and emerging risks. The Committee addresses questions on:

- health and environmental risks related to pollutants in the environmental media and other biological and physical factors in relation to air quality, water, waste and soils.
- complex or multidisciplinary issues requiring a comprehensive assessment of risks to consumer safety or public health, for example antimicrobial resistance, nanotechnologies, medical devices and physical hazards such as noise and electromagnetic fields.

SCHEER members

Roberto Bertollini, Teresa Borges, Wim de Jong, Pim de Voogt, Raquel Duarte-Davidson, Peter Hoet, Rodica Mariana Ion, Renate Kraetke, Demosthenes Panagiotakos, Ana Proykova, Theo Samaras, Marian Scott, Rémy Slama, Emanuela Testai, Theo Vermeire, Marco Vighi, Sergej Zacharov

Contact:

European Commission

DG Health and Food Safety

Directorate C: Public Health, Country Knowledge, Crisis management

Unit C2 – Country Knowledge and Scientific Committees

Office: HTC 03/073 L-2920 Luxembourg

SANTE-C2-SCHEER@ec.europa.eu

© European Union, 2016

ISSN 2467-4559

doi:10.2875/723392

ISBN 978-92-79-65682-8

EW-CA-17-001-EN-N

The Opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The Opinions are published by the European Commission in their original language only.

http://ec.europa.eu/health/scientific_committees/policy/index_en.htm

ACKNOWLEDGMENTS

Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are:

SCHEER

Emanuela Testai (Chair and Co-Rapporteur), Istituto Superiore di Sanità, Rome, Italy
Raquel Duarte-Davidson, Public Health England, Chilton, United Kingdom
Peter Hoet, Katholieke Universiteit Leuven, Leuven, Belgium
Theo Vermeire, National Institute for Public Health and the Environment (RIVM),
The Netherlands
Sergej Zacharov, General University Hospital, Prague

External experts:

Reinskje Talhout (Co-Rapporteur) National Institute for Public Health and the
Environment (RIVM), The Netherlands
Urmila Nair, German Cancer Research Center (DKFZ), Germany
Konrad Rydzynski, Nofer Institute of Occupational Medicine, Poland

All Declarations of Working Group members and supporting experts are available at the
following webpage:

http://ec.europa.eu/health/scientific_committees/experts/declarations/scheer_wg_en

ABSTRACT

The Commission has established a priority list of 15 additives contained in cigarettes and roll-your-own tobacco subject to enhanced reporting obligations, based on a scientific Opinion (Tobacco Additives I) of the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). The EU Tobacco Product Directive (TPD) prescribes that Member States shall require manufacturers and importers of tobacco products to carry out comprehensive studies on these additives.

The European Commission requested the SCHEER to provide guidance on the type and criteria for comprehensive studies, and on the most suitable methodologies to be used on the first 15 tobacco additives and for additives on future updated lists. The SCHEER has provided such guidance together with a reporting template in Annex I.

As tobacco additives have no benefits for health, but rather may promote use of and addiction to an extremely toxic product, a risk-benefit analysis is not the appropriate paradigm for assessing the additive. When comprehensive studies confirm that additives have any of the four properties listed in Article 6 of the TPD, regulatory action should be considered in line with Article 7 of the TPD. If uncertainties cannot be solved by comprehensive studies, the SCHEER recommends that the assessors consider the worst-case evaluation.

In the first part, the SCHEER proposes a step-wise strategy as the most pragmatic and efficient way to assess the toxic and addictive effects and the characterising flavour and facilitating inhalation properties as potentially contributing to the attractive effects of tobacco additives. The proposed strategy ensures that testing is minimised, including the possibility to evaluate groups of additives having similar structures and properties. In step 1, the collection and then the evaluation of the available data on toxicity, addictiveness, characterising flavour and facilitating inhalation properties of the additive need to be carried out by applying a Weight of Evidence approach (step 1). In step 2, collection/evaluation of data is extended to the additive's pyrolysis products; if no data are available on the identity of the pyrolysis products, they need to be generated using relevant test conditions. Here, it is important to note that no validated methods exist for the determination of pyrolysis products from tobacco additives, but some indications are given in the Opinion.

In case data retrieved in Step 1 and 2 are not sufficient or robust enough to make the evaluation possible, non-testing methods, such as quantitative structure-activity relationship (QSAR) and read across, are proposed, followed by *in vitro* approaches, addressing the different endpoints to be considered (Step 3).

Regarding types of effects, unless the previous step highlighted some concern for a specific end-point, toxicity should be assessed first, as accepted methods and evaluation frameworks are available, followed by assessing whether a product contains a characterising flavour. Next, addictiveness should be assessed, an effect for which no validated tests are available, although some mechanisms underlying addictiveness are known. The issue related to interaction of the additive with other additives/ingredients is also considered.

In addition to proposing specific steps and tests to be considered by industry, some general criteria were also identified. Most importantly, the test outcomes should be

relevant for tobacco smoking. This implies that they should be related to actual levels of human exposure and to tobacco-induced diseases. Furthermore, comparative toxicity testing strategies, where differences in the effect of the tobacco product with and without the additive are evaluated, are not considered suitable to address the properties outlined in the Terms of Reference with the currently available methodology. Indeed, at present, these studies lack discriminative power due to the high background toxicity of tobacco products and their results cannot be generalised to all products and brands, having a different composition with respect to tobacco type, blend and additives. Here, the effects of the pure additive, and its pyrolysis products, are considered in order to evaluate their contribution to tobacco product toxicity. Comparative studies are also not endorsed to study the effect of additives on addictiveness with animal models, for the same reasons. In human studies, there are two exceptions on this general rule: characterising flavour testing and inhalation facilitation or nicotine uptake. For ethical reasons, the performance of new animal studies is not endorsed to assess the contribution of an additive to the tobacco product toxicity. Therefore, as a principle, only *in silico* and *in vitro* studies should be considered for new testing in Step 3, following the EU policy to ban animal studies for chemicals to be used in voluntary products. Human studies are generally discouraged; they may be used (e.g. in case of flavour assessment), but only if the study subjects are informed and not exposed to the harmful smoke emissions of tobacco products.

The data gaps already identified in the Opinion on Tobacco Additives I for the 15 additives included in the EU Commission priority list have been now analysed and the activities to be performed upfront have been described. In general, important data gaps for the 15 priority additives are information on addictiveness, inhalation facilitation and characterising flavour, as well as on the identity of the pyrolysis products.

Keywords: tobacco, additives, combustion products, cigarettes, roll-your-own, smoking, toxicity, addictiveness, attractiveness, characterising flavour, facilitated inhalation.

Opinion to be cited as:

SCHEER (Scientific Committee on Health, Environmental and Emerging Risks), Additives used in tobacco products, Opinion II, 16 December 2016.

TABLE OF CONTENTS

ACKNOWLEDGMENTS	3
ABSTRACT	4
1 BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION.....	8
2 TERMS OF REFERENCE	10
3 SCIENTIFIC RATIONAL	12
3.1 Introduction.....	12
3.2 Knowledge gaps identified in Opinion 1	14
3.3 Methodology	14
3.3.1 Development of the general approach to assess the effects of tobacco additives	14
3.3.2 Addressing the data gaps identified in Opinion I for the priority list additives	15
3.3.3 Information collection	15
3.3.4 Information evaluation.....	15
3.4 Step-wise approach to assess the toxic and addictive effects, inhalation facilitation and characterizing flavour properties of tobacco additives	16
3.4.1 Step 1: Evaluation of the additive in unburnt form	18
3.4.1.1 Collection of available data	19
3.4.1.2 Evaluation.....	20
3.4.2 Step 2: Evaluation of the pyrolysis products.....	21
3.4.2.1 Collection of available data	21
3.4.2.2 Pyrolysis studies(if needed)	21
3.4.2.3 Evaluation of data	24
3.4.3 Step 3: Testing and evaluation of results.....	24
3.4.3.1 Comparative paradigms are not endorsed	25
3.4.3.2 The use of animal testing	27
3.4.3.3 Quality system	27
3.4.3.4 Toxicity testing	28
3.4.3.5 Addictiveness testing	36
3.4.3.6 Characterising flavour and inhalation facilitation properties ...	43
3.4.3.7 Interaction of the additive with other additives/ingredient.....	48
3.4.4 Step 4: Reporting	50
3.5 Specific knowledge gaps for the priority list tobacco additives used in cigarettes and roll-your-own tobacco.....	50
3.5.1 Carob bean	51
3.5.2 Cocoa and cocoa products (powder, extracts, shells of cocoa bean etc.)	52
3.5.3 Diacetyl	53
3.5.4 Fenugreek extract.....	54
3.5.5 Fig extract	55

3.5.6	Geraniol	57
3.5.7	Glycerol	58
3.5.8	Guaiacol	59
3.5.9	Guar gum	60
3.5.10	Liquorice	61
3.5.11	Maltol	63
3.5.12	Menthol	64
3.5.13	Propylene glycol	66
3.5.14	Sorbitol	67
3.5.15	Titanium Dioxide	68
4	OPINION	70
5	MINORITY OPINION	74
6	CONSIDERATION OF THE RESPONSES RECEIVED DURING THE CONSULTATION PROCESS	75
7	ABBREVIATIONS AND GLOSSARY OF TERMS	77
8	REFERENCES	80
9	Annex I	102

1 BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

The new Tobacco Products Directive 2014/40/EU strengthens the rules regarding the reporting and composition of tobacco products. In addition to tightening the obligations of manufacturers to report on ingredients¹ contained in tobacco products, the Directive regulates permissible additives (or levels thereof) in order to improve the functioning of the internal market whilst guaranteeing a high level of public health.

A) Article 7 of Directive 2014/40/EU foresees in particular the prohibition of the following:

- 1) tobacco products with a characterising flavour (Art 7(1))
- 2) tobacco products containing the following additives² (Art 7(6)):
 - a) vitamins or other additives that create the impression that a tobacco product has a health benefit or presents reduced health risks;
 - b) caffeine or taurine or other additives and stimulant compounds that are associated with energy and vitality;
 - c) additives having colouring properties for emissions;
 - d) for tobacco products for smoking, additives that facilitate inhalation or nicotine uptake; and
 - e) additives that have CMR³ properties in unburnt form.
- 3) tobacco products containing flavourings in any of their components such as filters, papers, packages, capsules or any technical features allowing modification of the smell or taste of the tobacco products concerned or their smoke intensity. Filters, papers and capsules shall not contain tobacco or nicotine. (Art 7(7))
- 4) tobacco products containing additives in quantities that increase the toxic or addictive effect, or the CMR properties of a tobacco product at the stage of consumption to a significant or measurable degree. (Art 7(9))

The provisions outlined above shall apply in the first stage to cigarettes and roll-your-own tobacco. The exemption for other product categories may be removed under certain conditions.

B) Moreover, in line with Article 6 the Commission has to develop and update a **priority list of at least 15 additives** contained in cigarettes and roll-your-own tobacco by May 2016. This list shall contain additives

- 1) for which initial indications, research, or regulation in other jurisdictions exist suggesting that they have one of the following properties:
 - a) contributes to the toxicity or addictiveness of the products concerned / increases the toxicity or addictiveness of any of the products concerned to a significant or measurable degree;
 - b) results in a characterising flavour⁴;

¹ 'ingredient' means tobacco, an additive, as well as any substance or element present in a finished tobacco product or related products, including paper, filter, ink, capsules and adhesives (TPD 2014/40/EU)

² 'additive' means a substance, other than tobacco, that is added to a tobacco product, a unit packet or to any outside packaging (TPD 2014/40/EU)

³ CMR - carcinogenic, mutagenic or toxic for reproduction

- c) facilitates inhalation or nicotine uptake; or
 - d) leads to the formation of substances that have CMR properties / increases the CMR properties in any of the products concerned to a significant or measurable degree; and
- 2) which are amongst the most commonly used additives by weight or number according to the reporting of ingredients.

For these priority additives, enhanced reporting obligations will apply in the form of comprehensive studies which shall examine for each additive whether it has any of the properties 1 a) to d) specified above. Those studies shall take into account the intended use of the products concerned and examine in particular the emissions resulting from the combustion process involving the additive concerned. The studies shall also examine the interaction of that additive with other ingredients contained in the products concerned. The results of these studies shall assist Member States and the Commission in their enforcement efforts regarding Art. 7.

The SCENIHR published a scientific Opinion on the attractiveness and addictiveness of additives in 2010⁵. In light of the time that has passed since then and the need to address the current regulatory requirements, the SCENIHR has been asked to address the questions outlined in the Terms of Reference below.

⁴ 'characterising flavour' means a clearly noticeable smell or taste other than one of tobacco, resulting from an additive or a combination of additives, including, but not limited to, fruit, spice, herbs, alcohol, candy, menthol or vanilla, which is noticeable before or during the consumption of the tobacco product (TPD 2014/40/EU)

⁵http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_031.pdf

2 TERMS OF REFERENCE

The main purpose of the requested scientific Opinion is to assist the Commission in identifying the additives that should be put on the priority list. The scientific Opinion can, however, also provide useful input for Member States and the Commission in their broader regulatory/enforcement activities (e.g. setting thresholds/banning of additives), in particular in areas where the knowledge base may currently still be limited. In particular, the Committee is asked the following:

Opinion 1:

1. Based on scientific evidence (including a review of relevant scientific data) and other relevant information currently available (initial indications, regulation in other jurisdictions), the Committee is asked to identify - for each category separately - those additives that fall/are suspected to fall within the scope of the following categories:

- a. Contributing to the toxicity or addictiveness of the products concerned / increasing the toxicity or addictiveness of any of the products concerned to a significant or measurable degree;
- b. Resulting in a characterising flavour;
- c. Facilitating inhalation or nicotine uptake;
- d. Leading to the formation of substances that have CMR properties / increasing the CMR properties in any of the products concerned (cigarettes/roll-your-own) to a significant or measurable degree;⁶

The assessment should include for each of the additives identified a comprehensive description of the type of information supporting its identification as well as a description and quantification of the strength of the observed characteristic and the strength of the available evidence supporting this finding⁷. If the Committee identifies more than 20 additives for a category, the Committee is entitled to prioritise in the light of the criteria set out in this section. In this case, the description is limited to the top 20 additives per category, whilst the other additives can be listed without description.

The Committee is asked to also consider in its assessment the interaction with other ingredients contained in the products concerned and the emissions resulting from the combustion process involving the additive concerned as well as the intended use of the products. Relevant knowledge gaps should be identified.

As far as relevant information is available, the Scientific Committee is asked to identify within its assessment the most commonly used additives by weight or number. If additives belong to a single group of substances with identical or very similar properties, both the group of substances and the list of substances falling into that group shall be presented and the most relevant substance(s) within that group identified.

⁶ If an additive is included in Annex VI of Regulation (EC) No 1272/2008, its CMR-classification should be provided and considered as appropriate. Additives that have CMR properties in unburnt form should be identified/listed, but do not require a comprehensive description.

⁷ Registrations/assessments of relevant substances under Regulation (EC) No 1907/2006 should be provided and considered as appropriate.

When examining the composition of tobacco products and the use of individual substances, the Scientific Committee is invited to consult the data on additives reported by the tobacco industry under the Tobacco Products Directive 2001/37/EC, but may also consider additional data sources. Furthermore, the Committee is invited to consider during their assessment the lists of additives permitted/prohibited for use in tobacco products as implemented by certain Member States.

2. Based on its assessment in point 1, the Committee is asked to establish a list of a minimum of 20 and maximum of 30 additives that are suitable/recommended to be added to the priority list of additives in line with Article 6 of TPD 2014/40/EU. When establishing the list, the Committee shall consider the public health risks associated with the additives (actual or suspected), strength of the available evidence and to the extent possible, the frequency of use of the additives in tobacco products. The Committee should indicate as far as possible rankings of additives in light of the above and provide an explanation for its ranking⁸.

Opinion 2:

3. Furthermore, the Committee is asked to advise the Commission on the type and criteria for comprehensive studies that should be requested from manufacturers to assess the relevance of the individual additives, considering inter alia the knowledge gaps identified in point 1 above and the interaction of the additive with other additives/ingredients. Advice is also sought on the most suitable methodologies to be used (including a structure of the reports that can be peer reviewed).

⁸Substances belonging to the same group of identical/very similar substances should be considered jointly.

3 SCIENTIFIC RATIONAL

3.1 Introduction

In response to the Commission's requests, the SCENIHR adopted Opinion I (Tobacco Additives I), in which 48 single chemicals were listed as priority additives, which met the 30 entries maximum limit because some chemicals with very similar structures (i.e. aliphatic gamma-lactones, including 8 chemicals) and/or properties (e.g. weak acids, including 8 group members) were grouped together. They were selected on the basis of two initial criteria: the frequency of use in different brands and the amounts used in cigarettes, then further screened based on their hazardous properties, because they have been or are suspected of having one or more of the following properties:

- a. Contributing to the toxicity or addictiveness of the products concerned / increasing the toxicity or addictiveness of any of the products concerned to a significant or measurable degree;
- b. Resulting in a characterising flavour;
- c. Facilitating inhalation or nicotine uptake;
- d. Leading to the formation of substances that have CMR properties / increasing the CMR properties in any of the products concerned (cigarettes/roll-your-own) to a significant or measurable degree.

On the basis of these criteria:

- 17 substances were identified because they fall or are suspected to fall in the category: toxic in unburnt form, among which 6 are suspected of CMR potential, which were ranked highest on the suggested list because the Tobacco Products Directive foresees the prohibition of additives that have CMR properties in unburnt form.
- 20 substances were identified because they are known or suspected of forming irritant, toxic and/or CMR chemicals after combustion including sugars, sugar-containing additives and cellulose.
- 14 substances were identified because they are suspected of facilitating inhalation or of increasing nicotine uptake.
- 19 substances were identified because they show a characterising flavour, a factor potentially contributing to attractiveness.

Since the SCENIHR was asked to prioritise the selected chemicals to the best of its ability, three groups were identified. In addition to the 6 chemicals suspected of CMR potential, menthol was included in the 'highest priority group'.

A second group was identified based on the possibility of forming CMR compounds after combustion.

All the remaining identified additives are categorised in the third group, although it was not possible to rank them on the basis of their specific hazard profile and the only possibility was to use content/frequency ranking as a possible criteria for prioritisation or a combination of more than one of four characteristics provided for in Article 6.

On May 18, 2016, the Commission adopted the Commission Implementing Decision (EU) 2016/787 laying down a priority list of additives contained in cigarettes and roll-your-own tobacco subject to enhanced reporting obligations⁹, identifying 15 chemicals among those listed in the SCENIHR Opinion (Additives used in tobacco products; Tobacco Opinion 1) adopted in January 2016.

In this Opinion 2, on the basis of the knowledge gaps mentioned in the next section, and after revising the available open literature and approaches taken by International Agencies, the SCHEER provides advice to the Commission on the type and criteria for comprehensive studies that should be requested by Member States from manufacturers to assess the contribution of the individual additives used in cigarette and roll-your-own tobacco to tobacco product toxicity, addictiveness¹⁰, adding to a characterising flavour or facilitating inhalation.. A step-wise strategy was proposed (Section 3.4)¹¹. The issue related to interaction of the additive with other additives/ingredients is also considered.

It should be noted that, by contrast to adding them to medicines or food, for example, additives in tobacco products have no health benefits for the consumer. On the contrary, by making smoking more attractive, they promote an extremely unhealthy behaviour. Therefore, a risk-benefit analysis is not the appropriate paradigm for assessing the additive. When comprehensive studies confirm that additives have any of the four properties listed in Article 6 of the TPD, regulatory action should be considered in line with Article 7 of the TPD. If uncertainties cannot be solved by comprehensive studies, it is a SCHEER recommendation that the assessors consider the worst-case evaluation.

The same reasoning applies to the addictive effects, inhalation facilitation and characterising flavour of tobacco additives, as they will indirectly lead to adverse health consequences by increasing consumption of the product.

In addition to the general strategy, the major data gaps already identified in Tobacco Opinion 1 have been analysed to determine the most appropriate steps (and end-points) to be carried out and then used for the evaluation (Section 3.5), in order to speed up the process, making possible testing feasible within the 18-month time-frame. To give an example, for the 6 chemicals for which a genotoxic potential could not be ruled out for the unburnt form, the first step will be to evaluate their genotoxicity: if the results were positive, no other testing would be necessary, since according to the TPD (Article 7) they would automatically be banned for use as tobacco additives. In case of negative results, they would enter the general strategy of testing and be considered as would any other compound.

⁹<http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016D0787&from=EN>

¹⁰ [For the concepts of addiction \(or "dependence"\), this Opinion refers to the definitions given in the previous evaluation \(SCENIHR, 2010, 2016\). Addictiveness refers to the pharmacological potential of a substance to cause addiction, in line with the TPD definition as 'the pharmacological potential of a substance to cause addiction, a state that affects an individual's ability to control his or her behaviour, typically by instilling a reward or a relief from withdrawal symptoms, or both'. In addition to the neurobiological characteristics of the substance itself, dependence potential is related to the dose, speed of absorption, metabolism, and the physical and chemical features of the formulation \(WHO, 2007\).](#)

¹¹ [SCHEER was not requested to give detailed protocols for specific studies and whenever possible referred to test guidelines or other approaches already adopted in areas other than tobacco products.](#)

3.2 Knowledge gaps identified in Opinion 1

There was generally scant toxicological information regarding tobacco additives analysed for Opinion 1, and the available information was often limited to the oral route of exposure, especially for flavouring substances that are used by the food industry, or, to a lesser degree, to the dermal route, for substances that are also commonly used in cosmetic products. Data on the effects of additives in tobacco following inhalation is generally scant, although this is the most relevant exposure route. Indeed, the additives are either transferred to inhaled smoke in pure form, or are combusted and converted via pyrolysis into potentially toxic products. Because there was also little data on their kinetic behaviour, it was difficult, if not impossible, to make route-to-route extrapolation for additives.

A general scarcity of information was observed regarding the actual level of exposure to additives both in the unburnt form in tobacco products and resulting from combustion – including data on pyrolysis. This is particularly relevant since toxic combustion products generated upon pyrolysis of additives have the potential to increase the exposure to toxic substances and thus increase the health hazard associated with cigarette smoking (National Institute for Public Health and the Environment, 2012). The fate of the additive depends on its physico-chemical properties such as its volatility and reactivity, the design of the cigarette and the smoking topography of the user. The additive may be distilled from the tobacco rod, and end up in smoke intact, or it may be (partly) combusted. In case of (partial) pyrolysis, not only the unburnt additive is relevant, as the smoker will be exposed to the pyrolysis products as well. In the tobacco matrix, either the intact additive or its pyrolysis products may react with other additives, tobacco- or smoke components (pyrosynthesis). For instance, only minor amounts of the non-volatile sugars in tobacco (approximately 0.5% of glucose and sucrose) are transferred unchanged into the mainstream smoke, whereas the major part will combust, pyrolyse or participate in pyrosynthesis processes (Talhout *et al.*, 2006).

Although for most tobacco additives, direct information about their possible contribution to addictiveness and characterising flavours does not exist, information can be derived from the mode of action of the additive (e.g. addictiveness can be related to increased nicotine bioavailability or to local anaesthetic effects facilitating the inhalation of tobacco smoke).

Generally speaking, the scarcity of information on exposure and on toxic effects as described in Opinion 1 made risk assessment for most additives difficult, if not impossible.

3.3 Methodology

3.3.1 Development of the general approach to assess the effects of tobacco additives

Given the fact that additives in tobacco products have no health benefits for the consumer, but rather promote an extremely risky behaviour, risk-benefit evaluations are not appropriate. Based on evaluation of approaches for regulation of other types of components, the SCHEER concluded that a step-wise approach is the most pragmatic and efficient way to proceed in the assessment of the toxic, addictive and attractive

effects of tobacco additives. The tiered approach proposed by DKFZ (DKFZ, 2010) was used as a starting point, but was then further developed and adapted to include the evaluation of the additives in view of their role in creating a characterising flavour, facilitating inhalation and making tobacco products more addictive. The order of the steps has been proposed in such a way to minimise testing. First, an evaluation of the available data is proposed for both the additive in unburnt form (Step 1) and its pyrolysis products (Step 2); if no data are available on the identity of the pyrolysis products, they need to be generated using relevant test conditions. Next, in Step 3 non-testing methods, such as quantitative structure–activity relationship (QSAR) and read across, are employed, followed by *in vitro* approaches. Each step represents a possible decision point, when data allow a proper evaluation based on a WoE approach: if it could be unequivocally demonstrated that the additive falls in one of the four categories of Article 6 of the TPD, no further testing is needed. Regarding types of effects, toxicity is assessed first, as CMR chemicals are not allowed as additives (Article 7), and accepted methods and evaluation frameworks are available for toxicity testing, followed by characterising flavours, because accepted methods and evaluation frameworks are available. Finally, addictiveness is assessed, and since no validated tests are available here, the assessment can be guided by the available knowledge of the mode of action.

3.3.2 Addressing the data gaps identified in Opinion I for the priority list additives

The data gaps already identified in Tobacco Opinion 1 for the 15 additives included in Commission Implementing Decision (EU) 2016/787 have been analysed. Based on the data gaps described in the 'Rationale for inclusion' in Opinion 1, the activities to be performed upfront have been described. Then on the basis of the obtained results, if the additive does not meet the criteria for exclusion as an additive listed in art. 7 of the TPD, it can be subject to the general evaluation step-wise procedure described in the Opinion.

3.3.3 Information collection

Information on guidance for the data collection and tests to be performed in the different steps of the step-wise approach was collected by the SCHEER on available open literature/websites and from documents by other Committees or International Organisations (e.g. WHO, EPA, EFSA, JECFA)

3.3.4 Information evaluation

For this Opinion on tobacco additives, the available information was analysed by the SCHEER to identify tests and testing structures that are appropriate for the assessment of the toxic and addictive effects, facilitation of inhalation and characterising flavours of tobacco additives.

3.4 Step-wise approach to assess the toxic and addictive effects, inhalation facilitation and characterizing flavour properties of tobacco additives

A pragmatic and efficient step-wise approach is suggested, in order to assess the toxic and addictive effects as well as the additives' properties that facilitate inhalation and lend a characterising flavour to cigarettes and roll-your-own tobacco. The tobacco industry has the burden of proof that an additive does not fall within the scope of the four categories mentioned in the terms of reference and it is tobacco industry's responsibility to deliver data. The data need to be evaluated by independent scientific bodies with expertise in risk assessment of the toxic, addictive, inhalation facilitation and characterising flavour properties of chemicals.

The formation of consortia and joint reports by industry is endorsed in order to limit the financial and administrative burden for industry and authorities, as well as the amount of literature evaluation and testing by industry, and subsequent evaluation of the submitted reports by independent institutes. For the toxicological evaluation of additives in tobacco products, the tiered approach proposed by DKFZ (DKFZ, 2010) has been taken as a starting point. This approach has been adapted to the SCHEER purposes and widened to allow for the evaluation of the addictive effects, inhalation facilitation and characterising flavour of additives (see Figure 1). This is because apart from toxicity, tobacco additives may indirectly increase tobacco-related harm by increasing the consumption rate of tobacco products, either by making the product more attractive to the consumer (e.g. by resulting in a characterising flavour and by facilitating inhalation), or by enhancing its addictiveness (National Institute for Public Health and the Environment, 2012). As far as possible, this possibility has to be considered. Although a standardised methodology is not available, it is possible to derive information from the mode of action of the additive (e.g. addictiveness can be related to increased nicotine bioavailability or to local anaesthetic effects facilitating the inhalation of tobacco smoke; see the SCENIHR Opinion, 2010).

Whenever the evaluation of the additive in the unburnt form gives rise to any concern in relation to art 7 of the TPD (e.g. foreseeing the prohibition of additives having CMR properties) based on data collected in Step 1, the evaluation is stopped, meaning that the additive does not meet the requirement of the TPD. The same rule is applied to Step 2 for the pyrolysis products. In these cases, industry can proceed to step 4 in their reporting.

In case data are not available, or are not sufficient or robust enough to make the evaluation possible, the procedure should go to the next step.

In case of high uncertainty about the evaluation based on available data, there are two possible options:

- Application of the 'worst-case' evaluation
- Delivering of additional data (i.e. via Step 3) by tobacco industry

Step 2 is analogous to Step 1 but related to the pyrolysis products; the two steps can take place concurrently, if this is more efficient and saves time. The collection of available data is mandatory in order to priorities the most appropriate end-point(s) to be assessed in Step 3, to limit useless testing.




Figure 1. Step-wise approach to be applied to the assessment of the toxic, addictive, inhalation facilitation and characterising flavour properties of tobacco additives. For terminology, please refer to the text. Please note that *in vivo* tests may only be considered in exceptional cases.

This procedure could be applied either to individual additives or to groups of additives. Additives could be indeed grouped, following rules previously established in other fora to evaluate e.g. groups of food flavouring at EFSA¹² or groups of chemicals in Regulation (EC) No 1907/2006 i.e. REACH (to apply the read-across principles)¹³ in order to limit the use of animal testing (as requested in art. 13). The ECHA provides practical guidance on the issue (available at the ECHA website link); however, to this aim, the approach described in the OECD GUIDANCE ON GROUPING OF CHEMICALS No. 194¹⁴ is recommended.

The approach described in the OECD guidance document (GD) is to consider closely related chemicals as a group, or category, rather than as individual chemicals, for assessing the hazards of chemical substances, increasing efficiency and improving animal welfare. Since the technique of assessing groups of substances is an evolving

¹² <https://www.efsa.europa.eu/en/topics/topic/flavourings>

¹³ <http://echa.europa.eu/support/grouping-of-substances-and-read-across>

¹⁴ GUIDANCE ON GROUPING OF CHEMICALS, SECOND EDITION Series on Testing & Assessment No. 194 (2014) available at [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono\(2014\)4&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2014)4&doclanguage=en)

science, the GD is revised periodically and it is therefore compulsory that the tobacco industry follows the most updated version when applying it. As it is recommended by the GD itself, early consultations between industry and authorities are recommended to ensure that any regulatory requirements are fulfilled.

The GD outlines a process for grouping chemicals to include the identification of analogues/members of categories, the mechanistic basis for using analogues or chemical categories and the robustness of both approaches. The GD also describes the use of (Q)SARs for data evaluation and data-gap filling (read-across, trend analysis and (Q)SARs).

3.4.1 Step 1: Evaluation of the additive in unburnt form

The first step starts with the identification of the additive chemical specifications, by literature or by experiment (for the physico-chemical characterisation, if not available, data can be obtained following the OECD or ISO test guidelines to this purpose). This initial step is absolutely necessary in order to identify the nature of the additives and comprises also qualifying and quantifying of any impurity present. CAS numbers need to be provided for all relevant chemicals (additives and impurities). The chemistry and specification of a substance (or mixture of substances), in terms of chemical structure(s) and physico-chemical properties is also asked for in other legislations, e.g. for food additives.

It may not always be possible to fully characterise natural extracts, but as much information as possible is required to understand the extent to which variability in composition is controlled during manufacture. Data on the chemical composition of a natural extract additive should be provided by industry with emphasis on the concentrations of constituents of relevance; this includes the concentrations of compounds classified according to their chemical structure (e.g. flavonoids, terpenoids, alkaloids, etc.), constituents being characteristic for tobacco additives (chemical fingerprint, markers). Information on maximum levels for microorganisms and possible contaminants, including e.g. heavy metals, mycotoxins, pesticide residues and polycyclic aromatic hydrocarbon (PAH) residues, should be provided (EFSA, 2012).

Then, all available information on the additive in unburnt form is collected and evaluated. This includes open literature on peer-review journals as well as grey literature (e.g. unpublished reports of studies used for regulatory purposes), including JECFA, EFSA and FEMA documents or data coming from any other regulatory request, in case the additive is used in other contexts.

This step allows the collection of available information on the additive in its unburnt form, useful for its risk assessment. In addition, it allows the identification of the major data gaps (if any) to be addressed in Step 3, with regard to toxicity and addictiveness data, as well as inhalation facilitation or increase nicotine uptake properties or resulting in characterising flavour.

For future reference by the regulator, industry is also asked to indicate which additives are closely related regarding chemical structure, functions, purpose and effects.

3.4.1.1 Collection of available data

Whenever possible, all information already available on the toxicity of the additive (obtained with different experimental models, i.e. *in vivo*, *in vitro*, *in silico* and human data) should be collected, used and evaluated before any testing is initiated (in Step 3). Some knowledge on the toxicity of tobacco additives exists; much less is known on their addictiveness or on how they facilitate inhalation and increase nicotine uptake properties or result in characterising flavour. Open literature as well as grey literature (e.g. unpublished reports of in-house performed studies with regulatory purposes) should be included. If studies have been already performed in view of seeking approval of the same chemical for uses other than tobacco additive by Applicants other than Tobacco Industry, a letter of access should be acquired, in order to avoid repeating the same tests.

Initial electronic literature searches with appropriate key words/dates should be a starting point for data gathering. The databases and search engines used may include for example PubMed, Web of Science, Scopus, Toxline, Chemical and Biological Abstracts, and Google Scholar. The data search methods will identify many papers that potentially could be used. A first screening is then needed in order to focus on those relevant for the specific purposes, using appropriate inclusion/exclusion criteria. Articles that do not appear to meet the inclusion criteria should be excluded from further analysis. To apply a standardised methodology it is recommended that the literature search strategy and selection criteria (inclusion/exclusion) for the review are based on the EFSA Systematic Review Guidance (EFSA Journal 2010).

In order to collect data on addictiveness and on properties that facilitate inhalation or result in characterising flavour, all investigations on possible related mode of action or mechanisms should be considered. In this respect, although never used in this context, an emerging approach is the adverse outcome pathway (AOP) – a framework designed to conceptually link a molecular initiating event to an adverse outcome of relevance to risk assessment (Ankley *et al.*, 2010). The AOP framework allows for a better understanding of the mechanistic linkages between cellular responses and downstream impacts on apical outcomes that are of concern within a regulatory context (Villeneuve and Garcia-Reyero, 2011). Potential practical uses of AOPs also include the above-mentioned grouping of common chemicals for read across (not only based on chemical structures but on biological activity), identification of research and data gaps, serving as a framework for regulatory priority setting, and informing hazard characterization and risk assessment (Becker *et al.*, 2015). AOP methodology may be useful in elucidation of molecular basis for addictiveness of tobacco products e.g. role of pH changes on nicotine absorption, MAO-A inhibition, Dopamine (DA) release and turn over, CYP metabolism and inhibition (for details see paragraph 3.4.3.5). Accordingly, the same applies to investigation on properties facilitating inhalation or resulting in characterising flavour (for details see paragraph 3.4.3.6). OECD developed a guidance document outlining methods and best practices for creating and assessing AOPs, in which it calls for the assessment of an AOP's weight of evidence (OECD, 2013; AOP-Wiki, 2014). AOP wiki represents a joint effort between the European Commission – DG Joint Research Centre (JRC) and the U.S. Environmental Protection Agency (EPA). This serves as one component of a larger OECD-sponsored AOP Knowledge Base effort and represents the central repository for all AOPs developed as part of the OECD AOP Development Effort by the Extended Advisory Group on Molecular Screening and Toxicogenomics.

3.4.1.2 Evaluation

Collected data give information regarding the possibility for the additive used in cigarette/roll-your-own to fall into one or more of the four categories:

- a) Contributing to the toxicity or addictiveness of the products concerned/increasing the toxicity or addictiveness of any of the products concerned to a significant or measurable degree;
- b) Resulting in a characterising flavour;
- c) Facilitating inhalation or nicotine uptake;
- d) Leading to the formation of substances that have CMR properties / increasing the CMR properties in any of the products concerned (cigarettes/RYO) to a significant or measurable degree.

The methodological quality of the selected papers should also be addressed, including the design, execution, analysis and reporting of the study. Expert judgement is vital in the assessment of the quality and the interpretation of data, therefore the appropriate identification and selection of relevant publications/reports is extremely important. When possible (e.g. for toxicity studies) this screening should be based on Klimisch scoring¹⁵.

The acceptance of each publication/report that is considered to be relevant should be based on the quality and relevance criteria summarised in by SCENIHR (2012).

All selected documents of potential importance should be subject to similar treatment in the evaluation process. Positive and negative studies should be evaluated using similar procedures and criteria and considered of similar importance if the quality is judged to be comparable. In positive studies the evaluation needs to consider both causal and non-causal explanations of the results. For example, one key question would be "with what degree of certainty can one rule out the possibility that the observed positive result is produced by bias, e.g. confounding or selection bias, or chance?". In the case of negative studies, it is necessary to assess the certainty with which it can be ruled out that the lack of an observed effect constitutes evidence against a hazard or whether it could result from (masking) bias, e.g., too small exposure contrasts, too crude exposure measurements, too small exposure groups/populations, or chance. Consideration should also be given to the possibility of a publication bias i.e. that positive findings are more likely to be published than negative findings.

It is recommended that the whole data set, judged as relevant, reliable, and of good quality, should be used for the (risk) assessment of the tobacco additive and its pyrolysis products, if any. Different approaches for assessment of whole data sets, referred to as weight of evidence (WoE) evaluation or systematic review (often used interchangeably), have been promoted (Koustas *et al.*, 2014; Rooney *et al.*, 2014; European Food Safety Authority, 2010; IARC, 2006). In general terms, these approaches are processes of summarising, synthesising and interpreting a body of evidence to draw conclusions, e.g. regarding the relationship between a chemical exposure and an adverse health effect. The WoE approach promotes the use and integration of information from all available evidence.

¹⁵H.J. Klimisch, M. Andreae and U. Tillmann (1997): *A Systematic Approach for Evaluating the Quality of Experimental Toxicological and Ecotoxicological Data*, [Regulatory Toxicology and Pharmacology](#) Vol 25, pp 1–5

Unfortunately, formal procedures and consistent terminology for WoE processes are lacking, although a WoE evaluation is mentioned in the REACH regulation, the Biocides directive, the Cosmetics regulation, and the regulation for Classification, Labelling and Packaging (CLP). Some guidance documents are only available for industrial chemicals or contaminants in food (Ågerstrand and Beronius, 2015). However, a number of organisations have established their own frameworks for assessing/evaluating evidence, including the SCENIHR (2012), and the work is still in progress in both the SCHEER and EFSA. Since the approach is rapidly evolving, it is compulsory that in applying it, the Tobacco Industry follows the most updated version.

As indicated above, it is possible to apply substance grouping of read-across principles: this approach uses relevant information from analogous ('source') substances to predict the properties of 'target' substances. The application and reporting of this approach as described in section 3.4 is recommended; if applied correctly, there is no need to have specific information on every additive.

Whenever the evaluation based on the WoE approach of the available data on the additive in its unburnt form unequivocally identifies no concern for any health effect, and it also falls in one of the 4 categories with no data gaps, there is no need to go for further testing in Step 3. On the contrary, whenever the evaluation based on the WoE approach of the available data on the additive in its unburnt form give rise to any concern regarding CMR properties, the evaluation is stopped, meaning that the additive does not meet the requirement of TPD art. 7. In both cases it is possible to directly proceed to Step 4.

In case data are unavailable, insufficient or not robust enough to make any evaluation possible, the procedure should go to Step 3,

3.4.2 Step 2: Evaluation of the pyrolysis products

In the second step, information available on the identification of pyrolysis products of additives must be collected and evaluated. This can be done on the basis of available data (see section 3.4.1.1 for criteria), but in case no sufficient data (in quantitative or qualitative terms) are available, the second step foresees that pyrolysis studies need to be performed in realistic, standardised experimental conditions (see section 3.4.2.2). Then available open and grey literature data on the toxicological profile, addictiveness or properties facilitating inhalation or resulting in characterising flavour on the identified pyrolysis products should be collected, as described in Step 1 for the additive in the unburnt form.

3.4.2.1 Collection of available data

Available data on the pyrolysis products of additives is collected in the same way as described in Step 1 (see 3.4.1.1).

3.4.2.2 Pyrolysis studies(if needed)

To identify the compounds formed during the combustion process of a tobacco additive, tobacco industry in general performs smoke chemistry studies on a comparative basis where a research cigarette is machine smoked with and without the additive present (Talhout *et al.*, 2006). Burning (smoking) the tobacco that contains a specific amount of the additive and subsequent analysis of selected smoke components is described for

many different additives (Baker *et al.*, 2004a; Baker *et al.*, 2004b, c; Carmines, 2002; Rustemeier *et al.*, 2002). However, subtle differences between the selected smoke components will not be noticeable, and it is not feasible to screen the effect on all 6000 known smoke components, hence usually only the so-called Hoffmann analytes are screened. Given the complexity of cigarette smoke, it is difficult to identify individual materials that may result from the pyrolysis of ingredient mixtures, unless radioactively labelled additives are used, but that method is sophisticated and expensive. Furthermore, this method cannot determine whether the additive is a precursor or a catalyst for the formation of a certain smoke component (Torikai *et al.*, 2005).

Pyrolysis, on the other hand, is a useful technique for evaluating materials used at low levels, where it is unlikely that smoke chemistry assays could detect a change. Therefore, combustion processes in a burning cigarette have also been simulated with pyrolysis methods (Baker *et al.*, 2004b; Busch *et al.*, 2012; Lee *et al.*, 2007).

This technique is useful as a first screening of potential pyrolysis products, their thermal stability and the temperature at which they are formed (Baker and Bishop, 2004). However, the pyrolysis conditions only approximate the burning cigarette with regard to temperature and atmosphere and make no allowance for the presence of other tobacco and/or smoke components that may interact with the additives. Pyrosynthesis processes related to the tobacco matrix will not occur when the additive is pyrolysed as a single component outside of the tobacco matrix. When it is suspected that such reactions will occur, one may consider pyrolysing a simple mixture containing the additive together with the component with which reaction is foreseen (either with the component itself or with its pyrolysis products. For instance, micro-vial pyrolysis of a glucose/proline mixture resulted in formation of Amadori intermediates, important in the formation of (Maillard) products that influence the aroma (Mitsui *et al.*, 2015). Pyrolysis was performed at 700°C, approximating the temperature of the pyrolysis zone of a burning cigarette, for 10 s under atmospheric conditions (headspace gas in vial not replaced by an inert gas).

Pyrolysis studies can be performed under a given set of experimental conditions that need to resemble processes in a burning cigarette in terms of e.g. temperature, rate of temperature change, and atmosphere (amount of oxygen). During the cigarette-burning process, the temperature of the tobacco and the burning cone can range from room temperature up to 900 °C, and the amount of oxygen can range from 0 to 18%. It is important that the design of the pyrolysis study reflects the conditions of burning cigarettes with oxygen levels ranging from 0% to 14% and the temperature in the burning zone ranging from ambient temperature to 900 °C (Baker and Bishop, 2004; Stotesbury *et al.*, 1999; Torikai *et al.*, 2004).

Many studies tried to simulate the processes during smouldering and combustion. Stotesbury performed pyrolysis at 14 sets of pyrolysis conditions: temperatures between 200 °C and 700 °C in 2 % and 10 % oxygen, and at 800 °C and 900 °C in 2 % oxygen. Baker used an atmosphere of 9% oxygen in nitrogen, arguing that this is the average amount throughout the pyrolysis/distillation zone inside the burning cigarette during a puff. From an initial temperature of 300°C, to simulate the smouldering before taking a puff, the sample is heated at 30 °C s⁻¹ to 900 °C, and kept for 5 seconds, to simulate the maximum duration of the high-burning zone temperature during puff under extreme human smoking conditions. According to Baker, 30 °C s⁻¹ is the approximate mean heating rate throughout the pyrolysis/distillation zone during a puff. This seems rather

slow, as that would imply it would take 20 seconds before the maximum temperature is reached, whereas a human puff only takes one or two second. However, most studies are performed with a similar heating rate (Torikai *et al.*, 2004). Purkis *et al.* programmed the temperature from 300 to 900 at 25 °C per second to reflect cigarette smoking and give an appropriate set of conditions to limit artefact formation (Purkis *et al.*, 2011). It is important that the reaction vial is not closed, so that the additive can distil away at lower temperatures.

Flash pyrolysis is performed when the sample is rapidly inserted in a pre-heated furnace that is already at the highest temperature, for instance at the temperature range of 200–300 °C to simulate cigarette smouldering (Zhou *et al.*, 2011). Time of flight spectroscopy allows for almost real time sampling, enabling identification of reactive compounds before being degraded (Hertz-Schunemann *et al.*, 2015) (Busch *et al.*, 2012).

Taking into account the studies described above, the SCHEER recommends the following experimental design in most cases performed by tobacco industry:

Thermal degradation (pyrolysis, pyrosynthesis and combustion products) of each additive is to be studied under different reaction regimes (inert and 2-14% oxygen) over the temperature range 200–900 °C. The thermal degradation products of two different pyrolysis conditions should be identified:

- (1) upon gradually heating the sample from 200–900 °C and
- (2) conventional pyrolysis, in which a new sample is pyrolysed at minimally 3 different temperatures (~ 300°C, 600°C and 900°C).

Pyrolysis experiments should be carried out at least in triplicate. Chemical analysis of the components in the pyrolysate needs to be performed with state of the art techniques in the field of GC-MS and LC-MS, as appropriate for the specific additive. The World Health Organization in its report to the Sixth Conference of the Parties¹⁶, identified eight non-exhaustive lists of toxicants: Health Canada, RIVM, USA FDA, Counts, Dybing and Fowles, Hoffman analytes, Philip Morris-Australian brands, and Philip Morris-Canadian brands. These toxicants need to be identified and quantified, if present, using analytical reference standards. Tobacco-specific components, such as nitrosamines and alkaloids, are not expected to be present.

For additional components, not on these lists, the following procedure is advised. For identification purposes, library software can be used, such as the Automated Mass Spectral Deconvolution and Identification System (AMDIS) software. Components with a peak-to-peak signal-to-noise ratio below three can be discarded. Also, components with a probability of correct identification below 70% can be excluded.

If components with a toxicological hazard are identified, their identification needs to be confirmed and their amount needs to be quantified using analytical reference standards.

Apart from components that may increase the toxicity, specific attention needs to be given to components that have addictiveness-enhancing properties, flavouring

¹⁶http://apps.who.int/gb/fctc/PDF/cop6/FCTC_COP6_14-en.pdf

properties, or inhalation facilitation properties (e.g. anaesthetic and/or bronchodilating properties) (SCENIHR, 2010).

3.4.2.3 Evaluation of data

The collected data will be evaluated according to a WoE approach (see 3.4.1.2). Again, when the available information is considered reliable and robust enough concerning both the identification of pyrolysis products and on their toxicological and addiction profile or on properties facilitating inhalation, increasing nicotine uptake or resulting in characterising flavour, a solid evaluation can be possible based on the WoE approach, on the basis of which a decision (positive or negative) can be taken. For instance, if the data set unequivocally identifies the additive as not falling into any of the four categories and not posing any concern for any health effect, with no data gaps, there is no need to go for further testing in Step 3. On the contrary, if it is demonstrated that compounds proven to have carcinogenic or mutagenic properties are generated from pyrolysis of an additive, this additive will contribute to the toxicity of the product concerned, considering the stochastic nature of the carcinogenic effect.

When data are unavailable, insufficient or not robust enough to make any evaluation possible, the procedure should go to Step 3.

3.4.3 Step 3: Testing and evaluation of results

The third step is related to the testing of additives or their pyrolysis products, whenever a data gap is identified in Step 1 and 2, or uncertainties have to be reduced, according to methods accepted by other regulations. The outcomes of tests must be related to actual human exposure and tobacco-induced diseases, and be relevant not only for subchronic, but also for chronic exposure in intermittent use sessions (Johnson *et al.*, 2009).

A relevant test design will not only consider methods to investigate toxicity, but also characterising flavour, facilitating inhalation and addictiveness. Therefore information should be collected if it is related to the known mechanisms that contribute to addictiveness or on properties facilitating inhalation, increasing nicotine uptake or resulting in characterising flavour.

Based on expert judgement of the major data gaps with regard to toxicity, characterising flavour, facilitating inhalation properties and addictiveness data identified in Step 1, it must be decided which endpoint to start with. This will generally be the endpoint for which most evidence is available of a potential concern. If no priority concerns have been identified, it is advised to start with toxicity, as in that case, accepted *in vitro* tests are available and there are frameworks for interpreting the results.

This step will also address the possible interactions, at chemical level (e.g. pyrolysis) and for the toxicological part based on the MeA/MoA.

It should be noted that whenever there is a good scientifically-based reason for asking for an exception for presenting data related to a specific end-point, a detailed justification reporting the rationale for the derogation must be provided.

Once data are collected by applying testing in Step 3, they should be evaluated together with data collected in Step 1 and 2 by using a WoE approach. If uncertainties cannot be

reduced by results coming from Step 3 testing, the SCHEER recommends that the assessors consider the 'worst-case' evaluation.

3.4.3.1 Comparative paradigms are not endorsed

In order to provide a relevant outcome to the question of whether an additive contributes to the toxicity, addictiveness and properties facilitating inhalation or resulting in characterising flavour of the products concerned (i.e. cigarette and roll-your-own tobacco; Article 6(2) of the TPD), the study design must adhere to some methodological criteria.

Strictly speaking, the only way to comply with Art.6 TPD2 (A6), to assess whether additives increase "toxicity or addictiveness ... to a significant or measurable degree" should be comparative testing (Kienhuis *et al.*, 2016). However, it must be noted that comparative testing strategies, where differences in effect of the tobacco product with and without the additive are evaluated, at the moment are not considered suitable, given the current toxicity tests and available methodology. Indeed, the emissions of tobacco products are highly toxic, in particular regarding cigarette smoke (Kienhuis *et al.*, 2016). Due to the high intrinsic toxicity of tobacco products, it is challenging to demonstrate any differences, whether they be increases or decreases, induced by an additive.

Due to the high toxicological activity of both the test product (tobacco product with additive) and the control (tobacco product without additive) in comparative testing strategies, the discriminatory power that can be obtained in toxicity assays may not be sufficient (COT/COM/COT, 2009; DKFZ, 2010; Oldham *et al.*, 2012).

Very sensitive tests would be required, with a clear dose-response relationship, in order to show any differences from these high background effects. As such tests are not currently available, no new comparative studies (tobacco product with and without additives) will be considered, since these studies lack discriminative power. Studies that are already available could be presented, but the relevance of their results has to be evaluated in a WoE approach based on these considerations.

In line with this, the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC, 2009) concluded: "*The Committee considered that the available studies used to assess the contribution of individual or mixed ingredients or additives to the overall toxicity of tobacco products are inadequate to assess the risks posed by conventional cigarettes, so it is not possible to assess the modulation of that risk resulting from inclusion of additives. The relationship between effect (an increase in biomarker) and exposure is also poorly understood. Furthermore, it is possible that additives might alter smoker behaviour, such as to increase product use; this increased exposure would be likely to result in an increased risk.*"

Furthermore, an international Working Group on Tobacco Additives (WG), assigned by the Brazilian regulatory agency ANVISA, assessed many industry-sponsored studies addressing the effects of mixtures of commonly used additives on cigarette smoke chemistry and toxicity. Although industry claimed that additives have no effect on the levels of chemical components of cigarette smoke and toxicity, the WG concluded that the available data were insufficient to accept the tobacco industry's claims that additives do not increase the inherent toxicity of tobacco smoke (Ferreira *et al.*, 2015; Working Group on Tobacco Additives, 2014): "*Given the current toxicity tests and test designs, it*

is not yet possible to determine whether or not addition of specific ingredients (tobacco additives) to tobacco products adds to tobacco mainstream smoke's inherent toxicity. This is because tobacco itself is already quite toxic, and any added toxicity is difficult to detect within the current test designs used by tobacco industry, i.e. combinations of in vitro testing and animal testing."

For the future, tests are needed that are sensitive enough to assess the toxicity attributed to additives above the overall toxicity of tobacco products, which can associate assay outcomes to human risk and exposure. In this respect, *in vitro* tests combined with toxicogenomics, using biomarkers of exposure and disease are the most promising (Kienhuis *et al.*, 2016). However, for the time being, no standardised methods have been validated to this purpose.

Another problem with comparative testing is the choice of the product to be tested, since the additional toxicity of the additive would differ between product types and brands. If an additive would be tested in the intended brand, the results (related to toxicity, addictiveness and attractiveness) could not necessarily be generalised to all products and brands, having a different composition. Therefore the obtained results may not lead to general prohibition/acceptance of specific additives but rather to prohibition/acceptance on a product-by-product basis (DKFZ, 2010).

When the addition of sugars is taken as an example, it will be very important whether a reference containing Burley tobacco, that does not contain natural sugars, or Virginia tobacco, with high sugar levels, is selected, or a blend of these tobacco types. This is even more important as cultural differences exist in the preference for Virginia-type cigarettes, American blend, or Burley. According to the TPD, the use of additives necessary for the manufacture of tobacco products should be allowed, as long as they do not result in a characterising flavour or increase the addictiveness, toxicity or CMR properties of the product. Thus, in this particular case, sugar addition to replace what is lost during the curing process, needs to be evaluated against the possibility of toxic and carcinogenic compounds forming following pyrolysis.

For similar reasons, comparative studies are in general also not endorsed for examining the effect of additives on addictiveness. In human studies, there are two exceptions to this general rule. The first is characterising flavour testing. By definition, this is a comparative testing paradigm, as clearly noticeable flavour is a property of a tobacco product, caused by the addition of flavour additives, and not a property of an additive itself (see section 3.4.3.6). In this experimental set-up, strong flavours other than that of tobacco can be distinguished, whereas more subtle flavours caused by an additive will not be consciously discriminated. The second includes additives that facilitate inhalation or nicotine uptake, and perhaps similar effects in humans, as e.g. reported for smokers of mentholated cigarettes vs non-mentholated cigarettes. In this case, large groups of test subjects are needed, and effects on e.g. sensory perception, smoking topography and biomarkers of exposure (e.g. nicotine in blood or cotinine in urine) can be discriminated. In most human studies, any effects of the additive will probably not be picked up in comparative testing designs, or at least be more prominent in non-comparative designs. For instance, when focusing on the dependence capacity of tobacco additives, studies on acute effects done within subject measurements (placebo vs. additive(s) of interest) are regarded as more valuable. This will improve the sensitivity to picking up small changes in neuronal activity caused by administration of the additive.

Instead of using a comparative study design, the effects of the pure additive and its pyrolysis products must be considered in a relevant testing strategy, such as the tiered approach proposed by the SCHEER (Fig.1).

3.4.3.2 The use of animal testing

So far, available inhalation or other animal studies have been used to assess the effect of tobacco additives. Whenever studies using animals are available, they should be evaluated in Step 1 and 2. However, it is ethically questionable to carry out any new animal studies to evaluate the 'safety' of a tobacco additive, as tobacco products are highly harmful with no benefits to individual or public health. Therefore, as a principle, only the use of *in silico* and *in vitro* studies applies to Step 3, following the EU policy recommending implementation of 3R methods for refinement, reduction, and replacement of animal models, leading to the ban of animal studies for chemicals to be used in voluntary products such as cosmetics (EU Regulation no. 1223/2009). Non testing or alternative testing approaches followed for the evaluation of cosmetic ingredients¹⁷, whenever relevant to tobacco products, could be considered.

Human studies are discouraged, although they may be used in specific case (e.g. for characterising flavour assessment or facilitating inhalation properties), but only if the study subjects are informed and not exposed to the harmful smoke emissions of tobacco products. Generally and especially in those specific cases in which animals are proposed, early consultations are recommended between Receiving Competent Authorities at Member State level and tobacco industry, presenting a testing strategy including *in silico*, *in vitro* and only in exceptional cases *in vivo* tests. In order to limit the testing, formation of Consortia is recommended.

In the exceptional cases when animal testing would be deemed necessary, it is compulsory to be compliant with the Animal Welfare EU policy and to respect the Regulation on Animal Testing.

3.4.3.3 Quality system

In line with the provisions of other regulatory contexts, the SCHEER recommends the use of a Quality system (e.g. Good Laboratory Practice or ISO17025) for carrying out the pyrolysis or other physico-chemical studies as well as pre-clinical toxicity studies (including those to assess the mode of action underlying possible contribution to addictiveness and characterising flavour, increasing nicotine uptake or facilitating inhalation).

In case the principle of the Mutual Acceptance of Data is applied (again to limit the testing) the quality system of choice should be the GLP, following the application of the GLP OECD principles, to which all the National Monitoring Authorities in the different OECD Member States make reference. Human studies should follow the appropriate Quality System, since GLP are usually not applied to this kind of testing. For the physico-chemical studies, GLP compliance is not always requested and the ISO17025 could be chosen.

¹⁷http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_190.pdf

3.4.3.4 Toxicity testing

In silico

If toxicological data on the additives are not available or are limited, they can be produced using *in silico* approaches. As a first step, QSAR methods are encouraged to identify alerts for genotoxicity, carcinogenicity and reproductive toxicity, to get information of potential CMR properties of the additive or of its identified pyrolysis products: this could also take advantage of similarities with other chemicals by applying the read-across methodology.

Non-test information about the biological activity of a substance can be derived in a variety of ways, ranging from simple inspection of the chemical structure through various read-across techniques, the use of expert systems, metabolic simulators, to global or local (Q)SARs. The usefulness of such techniques varies with the amount and nature of information available, as well as with the specific regulatory questions under consideration.

Models for the identification for alert of genotoxicity and carcinogenicity have a long tradition; (Q)SAR models for mutagenicity can apply to a limited set of congeneric substances (local models) or to a wide variety of non-congeneric substances (global models).

Many global models for mutagenicity are commercial and some of the suppliers of these global models consider the data in their modelling sets to be proprietary. Proprietary means that the training set data used to develop the (Q)SAR model is hidden from the user. In other cases it means that it may not be distributed beyond use by regulatory authorities.

There are hundreds of (Q)SAR models available in the literature for predicting test results for genotoxic endpoints for closely related structures (Naven *et al.*, 2012; Bakhtyari *et al.*, 2013). These are known as local (Q)SARs. However, quality of reporting varies from model to model and predictivity must be assessed case-by-case on the basis of clear documentation.

In case of robust data on the identification of structural alert or based on read across indication of CMR properties, it is not necessary to go further, since according to the TPD no CMR substance can be used as a tobacco additive. In case there are doubts, *in vitro* testing can be conducted (see below).

Regarding the other toxicological properties, other QSAR tools are available. Some of them are briefly described in the following:

OECD built an open software application (<http://www.qsartoolbox.org/>), named QSAR Toolbox. The Toolbox and guidance on its use are freely available. The OECD QSAR Toolbox facilitates the practical application of grouping and read-across approaches to fill gaps in (eco-)toxicity data, including but not limited to genotoxicity and carcinogenicity, for chemical hazard assessment. The Toolbox incorporates information and tools from various sources, into a logical workflow. Crucial characteristic of the workflow is the grouping of chemicals into categories (group of chemicals whose physicochemical and human health and/or ecotoxicological properties and/or environmental fate properties

are likely to be similar or follow a regular pattern, usually as a result of structural similarity). The most important features are:

1. Identification of relevant structural characteristics and potential mechanisms or mode of action of a target chemical.
2. Identification of other chemicals that have the same structural characteristics and/or mechanism or mode of action.
3. Use of existing experimental data to fill the data gap(s).

The Joint Research Centre of the EU provides several tools for modelling for the safety assessment of chemicals. They offer the following computational tools (freely downloadable or accessible from their webpages):

- JRC QSAR Model Database: database hosting structured and peer-reviewed information on QSAR Models (<https://eurl-ecvam.jrc.ec.europa.eu/databases/jrc-qsar-model-database>);
- Toxtree, software tool to generate prediction(s) on mechanisms of action or toxicological effects, the tool is based on a decision-tree approaches (<https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive-toxicology/qsar-tools/toxtree>);
- Dart, (Decision Analysis by Ranking Techniques) a software tool designed to rank chemicals according to environmental and toxicological concerns (<https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive-toxicology/qsar-tools/DART>);
- Toxmatch, a flexible application for grouping chemicals based on chemical similarity designed to be helpful in read-across (<https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive-toxicology/qsar-tools/toxmatch>).
- Stat4tox, a tool which carries out concentration-response analysis for *in vitro* experiments (<https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive-toxicology/qsar-tools/stat4tox>).

ECHA provides a detailed overview on non-testing methods in sub-section R.7.7.3.1 of Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7a: Endpoint specific guidance (see http://echa.europa.eu/documents/10162/13632/information_requirements_r7a_en.pdf), in particular with regard to the prediction models for mutagenicity and the OECD QSAR toolbox.

A list of the available (free and commercial) predictive software for ecotoxicological, toxicological and environmental endpoints, including mutagenicity models, has been compiled within the frame of the EU project Antares (<http://www.antares-life.eu/>). For example, the Danish EPA and the Danish QSAR group at DTU Food (National Food Institute at the Technical University of Denmark) have developed a (Q)SAR database that contains predictions from a number of mutagenicity models. The database is freely accessible via <http://qsar.food.dtu.dk>. The online database contains predictions for over 166,000 substances and includes a flexible system for chemical structure and parameter searching. A user manual with information on the individual models including training set

information and validation results is available at the website. The database is also integrated into the OECD (Q)SAR Toolbox.

Another example of a database with predictions on mutagenicity is the Enhanced NCI Database Browser (<http://cactus.nci.nih.gov>) sponsored by the U.S. National Cancer Institute. It contains predictions for over 250,000 substances for mutagenicity as well as other non-mutagenic endpoints, some of which may provide valuable mechanistic information (for example alkylating ability or microtubule formation inhibition). It is also searchable by a wide range of parameters and structure combinations.

Use of harmonised templates, such as the QSAR Model Reporting Format (QMRF) and the QSAR Prediction Reporting Format (QPRF) developed by the Joint Research Centre (JRC) of the European Commission (http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/qsar_tools/QRF), can help to ensure consistency in summarising and reporting key information on (Q)SAR models and substance specific predictions generated by (Q)SAR models. The JRC website also hosts the JRC (Q)SAR Model Inventory, which is an inventory of information on the validity of (Q)SAR models that have been submitted to the JRC (http://ihcp.jrc.ec.europa.eu/our_databases/jrc-qsarinventory).

If the exposure could be well characterised without uncertainties, the application of the Threshold of Toxicological Concern (TTC) concept could be foreseen providing the applicability domain will be expanded to include sufficient data coming from inhalation studies. Its use has been proposed, but never applied in regulatory context in relation to the inhalation route (Costigan and Meredith, 2015). In addition, the concept of the 'internal TTC', independent on the route of exposure, is a promising approach that is also starting to be considered in the area of cosmetic products (SCCS, 2016).

In vitro

There are a number of *in vitro* tests that can be used to assess many different toxicological end-points. *In vitro* toxicity tests are applicable to a wide variety of test materials including ingredients added to tobacco, tobacco extracts, tobacco smoke condensates, and whole or vapour phase smoke. These assays may also be used to explore interactions between components of cigarette smoke. The test item should be the additive in its unburnt form and relevant pyrolysis products (in case information coming from Step 1 and 2, as well as from non-testing methods in Step 3 give rise to insufficient data or high uncertainties in the evaluations) as well as to tobacco smoke particulate and whole or vapour phase smoke, when relevant.

The first choice has to be given to tests already adopted at international levels (e.g. OECD Test Guidelines¹⁸, or ISO methods) or tests validated by EURL-ECVAM. The OECD test guidelines (TGs) describe the applicability domain, the principles of methods, the test procedure and they also address reporting.

In case a non-TG *in vitro* method is used (e.g. a test validated by EURL-ECVAM), the reporting should be appropriate, following what it is indicated in the OECD Guidance

¹⁸<http://www.oecd.org/chemicalsafety/testing/oecdguidelinesforthetestingofchemicals.htm>

Document for describing Non-Guideline *in vitro* test methods No.211 (2014)¹⁹. The application of integrated approaches on testing and assessment (IATA) is highly recommended, as described in documents adopted by both EURL-ECVAM and OECD²⁰.

Since the acceptance at regulatory levels is evolving, the TG as well as the GDs are periodically revised, therefore it is compulsory that in choosing the appropriate test, the tobacco industry follows the most updated version. Indeed, as requested by EU regulation 1223/2009 on cosmetics, the EU Commission has to report every year to the European Parliament as well as to the EU Council on the progress related to the development, validation and regulatory acceptance of alternative methods as communicated by a Report from EURL-ECVAM²¹.

If information gathered through *in silico* methods are not conclusive and there are doubts related to genotoxicity potential, an *in vitro* genotoxicity test battery or *in vitro* transformation test for carcinogenicity can be applied to clarify these end-points. The *in vitro* genotoxicity testing methodologies are well described in the several adopted OECD TG. Please refer to the OECD Guidance Document on Revisions to OECD Genetic Toxicology Test Guidelines²² or to the OECD web site for the last update on adopted TG. In the battery, it would be necessary to include tests able to identify point mutations in prokaryotic and mammalian cells as well as chromosomal aberrations or *in vitro* micronucleus assay and DNA damage and repair (for details, see also the SCCS Note for Guidance 9th Revision, 2016)²³.

In vitro methods to address local toxicity (i.e. phototoxicity, skin corrosion and irritation, eye irritation, skin sensitisation) are available (see table 1) and should be performed, whenever relevant, using the air-liquid interface.

IT is more difficult, however, to address systemic toxicity by means of *in vitro* testing only, since at the moment no adopted TGs are available.

For carcinogenicity, two cell transformation assays have been included in OECD guidance Documents (table 1), which - using an IATA with *in silico* and read across data - could give sufficiently robust information.

Only a few *in vitro* studies are available to address only very specific reactions possibly leading to reproductive problems, such as *in vitro* binding to estrogen and androgen receptors (see the OECD conceptual framework to evaluate endocrine disrupting chemicals). Nevertheless, they can be included, and evaluation should be carried out also considering the indication coming from QSAR and read across in a WoE approach.

¹⁹GUIDANCE DOCUMENT FOR DESCRIBING NON-GUIDELINE *IN VITRO* TEST METHODSSeries on Testing and Assessment No. 211

²⁰<http://publications.jrc.ec.europa.eu/repository/bitstream/JRC96418/eurl%20ecvam%20toxicokinetics%20strategy.pdf><http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO%282015%2922&doclanguage=en>

²¹ http://ihcp.jrc.ec.europa.eu/our_lab/eurl-ecvam

²²<https://www.oecd.org/chemicalsafety/testing/Genetic%20Toxicology%20Guidance%20Document%20Aug%2031%202015.pdf>

²³http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_190.pdf

Cytotoxicity testing after repeated exposure (e.g. 14 days) is considered a possible end-point of choice (acute toxicity is not relevant for tobacco products, hence also for additives). Positive and negative controls should be used, cells of human origin have to be preferred; non-specific tests as well as organ specific cells should be used (e.g. cells coming from the lung or intestinal cells, accounting for inhalation and swallowing of smoke, but also cells representing CNS, cardiovascular system, etc. to be evaluated on a case-by-case basis). For a correct interpretation of results, it should be considered that whenever cell lines are used, they are generally characterised by a low and unbalanced metabolic capability, therefore at least one of them should maintain this function over the treatment period (e.g. HepaRG cells) or primary cells should be used. The use of primary cell lines can also account for the interindividual variability that in some cases is translated to differences in susceptibility to toxic effects.

The major endpoints evaluated in *in vitro* cytotoxicity assays include the effect of a substance on cell viability (survival) and growth rates, but other end-points (such as mitochondrial functionality, induction of apoptosis) can be included. Cytotoxicity testing is used in the area of medical devices: methods to be considered can be found within the harmonised European standard ISO 10993-1:2009 "Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process". The ISO 10993 – 5:2009 describes test methods to assess the *in vitro* cytotoxicity of medical devices.

However, the study design should take into account that the most relevant route of exposure for tobacco additives is inhalation.

There has been significant progress made in recent years in approaches to expose cells *in vitro* to chemicals that pose a toxicological concern via the inhalation route (Aufderheide *et al.*, 2011; Bakand and Hayes, 2010). A number of *in vitro* exposure systems have been developed (although not yet validated) to facilitate the study of the effects of the whole smoke mixture on both mammalian and bacterial cells, and this has been the subject of a recent review (Thorne and Adamson, 2013).

Current cell-based *in vitro* models of the respiratory tract consist mainly of 2D monolayers of primary tracheobronchial epithelial cells or an immortalised cell line cultured on a semipermeable membrane insert at an air-liquid interface to induce cell polarization, differentiation, and mucus production (Forbes *et al.*, 2005). A more sophisticated technique that enables the stable and reproducible exposure of cultivated cells to cigarette smoke at the air-liquid interface such as CULTEXW Radial Flow System (RFS) module has been proposed recently (Rach *et al.*, 2013).

It was documented that air-liquid interface culture played a significant role toward the *in vitro* recapitulation of the *in vivo* environment, presenting the cells with an apical side resembling the lumen of the respiratory tract and a basolateral side representing vascular supply of nutrients (Berube *et al.*, 2010), with increased expression of cilia in primary cells and differences in barrier and mucus-secreting properties of cell lines observed (de Jong *et al.*, 1994, Grainger *et al.*, 2006). However, the absence of an extracellular component with co-cultured cells in a 3D environment can result in an oversimplification of the airway barrier, lacking in physiological relevance. Therefore, more sophisticated models based on 3D human normal and diseased tissue are required to provide *in vitro* models that improve validity of tested compounds in humans. Much of respiratory tissue engineering research has seen a transition from single cell-type culture

on inserts toward co-culture and the inclusion of scaffold material. Accordingly, models, in which the epithelium is cultured at an air-liquid interface over a scaffold substrate embedded with co-cultured cells, are the subject of much interest and are even available now as commercial 3D research products, such as the MatTek EpiAirway-FT technology (Berube *et al.*, 2010). Indeed, there is an overall consensus in the literature that introducing an epithelial cell analogue into the co-culture environment, often through the use of a biomaterial scaffold, could enhance cell culture, cell-cell signalling, and functionality. A triple co-culture system, in which human bronchial epithelial cells A 549, human mesenchymal cells and dendritic cells were cultured in monolayers, has shown promise for studying immunological responses to inhaled particulates (Rothen-Rutishauser *et al.*, 2005, Herzog *et al.*, 2013), Co-culture of Calu-3 cells with Wi38 lung fibroblasts was achieved on the scaffold to create a submucosal tissue analogue of the upper respiratory tract, validating system as a platform to support co-culture and cellular organisation reminiscent of *in vivo* tissue architecture. These scaffolds were validated as a substrate to support functional mucus express from an airway epithelium. Calu-3 cells cultured on CHyA-B scaffolds also expressed the tight junction protein ZO-1 and F-actin, indicating the formation of an epithelial barrier layer on the constructs and differentiation of the Calu-3 cells. Recently, another *in vitro* model system using tissue-engineered constructs has been developed which might improve our understanding of epithelial tissue and disease and use for testing toxicity of different compounds (O'Leary *et al.*, 2016).

Tobacco smoke assessment *in vitro* has traditionally focused on the particulate phase captured on a Cambridge filter pad and eluted in DMSO (Crooks *et al.*, 2013) or bubbled through cell culture media or PBS (Andreoli *et al.*, 2003). Cell cultures are then exposed under submerged conditions to the particulate phase. The gas vapour phase of cigarette smoke has been also considered as described in Health Canada Official Method T-501, T-502, and T-503.

Submerged culture conditions and particulate-based exposures do not represent physiologically that of mainstream tobacco smoke exposure in the human lung. Furthermore, separating smoke fractions in this way could lead to alterations and chemical changes that may not be representative of the whole smoke aerosol. In order to address these challenges, whole smoke exposure systems have been developed. Whole smoke exposure systems offer many technical challenges, but represent a more physiologically relevant test system that captures the full interactions of both the particulate and vapour phases together (Fukano *et al.*, 2004). An additional advantage of these systems is that a multitude of different cell cultures can be exposed at the air-liquid interface (ALI) to whole smoke, better simulating human exposure (CORESTA, 2006).

Whole smoke exposure systems offer the advantage that all phases of smoke can be analysed together or independently depending on the experimental set-up. This has allowed researchers to tailor their experiments to investigate both phases of tobacco smoke, yielding useful information. There is a variety of whole smoke systems available and the majority of these systems can also be used to deliver individual aerosols or other complex aerosol mixtures to cell cultures. However, there are no defined regulatory protocols for tobacco whole smoke exposure systems, and so far there is no recognised approach to the measurement of dose. The vapour phase of cigarette smoke within these systems remains poorly understood. With the variety of exposure options

available to researchers and bespoke systems relatively easy to fabricate or replicate, dosimetry tools may bridge the gap and play an important role, not only in the measurement of actual cellular dose but also in the characterisation and validation of these systems (Thorne and Adamson, 2013).

There are continuous efforts to introduce existing testing methods into regulatory framework of tobacco products risk assessment: product testing protocols are being developed for assays such as Ames bacterial mutagenicity and Neutral Red Uptake (NRU) cytotoxicity (Adamson *et al.*, 2014).

The Cooperation Centre for Scientific Research Relative to Tobacco (CORESTA, 2004) *in vitro* Toxicology Task force of industry recommends using a test battery composed of the following assays:

1. A bacterial mutagenicity assay. The Ames Salmonella mutagenicity assay is recommended.
2. A mammalian cell assay for cytogenetics/mutation. The Task Force recommends the micronucleus assay, the chromosome aberration assay or the L5178Y mouse lymphoma assay.
3. A cytotoxicity assay conducted with an appropriate mammalian cell line. The Task Force recommends the neutral red cytotoxicity assay (CORESTA, 2004).

Analysis of the recent publications has shown that these recommendations are used increasingly in the toxicity assessment of different tobacco products (see e.g. Manuppello and Sullivan, 2015).

Considering non-cancer endpoints, a battery of *in vitro* tests have been proposed for assessing CVD risk associated with cigarette smoking (Fearon *et al.*, 2013). The battery is comprised of functional *in vitro* assays to model endothelial damage, angiogenesis, and migration of vascular smooth muscle cells as initial and subsequent events in CVD (Fearon *et al.*, 2013). Other tests, such as for oxidative stress or inflammatory response, may be conducted to assess the adverse effects of cigarette smoke *in vitro*.

However, it is the opinion of the SCHEER that the choice of the test battery should not be fixed *a priori*, and should be rather tailored on the basis of information coming from the *in silico* and read-across analysis (e.g. bridging *in vitro* studies can be necessary to support the read across).

Table 1 summarises the most recent, internationally accepted, validated *in vitro* methods, which may be used for the toxicity assessment of the tobacco products.

Modified after AltTox (<http://alttox.org/mapp/table-of-validated-and-accepted-alternative-methods>) and PISC (<http://www.piscldt.org.uk/alternatives-approved-by-regulators/>).

Table 1: *IN VITRO* METHODS ADOPTED FOR REGULATORY USE

Toxicity endpoint	<i>In vitro</i> methods	Recommendations and standard methods (OECD)	
ACUTE TOXICITY	3T3 neutral red uptake (NRU) cytotoxicity test to estimate starting doses for oral acute systemic toxicity	OECD GD 129, published in 2010	
	NHT neutral red uptake (NRU) cytotoxicity test to estimate starting doses for oral acute systemic toxicity	OECD GD 129, published in 2010	
ACUTE PHOTOTOXICITY	3T3 neutral red uptake (NRU) phototoxicity test	OECD TG 432, published in 2004	
SKIN IRRITATION	Integrated approach on testing and assessment (IATA)	OECD GD 203, published in 2014	
	Reconstructed human epidermis (RhE) test	EpiSkin™ (L'Oréal, France)	OECD TG 439, revised in 2015
		EpiDerm™ (MatTek, US)	OECD TG 439, revised in 2015
		SkinEthic™ (L'Oréal, France)	OECD TG 439, revised in 2015
		LabCyte EPI-Model (J-TEC, Japan)	OECD TG 439, revised in 2015
SKIN ABSORPTION/PENETRATION	<i>In vitro</i> diffusion method	OECD TG 428, published in 2004	
SKIN SENSITISATION	Adverse outcome pathway (AOP) for skin sensitisation	OECD series on testing and assessment 168, published in 2012	
	Direct peptide reactivity assay (DPRA)	OECD TG 442C, published in 2015	
	ARE-Nrf2 luciferase test method (e.g. KeratinoSens™ assay)	OECD TG 442D, published in 2015	
	Human cell line activation test (h-CLAT)	OECD TG 442E, published in 2016	
CARCINOGENICITY	Cell transformation assay (CTA) (Syrian hamster embryo cell transformation assay (SHE CTA))	OECD Guidance Document Env/JM/Mono(2015)18, May 2015	
	<i>In vitro</i> cell transformation assays (CTA) Bhas 42 cell transformation assay (Bhas 42 CTA)	OECD Guidance Document Env/JM/Mono(2016) 1, January 2016	

Besides these internationally validated methods and the ISO 10993 – 5:2009 adopted for medical devices, there is a great number of other methods employing technological innovations, such as reconstituted human tissue cultures, 3-D organotypic cultures comprised of differentiated human cells in co-cultures, air-liquid interface exposure systems, cell transformation assays and high content genomic analysis, that are used for tobacco product analysis.

3.4.3.5 Addictiveness testing

Tobacco comprises of thousands of substances, of which nicotine is the most characterising and most addictive component. Additives, as well as natural tobacco substances other than nicotine, may have addictive capacities themselves or can interact with nicotine and the nicotine receptor system, herewith enhancing the effects of nicotine. For example, these additives can have effects on nicotine bioavailability, duration, and concentration in the blood circulation or nicotine-dependent activation of mesolimbic pathways in the brain. The term 'dependence potential' is commonly used to describe addictive capacity.

Guidelines to assess the impact of tobacco product contents on dependence potential could be similar to those already established for testing the dependence potential of pharmaceutical products (the used methods are known as Abuse Liability Assessment). Special challenges include product complexity and the diverse range of tobacco products (Henningfield *et al.*, 2011; WHO Study Group on Tobacco Product Regulation TobReg, 2012). For example, the US FDA has issued guidance that covers dependence potential assessment for a range of different substances, formulations, and product types in which factors such as additives and product design features may act to either promote or deter dependence potential (U.S. Dept. of Health and Human Services, 2010, 2015).

Experimental testing of the dependence potential of tobacco additives is still limited due to the lack of validated administration models for the examined individual compound itself and in co-administration with other tobacco additives. In the proposed step-wise approach, the possibilities to experimentally quantify the dependence potential of tobacco additives (often) co-administered with nicotine is discussed.

In silico

Nicotinic acetylcholine receptor (nAChR) Computer models. nAChRs are ligand-gated cation channels found throughout the central and peripheral nervous systems (Gotti *et al.*, 2006; Jensen *et al.*, 2005). Neuronal nACh receptors participate in many neurological processes including cognition (Levin and Simon, 1998), pain sensation (Damaj *et al.*, 2000), and nicotine reward mechanisms (Dani and De Biasi, 2001; Pavlovicz *et al.*, 2011; Tapper *et al.*, 2004). In the past years several nAChR *in silico* models have been developed integrating protein (sub-) structures, dynamics and functional relationships. Among those, the most widely expressed nAChR subtype in the brain is the neuronal $\alpha 4\beta 2$ nACh receptor (Haddadian *et al.*, 2008). The $\alpha 4\beta 2$ nAChR comprises high-affinity nicotine-binding sites (Tapper *et al.*, 2004) but the mechanism how ligand binding leads to channel opening remains elusive. The quality of the current $\alpha 4\beta 2$ nAChR model was evaluated using flexible docking of nicotine docking to the closed- and open-channel models. Besides the potential nicotine interactions with surrounding residues that could stabilize nicotine positions, a high degree of involvement of aromatic residues in the nicotine binding sites was also observed (Haddadian *et al.*,

2008). Further development of these models may provide information about how nicotine and other tobacco additives (ligands) regulate nAChR activation in smoking dependence.

Ligand-based Monoamine oxidase (MAO) models. The enzyme MAO plays an important role in the metabolism of several neurotransmitters by oxidative deamination. MAO-A inhibition is associated with enhanced dopamine activity leading to increased reinforcement behaviour. The combustion of, among others, natural or added (poly-)sugars in tobacco products result in acetaldehyde which reacts in the body with tryptophan and tryptamine. This reaction results in the formation of the beta-carbolines, harman and norharmane, which are MAO inhibitors (Herraiz and Chaparro, 2005; Talhout *et al.*, 2007). Other examples of MAO inhibitors isolated from tobacco leaves or present in tobacco smoke are 2,3,6-trimethyl-benzoquinone, 2-naphthylamine and a coffee-extracts and synthesized and modified natural coumarin derivatives (Fowler *et al.*, 2003; Gnerre *et al.*, 2000; He *et al.*, 2014; Herraiz and Chaparro, 2006).

Ligand-based models can provide new insights in enzyme selectivity, mechanisms of action and the relationship between the MAO inhibitory activity and the molecular structure of the different inhibitors (Vilar *et al.*, 2012). There are different types of ligand-based models which can be used, such as Quantitative Structure-Activity Relationship (QSAR) with 2D and 3D descriptors (Johnson, 1976; Vilar *et al.*, 2008; Winkler, 2002), 3D- Comparative Molecular Field Analysis (CoMFA) (Cramer *et al.*, 1988; Zhang *et al.*, 2011), 3D-pharmacophores (Langer and Hoffmann, 2006) or ligand-network models (Keiser *et al.*, 2007; Park and Kim, 2008). QSAR studies have become one of the most popular ligand-based approaches in modern chemistry (Shelke *et al.*, 2011; Vilar *et al.*, 2008; Vilar *et al.*, 2012) and can also be used to model ligand-based selectivity of different tobacco additives and the potency to inhibit MAO activity.

In vitro

Three-dimensional lung tissue constructs (3D lung-on-a chip) and mathematical computer models. These kinds of models are the results of the integration between *in vitro* models (the 3D organ-on-a-chip) and *in silico* models. It has been shown that inhalation during smoking results in a rapid brain increase of nicotine in the brain thereby contributing to nicotine dependence in smokers. Inhalation can be facilitated by certain additives leading to deeper and more frequent inhalation by the cigarette smoker resulting in an increase in lung exposure and nicotine uptake. Additives (e.g. menthol, theobromine and eucalyptol) can achieve this by enhancing sensory properties such as cooling effects or by having local anaesthetic and bronchodilating properties (Usmani *et al.*, 2005). Also, a change in the physical properties of tobacco (e.g. particle size) can be altered by certain additives to allow (nicotine) particles to enter deeper levels of the lungs (SCENIHR, 2010).

The efficiency of nicotine uptake and tobacco additives via the lung in the blood stream is difficult to measure. Engineered 3D lung tissue constructs and mathematical computer models can be used to provide predictive information on lung uptake and particle deposition (Asgharian *et al.*, 2012; Nichols *et al.*, 2014; Nichols *et al.*, 2013). These engineered 3D models of human tissue mimic *in vivo* conditions and allow for more natural and robust human *in vitro* respiratory tract models compared to multi-cell *in vitro* models. These constructs can be used to assess cell-based responses, physiologic functions, pathologic changes and even toxicity or responses to tobacco additives.

The (3D) airway models or lung-on-a-chip models can be also used to measure experimentally effects due to any additive in **altering nicotine uptake** such as alkalizing compounds or that result in easier absorption of nicotine by epithelial.

Capacity to change pH values. Additives that exert capacities to increase the pH values will result in higher amounts of uncharged nicotine (Hurt and Robertson, 1998; Wayne and Carpenter, 2009). This may result in more easily absorption of nicotine by the epithelial cells in the mouth and probably also in the lungs (Tomar and Henningfield, 1997). Opposing positions on smoke pH and its effect on unprotonated nicotine have been published and studies have been designed in an attempt to evaluate this effect empirically, but there is insufficient evidence available to prove or disprove this point. Although the tobacco industry stresses that the buffering capacity of the lung surface liquid (7mval/pH unit) at pH 7.4 is not changed by nicotine concentrations of 0.1 mg per puff (Holma and Hegg, 1989; Klus *et al.*, 2012), it is valuable to check additives or substances for their capacity to change the pH of the tobacco and the smoke.

(Inhibition of) The enzymatic activity of MAO. Additives may influence the dependence potential of nicotine by interacting with the neural responses to the drug. For example, MAO inhibitors that are not leading to dependence on their own slow the breakdown of monoamines such as DA, thereby affecting the overall motivational impact of nicotine. Inhibition of the enzymatic activity of MAO can be measured *in vitro* using peroxidase-linked spectrophotometric assay. Enzymes can be isolated from rat liver microsomes or by recombinant generated enzymes. Using recombinant human MAO-A and MAO-B, IC50 values for enzyme inhibition can be experimentally determined (Lewis *et al.*, 2007). *In vivo* MAO activity can be analysed using PET (see paragraph 'neurobiological effects using imaging techniques' below).

CYP metabolism inhibitor ratio. The metabolism of nicotine is a complex pathway : as first step it is metabolized in the liver by cytochrome CYP2A6 and CYP2B6 enzymes, which can be induced or inhibited by some chemicals (Hukkanen *et al.*, 2005). Inhibition of nicotine metabolism enhances its bioavailability and alters the behavioural effects in mice (Alsharari *et al.*, 2014; Bagdas *et al.*, 2014). Additives modulating the activity of metabolic pathways are therefore likely to affect the dependence potential of nicotine. The effectiveness of an additive in inhibiting nicotine metabolism is expressed as relative CYP inhibitor ratio (Rahnasto *et al.*, 2008). The inhibitory concentration of human CYP2A6 can be tested in an *in vitro* assay using recombinant enzyme or human liver microsomal preparations (Rahnasto *et al.*, 2003). Examples of known tobacco additives that inhibit CYP2A6 enzymes are menthol, benzaldehydes and several lactones added to tobacco (Benowitz *et al.*, 2004; Kabbani, 2013; Kramlinger *et al.*, 2012; Rahnasto *et al.*, 2003).

In vivo (not recommended as the first choice)

Analysis of nicotine as Biomarker of exposure in humans. Nicotine bioavailability is defined by an optimal rate of adsorption and distribution from the lungs into the bloodstream. Upon uptake in the lungs, the bioavailability of nicotine in the body is determined by properties such as its hydrophobicity and solubility. It has been proposed that the use of alkalizing compounds (such as ammonia) as tobacco additive increases the absorption of nicotine in the lungs. A biomarker analysis of nicotine in blood samples from smokers of cigarettes with different ammonia yields was performed to evaluate the effects on nicotine bioavailability. Different ammonia yields in cigarettes did not increase

the rate or amount of nicotine absorption from the lungs to the arterial blood circulation (McKinney *et al.*, 2012; van Amsterdam *et al.*, 2011). It cannot be excluded from these studies that ingredients other than ammonium salts influence nicotine adsorption in a similar way.

Dopamine (DA) release and turn over. Activity of neurons in the mesolimbic DA brain area is not only measured by nACh receptor activation but also by measuring the result of this receptor activation, a change in the release or turnover of DA. DA release and turnover can be measured either *ex vivo* or *in vivo* via isolation of specific brain tissue or microdialysis. A study in mice showed up-regulation of nAChR subtypes in various brain regions upon exposure to nicotine and menthol using western blots. A significant increase in nicotine plasma levels was observed, which was accompanied by an increase of withdrawal intensity (Alsharari, 2015).

Neurobiological effects using imaging techniques. Exerting additive effects on nicotine dependent activation of the mesolimbic pathway can be studied *in vivo* using several neuroimaging techniques like functional magnetic resonance imaging (fMRI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT) (Jasinska *et al.*, 2014). Each technique can be used to understand only some aspects of processes involved in tobacco consumption like brain structure (MRI), different aspects of brain function (PET, SPECT, fMRI, and ASL), and pharmacokinetics (PET, SPECT) in animals as well as humans (Kober and Deleone, 2011).

The neuronal activity upon exposure to nicotine and other tobacco additives can be measured by the activation of nACh receptors, neurotransmitter release and transcriptional activation of specific mRNAs (van de Nobelen *et al.*, 2016). Labelling and tracing of nicotine, MAO or nAChR can demonstrate nicotine occupancy at nAChRs, nAChR availability and upregulation of nAChRs induced by tobacco smoking (Brody *et al.*, 2014; Jasinska *et al.*, 2014; Volkow *et al.*, 1999). Substances that inhibit the nicotine degradation or metabolism or serve as a carrier for nicotine can be identified by these derivative endpoints.

PET. PET is a common functional neuroimaging technique which uses a short-lived radioactive tracer (incorporated into a biologically active molecule as glucose) infused into a living subject. As the tracer decays, the PET system detects pairs of gamma rays that are indirectly emitted in the process, and uses them to localise the tracer to a particular region in the brain. In this way, the concentration of tracer molecules can be estimated at different locations in the brain or other tissue. Several tracers are discussed below.

Radiotracers:

- **for nicotine.** A PET study with radiolabelled nicotine [¹¹C]nicotine demonstrated that a single puff leads to a rapid rise in brain nicotine concentration with a gradual wash-out period (Berridge *et al.*, 2010). In addition, the nicotine accumulation in the brain during smoking of one full cigarette increases in a linear fashion with successive puffs, rather than in puff-associated spikes and rapid wash-outs. Relating to this finding, the authors reported that dependent smokers showed a slower rate of brain nicotine accumulation than non-dependent smokers (Kober and Deleone, 2011; Rose *et al.*, 2010).

- **for $\alpha 4\beta 2$ nACh receptors.** Researchers have also developed brain-imaging radiotracers for $\alpha 4\beta 2$ nACh receptors with radiolabelled A-85380 compounds (Abreo *et al.*, 1996) or analogues (2-FA /6-FA for PET and 5-IA for SPECT), having the most widespread use (Koren *et al.*, 1998). However, the slow kinetics of these radio ligands restricts the large-scale use in experimental studies (Sabri *et al.*, 2015). New generation $\alpha 4\beta 2$ nAChR specific radioligands are now under development, like [^{18}F]Flubatine, [^{18}F]AZAN and [^{18}F]nifene, demonstrating faster kinetic properties in PET research (Brust *et al.*, 2008; Hillmer *et al.*, 2011; Hockley *et al.*, 2013; Kuwabara *et al.*, 2012; Wong *et al.*, 2013).

PET imaging studies demonstrated the effect of cigarette smoking on $\alpha 4\beta 2$ nAChR occupancy, showing that smoking causes displacement of 2-FA for prolonged time (at least several hours) (Brody *et al.*, 2006a). Dose-dependent reduction in 2-FA displacement was observed by both controlling the number of puffs smoked and the nicotine concentration smoked (Brody *et al.*, 2009). These findings suggest that nicotine mediates 2-FA displacement by occupying $\alpha 4\beta 2$ nAChRs. Several authors, using 5IA-SPECT and 2-FA-PET, have shown that habitual cigarette smoking is associated with up-regulation of $\alpha 4\beta 2$ nAChRs (Cosgrove *et al.*, 2009; Mamede *et al.*, 2007; Mukhin *et al.*, 2008; Staley *et al.*, 2006; Wullner *et al.*, 2008). The nAChR density returns to normal after a prolonged abstinence of weeks to months (Cosgrove *et al.*, 2009; Mamede *et al.*, 2007). In addition, exposure to nicotine from second-hand smoke resulted in substantial brain $\alpha 4\beta 2$ nAChR occupancy in smokers and non-smokers (Brody *et al.*, 2011). Taken together, these results suggest that exposure to cigarette smoke, most likely through the effects of nicotine, influences $\alpha 4\beta 2$ nAChR density in the human brain (Lotfipour *et al.*, 2011).

- **for Dopaminereceptor (DA).** With radiotracers such as [^{11}C]raclopride and [^{11}C]PHNO (PET) or [^{123}I]IBZM (SPECT), striatal DA release has been reliably measured using PET and SPECT imaging (Laruelle, 2000). An increase in DA competes with the radiotracer to bind at the dopamine receptor; resulting in a decrease in radiotracer binding compared to baseline. This allows calculation of the 'occupancy' of the receptors by DA or a change in binding potential and is an indirect measure of DA release based on the 'occupancy model' (Cosgrove *et al.*, 2015; Laruelle, 2000).

Many studies have examined nicotine and tobacco smoking-induced DA release in human subjects. All these studies confirm that smoking elicits ventral striatal dopamine release and is associated with a reduction of craving (Barrett *et al.*, 2004; Brody *et al.*, 2006b; Brody *et al.*, 2004; Montgomery *et al.*, 2007; Scott *et al.*, 2007; Takahashi *et al.*, 2008). In the most recent study, smokers were imaged with [^{11}C] PHNO before and after a cigarette (Le Foll *et al.*, 2014). Binding potential was reduced after smoking by 12 and 15 % in D2-rich and D3-rich regions, respectively.

A major concern with the existing studies is the timing of the dopamine response. The response to smoking a cigarette is a transient increase in DA. The analysis in these studies, however, use an average of all the data collected over 30 min to up to 2 h. This significantly dilutes measurement of a transient dopamine response (Sullivan *et al.*, 2013). Thus, analysis techniques with improved

temporal resolution may be better suited to more transient DA release (Cosgrove *et al.*, 2015).

- **for μ -opioid receptors.** There is strong evidence for a link between nicotine administration and endogenous μ -opioid mechanisms, mediating some of nicotine's addictive properties and distress during withdrawal (Nuechterlein *et al.*, 2016). Acute endogenous opioid release upon nicotine administration was demonstrated in animal and cell culture studies (Boyadjieva and Sarkar, 1997; Davenport *et al.*, 1990). However, in human studies the findings are inconsistent. The indirect measures of neurotransmitter release and μ -opioid receptor activation upon nicotine administration, as measured with PET, have shown both a reduction in binding potential (suggesting activation of neurotransmission) and an increase in binding potential (deactivation) or no significant change in different regions of the brain (Domino *et al.*, 2015; Kuwabara *et al.*, 2014; Ray *et al.*, 2011; Scott *et al.*, 2007). Measures at baseline have also shown either lower or no significant differences between smokers and non-smoking controls (Kuwabara *et al.*, 2014; Scott *et al.*, 2007). The μ -opioid system is suggested to be strongly influenced to placebo treatment (Nuechterlein *et al.*, 2016; Pecina *et al.*, 2015; Scott *et al.*, 2008; Zubieta *et al.*, 2005). Therefore, studying the opioid system does not appear to be the most sensitive and robust way to define tobacco dependence.

How the administration of tobacco additives changes these effects as measured is largely unknown. A recent PET study showed that in brains of female menthol cigarette smokers, nicotine accumulated faster thereby contributing to dependence. However a role of menthol in enhancing brain nicotine accumulation was not supported by this study (Zuo *et al.*, 2015). Another PET study using labelled nAChR subunits showed an upregulation of these receptors in the brain of menthol smokers, indicating a higher nicotine exposure in smokers of menthol cigarettes (Brody *et al.*, 2013). However, other mechanisms for menthol-influencing receptor density are possible. Analysis of nicotinic acetylcholine receptor activity *in vitro* shows that menthol inhibits nAChR subtypes in a non-competitive manner (Ashoor *et al.*, 2013; Hans *et al.*, 2012).

SPECT. In SPECT, the same mechanism is used as in PET, but differs in a way that the radioactive tracer directly emits a single gamma ray during decay. The nature of the signal allows for lower resolution images than PET as the SPECT tracers typically have a longer half-life, but scans are more easily performed. There are differences in the physics and chemistry used in PET versus SPECT, but the outcome measure of receptor availability is the same. Depending on the tracer used, PET and SPECT data can quantify regional brain activity (e.g. via glucose metabolism when the tracer is a modified sugar, as in ^{18}F -fluorodeoxyglucose), receptor occupancy (e.g. with ^{11}C -raclopride and dopamine receptors), and pharmacokinetics when multiple measurements are taken after drug consumption.

Functional Magnetic Resonance Imaging (fMRI). Besides PET, which is already an advanced technique in this field of research, fMRI is a promising and non-invasive upcoming technique. In fMRI, blood oxygen levels (brain activity) can be measured in the brain by use of strong magnetic fields. In the first fMRI study on the effect of acute nicotine administration, active smoking participants were injected with nicotine in

different concentrations. A dose- and time-dependent increased BOLD signal occurred in several cortical and subcortical regions, with prominent signal changes in the cingulate cortex, dorsolateral and medial orbitofrontal regions (Stein *et al.*, 1998) as well as the ventral striatum, amygdala, thalamus and insula (Menossi *et al.*, 2013). fMRI studies assessing tobacco additives with a (passive) inhalation tobacco devices can be used to identify brain areas involved in addiction. As there are no validated administration models for smoking or nicotine administration which can be used during scanning, this is an important limiting factor in fMRI research.

The majority of the above-mentioned imaging studies focus on chronic exposure in a cross sectional design (smokers vs. non-smokers) at a single point in time. When focusing on the dependence capacity of tobacco additives, studies on acute effects using within subject measurements (placebo vs. additive(s) of interest) is regarded as more valuable. This will improve the sensitivity to picking up small changes in neuronal activity caused by administration of the additive. Repeated exposure and repeated measurements can predict dependence capacity. Further improvement of the study protocol and development of even more efficient radio ligands may be beneficial to finding indications for tobacco additives that increase dependence.

Behavioural responses in rodents. Current animal models for tobacco product dependence are based on assessing nicotine dependence rather than dependence of tobacco additives or tobacco products as a whole. These models aim to deliver pure nicotine using an intravenous self-administration paradigm despite the fact that nicotine itself is regarded as a relatively weak reinforcer (Caille *et al.*, 2012). Current tests to analyse dependence potential can monitor self-administration, speed of acquisition, conditioned rewarding effects and drug discrimination (Hoffman and Evans, 2013; Wilkinson and Bevins, 2008; Yararbas *et al.*, 2010). Also severity of withdrawal can be measured (Bagdas *et al.*, 2014). Animal models also allow controlling of factors that can affect study outcome such as environmental factors, genetic background and prior drug exposure. The self-administration paradigm has been widely accepted as a reliable animal model with high predictive value for the dependence potential of a drug and can be used to support findings observed in humans. The current available models can possibly be adapted to assess the effect of (nicotine in combination with) other tobacco-related additives on dependence. A recent animal study showed that the sensory properties of menthol can serve as a conditioned reinforcer for nicotine (Wang *et al.*, 2014).

Behavioural outcome measures in human. Several behavioural measures can be used to assess dependence in human. Dependence for nicotine and smoke(less) tobacco can be self-assessed using the Fagerström Test for Nicotine Dependence (FTND) or the cigarette withdrawal scale (CWS-21) (Etter, 2005; Etter *et al.*, 2003; Fagerstrom, 2012). The FTND uses a twelve-item cigarette dependence scale that covers the main definitions of dependence: compulsion, withdrawal symptoms, loss of control, neglect of other activities, time allocation and persistence despite harm. The FTND can assess the degree or severity of tobacco dependence using a scale indicative for the level of dependence.

The cigarette withdrawal scale (CWS-21) is a 21-item multidimensional self-administered scale that measures withdrawal symptoms and predicts relapse to smoking (Etter, 2005). Recently, a revision for DSM-V was proposed in order to increase the predictive

value of these criteria for tobacco dependence assessment (American Psychiatric Association, 2013; Baker *et al.*, 2012).

Indicators of nicotine dependence were assessed in menthol and non-menthol cigarette smokers using the FTND. Differences were observed in time to first cigarette of the day (TTF) suggesting greater urgency to smoke but not on amount of cigarettes smoked on a day (CPD) (Collins and Moolchan, 2006; Hoffman and Simmons, 2011). An important limitation of these methods is that these tests are a diagnostic instrument for assessing dependence in people and not necessarily the dependence potential of the given substance or product type. However, these questionnaires can be adapted for the assessment of dependence to tobacco-related additives.

Recommendations

To accurately assess tobacco dependence potential for regulatory purposes, it is necessary to use multiple evaluation methods, whereby several factors associated with tobacco dependence are analysed. Combinations of techniques examining neurochemical physiological and behavioural changes in specific brain regions with nicotine dependence may provide sufficient and robust information. Correlations between responses and convergence of studies will lead to evidence-based conclusions. For regulatory purposes, consensus needs to be established on the (combination of) tests that are preferred. The SCHEER therefore proposes to use a step-wise approach of 1) *in silico*, 2) *in vitro*, 3) *ex vivo*, and 4) *in vivo* methods- only in exceptional cases, to be agreed with the Receiving Authority on a case-by-case basis. The use of *in vivo* studies is indeed questionable for ethical reasons, therefore the performance of new studies are only justified under exceptional circumstances. After negative results of testing the tobacco additive on dependence capacity in the first agreed appropriate method (*in silico*), the next step should be considered, and appropriate test(s) should be selected (*in vitro* models), and so on. It is strongly recommended that *in silico* and *in vitro* tests to assess additive-induced addictiveness are developed and validated in the future by independent organisations.

3.4.3.6 Characterising flavour and inhalation facilitation properties

This section will discuss a procedure to assess tobacco products with characterising flavours that are prohibited in the TPD, as well as some other mechanisms such as inhalation facilitation, that may contribute to additive-induced attractiveness.

Animal models do not currently exist for this kind of assessment. In humans, the attractiveness of individual tobacco products can be compared in panel studies, surveys and by experimental measures. To test the response to a specific additive, tobacco products can be produced to exclude or include individual additives. However, this type of research is difficult nowadays due to ethical considerations that will often preclude human testing (SCENIHR, 2010).

Characterising flavours

Over 80% of all Dutch cigarettes contain at least one flavour, and almost half of all additives in any tobacco product is added as a flavour (Pennings *et al.*, 2016). Flavours may be added to tobacco, cigarette paper, the filter or to the foil wrapper, in an attempt to enhance the tobacco flavour, mask unpleasant odour, and deliver a pleasant cigarette-pack aroma (WHO, 2007). Many different additives are used to create a specific taste/flavour in order to attract certain target groups. Regarding flavour, the EU

Tobacco Product Directive (TPD, Article 7) prohibits cigarettes and roll-your-own tobacco having a characterising flavour other than the of tobacco, as they could facilitate initiation of tobacco consumption or affect consumption patterns (European Union, 2014). A characterising flavour is defined as a '*clearly noticeable smell or taste other than one of tobacco, resulting from an additive or a combination of additives, including, but not limited to, fruit, spice, herb, alcohol, candy, menthol or vanilla, which is noticeable before or during the consumption of the tobacco product.*' The prohibition of tobacco products with characterising flavours does not preclude the use of individual additives outright, but it does oblige manufacturers to reduce the additive or the combination of additives to such an extent that the additives no longer result in a characterising flavour.

Talhout *et al.* (2016) published an inventory of methods suitable to assess additive-induced characterising flavours of tobacco products, and concluded that because flavour perception is subjective and requires human assessment, sensory analysis in consumer or expert panel studies is necessitated. They recommend developing validated tests for descriptive sensory analysis in combination with chemical-analytical measurements. Testing a broad range of brands, including those with quite subtle characterizing flavours, will provide the range of concentrations above which an additive will impart a characterising flavour (Talhout *et al.*, 2016).

The Commission has recently adopted two implementing acts establishing the rules and mechanism for determining products with characterising flavours²⁴.

The determination of such flavours can concern products before consumption (e.g. before combustion) as well as emissions resulting from normal use (direct and indirect) of the products. To develop a method for determining characterising flavours and to perform some pilot experiments, the Commission contracted the HETOC Consortium in August 2014²⁵. The HETOC-consortium carried out, as an external contractor, a study on the determination of characterising flavours. Sensory testing complemented by chemical analysis was concluded to be an appropriate method to determine characterising flavours. Their pilot had confirmed that an expert panel is a good approach, but the training phase needs to be more extensive when the real panel is set up. Smelling is the preferred starting point for determining characterising flavours and it was recommended to consider, as a future step, whether a smoking experiment was needed. It was concluded that specific reference spaces for cigarettes and RYO are needed.

Beside the characterising flavour features, other phenomena can contribute to make a tobacco product more 'attractive'. According to the partial guidelines for implementation

²⁴Commission Implementing Regulation (EU) 2016/779 of 18 May 2016 laying down uniform rules as regards the procedures for determining whether a tobacco product has a characterising flavour

http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2016.131.01.0048.01.ENG&toc=OJ:L:2016:131:TOC

Commission Implementing Decision (EU) 2016/786 of 18 May 2016 laying down the procedure for the establishment and operation of an independent advisory panel assisting Member States and the Commission in determining whether tobacco products have a characterising flavour

http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2016.131.01.0079.01.ENG&toc=OJ:L:2016:131:TOC

²⁵http://ec.europa.eu/health/tobacco/products/implementation/characterising_flavours_en.htm

of Articles 9 and 10 of the WHO framework convention on tobacco control, “attractiveness” refers to factors such as taste, smell and other sensory attributes, ease of use, flexibility of the dosing system, cost, reputation or image, assumed risks and benefits, and other characteristics of a product designed to stimulate use. Note that not all of these properties are related to additives. WHO-FCTC advises Parties to regulate, by prohibiting or restricting, ingredients that may be used to increase attractiveness of tobacco products (WHO, 2012). The FCTC guidelines in relation to the regulation of the contents of tobacco products and regulation of tobacco product disclosures call in particular for the removal of ingredients that increase palatability, create the impression that tobacco products have health benefits, are associated with energy and vitality or have colouring properties.

The TPD includes two references to attractiveness. In the introductory considerations, point 13, it is mentioned that *“In order to carry out their regulatory tasks, Member States and the Commission require comprehensive information on the ingredients and emissions from tobacco products to assess the attractiveness, addictiveness and toxicity of tobacco products and the health risks associated with the consumption of such products.”* In article 19, Notification of novel tobacco products, it is mentioned that manufacturers and importers of such a product shall provide *‘available scientific studies on toxicity, addictiveness and attractiveness of the novel tobacco product, in particular as regards its ingredients and emissions.’*

In the following, the possibility to assess characteristics other than the characterising flavour as contributors to attractiveness are briefly presented, some of which having the possibility of “Facilitating inhalation or nicotine uptake”, which is a criterion of the mandate (category c) included in the ToR).

Other sensory attributes which can facilitate inhalation or nicotine uptake

Low irritation to mouth, throat and chest and satisfaction can facilitate inhalation and possibly nicotine uptake (Jaffe and Glaros, 1986; Kochhar and Warburton, 1990). Mildness, a combination of improved aftertaste, less bitterness, improved mouth feeling and reduced irritation, is reported to be appreciated, especially by younger and beginner smokers, with their undeveloped tastes and a low tolerance for irritation from tobacco smoke (Carpenter *et al.*, 2007).

Additives that influence these sensory attributes, such as mildness, and a pleasant aftertaste, possibly facilitate smoking initiation. By reducing and changing the harshness of the smoke, special target groups may be reached (Carpenter *et al.*, 2005a, Carpenter *et al.*, 2005b, Cummings *et al.*, 2002, Klein *et al.*, 2008, Wayne and Connolly, 2002). A confidential tobacco industry document describes a class of casing materials referred to as ameliorants used to *“...smooth out harshness and bitterness and/or eliminate pungent aromas from tobaccos”*(Jenkins *et al.*, 1997). Examples of such ameliorants included sugars, cocoa and liquorice. Cocoa, also at levels that do not impart a characterising flavour, can alter cigarette flavour and improve product acceptability (Sokol *et al.*, 2014). Various sugars constitute a large proportion of additives, and the sweetness of the smoke resulting from its caramel combustion products is an important characteristic. Thus, product appeal for starters may be further diminished by regulating trigeminal attributes as well. Smoking panels can be used to assess sensory attributes like irritation, impact, flavour, aftertaste. For irritation, it may also be possible to use *in vitro* models.

Some additives have multiple chemosensory effects. Pyrazines, which are flavours resulting from pyrolysis of amines and sugars, are reported to induce chemosensory effects such as reducing the harshness and irritating effects of nicotine and other tobacco smoke constituents in the airways. In addition, they may reinforce the learned behaviour of smoking, enhance elasticity and help optimise nicotine dosing. Wayne and Henningfield also describe evidence from internal industry documents that “smokers develop a taste for specific flavors or characteristics of tobacco use other than nicotine, and come to associate use with these characteristics” (Wayne and Henningfield, 2008). Vanilla, for example, increases mildness, and smokers will switch to other vanilla-containing brands, but not to brands without vanilla taste. Menthol is also known for its taste, as well as inducing a “cooling” effect which masks the harshness and the taste of raw tobacco (Lawrence *et al.*, 2011).

Harshness and smoothness. According to the tobacco industry definition, harshness is a chemically-induced physical effect associated with a roughness, rawness experience generally localized in the mouth and to a lesser degree in the upper reaches of the throat and the trachea due to inhalation of tobacco smoke. Harshness can also cause a drying, rasping, coarse, astringent sensation usually associated with the smoke flavour of Virginia or air-cured type tobaccos. Harshness is classically measured in four degrees: (i) Free – an absence of harshness; (ii) Touching – a slight awareness of a sensation; (iii) Scratchy – some discomfort, a stinging effect; and (iv) Harsh – rough, raw, raspy, coarse, astringent, painful inhalation. Reducing the harshness of the smoke makes it possible to inhale deeper and increase the number of puffs, as physical barriers will be reduced (Wayne and Henningfield, 2008).

The harshness depends partly on the tar/nicotine ratio, but may also be decreased by certain additives such as propylene glycol or levulinates. Tar provides a strong flavour and mouth sensation, masking the harsher, bitter taste of nicotine which may be unpalatable to new smokers and uncomfortable to established smokers. Certain highly flavoured additives may also have the same properties to “smoothen” or reduce the harsh irritation of nicotine in tobacco smoke. In order to make the smoke less aversive and permit deeper inhalation, additives such as liquorice and menthol are used. Another approach is to use nicotine salts that do not cause the same irritation, but are still delivering nicotine or keeping the nicotine effect by means of a quicker absorption by ensuring larger amounts of free nicotine (SCENIHR 2010, Bates *et al.*, 1999, Keithly *et al.*, 2005). Finally, the addition of humectants such as glycerol, propylene glycol and sorbitol keep the humidity of the tobacco product at a desired level; dry tobacco generates an unpleasant harsh smoke.

Impact and smoothness. The term “impact” is widely used in tobacco industry research and documents, and is a tobacco industry term for smokers’ subjective awareness of the drug effects of nicotine. Organic acids have been used since the 1950s to improve “smoothness” of cigarettes. For example, Philip Morris found that lactic acid decreased subjective ratings of harshness and bitterness, and produced a sweeter flavour. Citric additives have been used not only for reduced harshness and flavour modification, but also to modify smoke pH, to neutralise nicotine “impact” (an industry term denoting the organoleptic sensation caused by nicotine; smokers often describe this as “throat catch” or “throat hit”). Tartaric and lactic acids likewise modify the pH of smoke. All of these organic acids increased smoothness and are associated with a decrease in nicotine “impact” (Philip Morris, 1989) However, it is unclear whether these

effects are due directly to pH modification. Unregulated botanical and chemical additives might have “multiple-use” purposes, such as enhancing flavour and producing “smoother” cigarette smoke, as well as potentially preventing or masking symptoms associated with smoking-related illnesses (Rabinoff *et al.*, 2007).

Facilitate the inhalation of tobacco smoke. Certain ingredients have local anaesthetic effects. As a result, coughing due to inhalation of irritating smoke is dampened and the smoker can inhale the smoke deeper (and more frequently). Examples are components of etheric oils, such as menthol and thymol (SCENIHR 2010).

Appearance, smell and irritation of tobacco smoke. In order to make the smoke more attractive not only to the smoker, but also to other people in the proximity of the smoker, it is important that the smoke is appealing and not annoying. This may be attained with additives that make the smoke whiter and more attractive to people seeing the smoke. The TPD prohibits additives having colouring properties for emissions.

Reduced visibility of side-stream is accomplished by the addition of magnesium oxide, magnesium carbonate, sodium acetate, sodium citrate and calcium carbonate to the wrapper (cigarette paper). This has an effect on particle size; particles become smaller and therefore do not easily scatter light and become less visible. Reducing side-stream emissions is based on encapsulating the smoke in an impermeable cone using different types of additives such as potassium succinate, potassium citrate and magnesium carbonate. By combining the use of additives and the look of the tobacco product, greater acceptance of the smoke may be created. Less resistance may be encountered from persons who do not smoke, and at the same time greater pleasure for the smoker may be created. The same agents may also be used to target the individual product at certain target groups (Carpenter *et al.*, 2005a, Connolly, 2004).

The smell of the smoke may be also changed so that it is also more attractive and less irritating (Connolly *et al.*, 2000, Ling and Glantz, 2005). Connolly *et al.* (2000) examined tobacco industry patents covering the function of environmental tobacco smoke masking. These strategies include reducing smoke odour and reducing side-stream smoke visibility and emissions. Methods to neutralise or reduce lingering smoke odour include addition of acetylpyrazine, anethole and limonene to modify the side-stream odour. These compounds have rather low odour thresholds, and are subsequently easily picked up, while they elicit no trigeminal nerve response. Aroma precursors, e.g. polyanethole provided a noticeable fresher, cleaner and less irritating cigarette side-stream aroma, while others (e.g. cinnamic aldehyde, pinanediol acetal) produce slightly sweet, spicy, clean, fresh, and less cigarette-like aroma. In addition, more “classic” additives (e.g. vanillin, benzaldehyde, bergamot oil, cinnamon/cinnamon extract, coffee extract and nutmeg oil) modify sidestream odour.

Studying sensory effects

Neuro-imaging techniques are used to provide insight into brain processes related to sensory perception. The brain integrates sensory inputs such as taste, touch and smell, and the resulting neural activation can be studied by e.g. fMRI and PET (Small, 2012). Many brain areas are involved, such as brainstem, amygdala, and the orbitofrontal cortex. Odours, tastants, and trigeminal stimuli (intranasal irritants) are processed within the olfactory network, gustatory network, and trigeminal network, which are interacting networks (Lundstrom *et al.*, 2011). The widespread network involved in the processing

of odorants, tastants, and chemical irritants recruits several key cerebral areas, including those responsible for emotions, memories and reward. Reward consists of the psychological components learning, affect, and motivation (Berridge and Robinson, 2003). Physiological, emotional, cognitive and sensory responses caused by flavours and odours can be tested, also in relation to 'reward dose' in the brain (SCENIHR, 2010b). In research projects conducted by Philip Morris from 1982 to 1995, electroencephalography (EEG), pattern reversal evoked potential (PREP), and chemo-sensory event-related potential (CSERP) were used to measure physiological, sensory and cognitive changes related to nicotine and to cigarette additives (Rabinoff *et al.*, 2007).

3.4.3.7 Interaction of the additive with other additives/ingredient

Tobacco smoke is a complex mixture: 9582 chemical components have been identified so far in tobacco and tobacco smoke (Rodgman and Perfetti, 2013), its composition is qualitatively and quantitatively not fully known and may change, depending on the brand. In addition, tobacco being a natural product, its composition is variable over time from batch to batch even within the same brand. One of the major limitations of using *in vitro* and *in vivo* test systems for the toxicological study of inhalational exposures to compounds in tobacco mixtures is the very high number of components in tobacco smoke and the extreme variability of the mixture. The large number of additives (~ 1260 –SCENIHR Tobacco Opinion 1, 2016) present in the Industry's repertoire add further qualitative and quantitative variability to the mixture. The list is open ended, which means that at present there is no restriction on the number of additional additives as alternative chemicals, precursors etc. Moreover, several of these additives are botanical extracts, which, per se are composed of hundreds of components such as flavours, sugars, pH modifiers. These botanical and phytochemical additives are claimed to have a number of properties, including anaesthetic, antibacterial, anticancer, anti-inflammatory, antifungal, and antiviral properties (Rabinoff, 2007), but these 'apparently beneficial' activities cannot justify their use as additives in tobacco products. Indeed, in some cases, they provide for a "smoother" smoking experience by masking adverse symptoms caused by smoking (e.g., cough), preventing awareness in the consumer and reductions in cigarette consumption.

The specific purpose and the required concentration is well researched and optimised by the tobacco industry before any product is marketed; therefore additives included in the composition of each tobacco product represent a mixture itself. This 'optimal' mixture of additives is intentionally added to a known toxic, carcinogenic and addictive product in order to make the product more palatable by masking the bitter taste, improving the flavour and reducing the irritation of inhaled smoke, optimising nicotine uptake.

The possibility that chemical interactions can occur among different tobacco components and additives and among different additives cannot be excluded. These interactions can consist of direct chemical reactions, forming additional different compounds, or being translated in addition, potentiation or antagonism of the effects induced by additives and tobacco components (with the possibility that such an interaction occurs at the level of toxicokinetics and at toxicodynamic level). The number of possible interactions and the number of test combinations increase exponentially with increasing numbers of compounds in a mixture. Moreover, the number of experimental groups will also increase with the number of doses of each compound.

As for the general issue of mixture toxicity, in this specific case it can also not be solved by applying an experimental approach, since to test the thousands of possible mixtures is not feasible, beside the fact that, as previously discussed, their composition is variable. This is an additional reason for considering the approach of using comparative testing strategies insuitable, where differences in effect of the tobacco product with and without the additive are evaluated (see paragraph 3.4.1).

The frameworks for assessing chemical mixtures have been proposed at international and national levels and addressed in several guidance documents.

In most of these documents, the focus is on the mode of action of specific compounds: chemicals with common modes of action will act jointly to produce combination effects that are larger than the effects of each mixture component applied singly. The approach suggested by the non-food SC on mixture toxicity opinion (SCHER, 2012) as well as the one proposed by EFSA (EFSA, 2012 and EFSA, 2013 on pesticides) can be followed. A case-by-case approach could be useful to define specific testing.

Both the non-food SC and EFSA made use of the WHO/IPCS Framework for Risk Assessment of Combined Exposures to Multiple Chemicals. It is a tiered framework for organising risk assessment tools and data in order to conduct an assessment of combined exposure to multiple chemicals, starting with screening level assessment and proceeding to more complex approaches. The tools and data to be employed are decided on a case-by-case basis by the risk assessor, in order to address the problem at hand, e.g. contaminated site, chemicals in surface water, etc. (Meek *et al.*, 2011).

In the future, the EU project EuroMix (European Test and Risk Assessment Strategies for Mixtures) will provide a test strategy and test instruments using novel techniques for mixture testing based on new and already existing toxicological tests. The tests will result in data needed for refining future risk assessment of mixtures relevant to national food safety authorities, public health institutes, the European Food Safety Authority (EFSA), the European Chemical Agency (ECHA), industry, regulatory bodies and other stakeholders. <https://www.euromixproject.eu/>

The following examples show the interactions of compounds with similar function/activity on the one hand and the camouflaged effect of botanicals on the other hand, revealing the complexity of ascertaining interaction between additives.

Any additives able to interfere with nicotine bioavailability independent of the mechanism can be the cause of addition or synergism of effects. Using at the same time additives altering the pH of tobacco (e.g. alkalisating agents such as ammonium compounds facilitating nicotine passage through the cell membrane in the uncharged volatile form), together with substances such as menthol and thymol, facilitating the inhalation of tobacco smoke (due to local anaesthetic effects) or bronchodilators, such as theobromine (generated from cocoa, caffeine and glycyrrhizine) would, all together, have a non-negligible impact on nicotine bioavailability in the body. Although they present a low concentration singularly and their action can be deemed as non-relevant (SCENIHR 2010), taken together the impact is very different.

To these considerations should be added the use of additives that interfere with nicotine metabolism, additives such as the gamma-aliphatic lactones group (see SCENIHR opinion 1, 2016) are mild to weak inhibitors of CYP2A5 and CYP2A6. As CYP2A6 is

involved in the metabolism of nicotine, the presence of these chemicals could decrease smokers' metabolism of nicotine and maintain higher blood levels (thus increasing smokers' exposure to nicotine by slowing degradation of nicotine in the bloodstream). Furthermore, the inhibitory effect of these chemicals on CYP2A6, although relatively weak in isolation, might be greater when the chemicals act in combination.

Several patents discussed direct "beneficial" physiological actions of botanical additives. In one US patent cited, it was noted that nicotine in cigarettes has a deleterious vasoconstrictive effect on the cardiovascular system, particularly the blood vessels within and surrounding the heart. It was also noted that vaporised niacin in cigarette smoke has a vasodilating action that helps counteract the vasoconstrictive effect of nicotine. Furthermore, additional "beneficial" effects may be obtained when niacin is combined with rutin (a chemical found in many botanicals), "which is considered effective in reducing and preventing capillary fragility." The patent listed 33 botanicals or vegetable materials, or compounds within them, which also appear on the tobacco industry cigarette additive list (Rabinoff, 2007).

Usage of fruit and vegetable extract concentrates/ botanicals can also give an impression of health benefit to the consumer, so could be considered under the TPD Article 7 2 a. This kind of information is very important as more than 100 of 599 documented cigarette additives have pharmacological actions that camouflage the odour of environmental tobacco smoke emitted from cigarettes, enhance or maintain nicotine delivery, could increase the addictiveness of cigarettes and mask symptoms and illnesses associated with smoking behaviours (Rabinoff, 2007).

3.4.4 Step 4: Reporting

In the fourth and last step, a report needs to be drafted on the activities carried out in Steps 1 to 3, to be sent to the relevant authorities. The report should include an overall evaluation of the results from Step 1 to 3. In Annex I a reporting template is provided for this purpose.

The formation of consortia and joint reports by industry is endorsed in order to limit the financial and administrative burden for both industry and authorities, and for the subsequent evaluation of the submitted reports by independent institutes.

3.5 Specific knowledge gaps for the priority list tobacco additives used in cigarettes and roll-your-own tobacco

In addition to the general strategy described in the previous paragraphs, the data gaps already identified in Tobacco Opinion 1 for the 15 additive included in the EU Commission priority list have been analysed. The analysis was based on the 'Rational for inclusion' taken from Opinion I.

Based on that, the activities to be performed upfront will be described, in order to identify the most appropriate steps (and end-points) to be carried out and to speed up the process, making possible testing feasible in the 18 month time-frame. In some cases (e.g. identification of CMR properties of the unburnt form) it would be possible to identify whether or not they should enter the evaluation procedure (e.g. having or not having properties that do not meet the criteria of the TPD, art. 7). Starting at the lowest step, for each of the 15 additives on the priority list, recommendations for experimental

activities to fill the data gaps recognised in Tobacco Opinion 1 are given. If the outcome is negative (i.e. no effect which does not meet the TPD criteria is demonstrated), they will enter the general strategy of testing and be considered as any other compound. It is recommended to address the extensive data search also for the 15 priority list chemicals and to apply the WoE approach, as described in step 1, since the SCENIHR in Opinion 1 was not asked to carry out a risk assessment but a prioritization (based on hazard) of a large number of additives to assist the Commission in the compilation of the priority list.

3.5.1 Carob bean

Synonyms: Locust bean extract, St. Johns bread extract

CAS number: 9000-40-2/84961-45-5

Rational for inclusion

Carob bean extract is a chemically undefined complex additive containing hundreds of chemicals, rich in carbohydrates/sugars. Information on the exact chemical composition of this complex tobacco additive is lacking (e.g. carbohydrate, proteins/amino acids and fats, pH modifiers. It pyrolyses extensively and the combustion of the high carbohydrate/sugars leads to formation of carcinogenic and toxic compounds (e.g. benzene, polycyclic aromatic hydrocarbons, and phenol), aldehydes (acetaldehyde, formaldehyde, furfural and acrolein), organic acids and caramel colour and flavours (Baker & Bishop, 2004, Coggins *et al.*, 2011).

Some of these pyrolysis compounds are reported to reduce nicotine delivery, leading to increased smoking frequency and deeper inhalation of smoke to enable higher absorption of nicotine in the airways. Compounds resulting from sugar combustion, such as acetaldehyde and more complex aldehydes, are MAO inhibitors, may play a crucial role in tobacco addiction. MAO inhibitors increase serotonin extracellular levels and desensitize 5-HT_{1A} autoreceptors, thereby allowing nicotine to activate serotonergic neurons and become addictive.

Moreover, it should be noted that pyrazines (reported as additives to cigarettes to impart flavour in low tar cigarettes; Alpert *et al.*, 2016 may be formed under pyrolytic conditions via reactions between amines and carbonyl compounds, generally sugars. Carob bean extract has a sweet, fruity, chocolaty flavour and contributes to making smoking more attractive by improving flavour, thereby masking its bitter taste and reducing the harshness of smoking.

This information can facilitate the assessment of the influence on the carob bean extract on palatability (a key component of attractiveness), the pro-addictive effect and the interaction with other additives and tobacco chemicals.

Priority activities

Step 1: Data on the chemical composition of the carob bean extract should be provided by industry with emphasis on the concentrations of constituents of relevance;

Step 2: Some information on the effect of pyrolysis of carob bean extract is available, however, it is necessary to:

- further chemically define its pyrolysis products and

- evaluate the CMR properties of its pyrolysis products.

In case of concern for genotoxicity/carcinogenicity of its pyrolysis products, additional testing would be required to continue with **Step 3** in order to generate additional data for a WoE assessment,

If no concerns arise, the additive can enter the tiered procedure for evaluation. The assessment of its pyrolysis product on palatability, pro-addictive effect and the interaction/synergistic effect with other additives and tobacco chemicals should be presented (Step 4).

3.5.2 Cocoa and cocoa products (powder, extracts, shells of cocoa bean etc.)

Complex mixture from Theobroma cocoa beans

CAS Numbers: 95009-22-6 (cocoa powder), 84649-99-0, 84649-99-3 (cocoa extract)

Rational for inclusion

Many forms of cocoa additives such as extracts and powders are used frequently and in relatively high amounts. Added as flavour or casing to tobacco (cocoa extract is the most abundantly used, with 847 counts in NL ingredient lists, none in NTM, total number of brands 4265), average (weight %) 0.105 (0.198). The maximum amount of cocoa as tobacco additive is around 1 % of the total tobacco weight (RIVM, 2012).

Regarding toxicity, the effects of cocoa inhalation through smoking have not been studied. The risk associated with the generation of combustion products produced upon cocoa pyrolysis has not been thoroughly studied and thus, conducting an adequate risk assessment for cocoa or its pyrolysis products is currently not possible.

Regarding addictiveness, several pharmacological effects of cocoa-derived ingredients were reported, including the bronchodilatory effect of theobromine and caffeine, which result in improved bioavailability of nicotine, although data available so far indicate that the content of theobromine per cigarette seems to be too low to have a bronchodilating effect on the lungs (SCENIHR, 2010). Furthermore, reaction products of tryptophan, phenylethylamine, tryptamine and tyramine, are thought to exert monoamine oxidase-inhibiting properties. In general, the pharmacologically active substances present in cocoa do not exclude a psychopharmacological effect in humans, owing to the low exposure concentrations and/or the inability of these substances to cross or reach the blood-brain barrier. Due to a lack of studies specifically on the psychoactive effects of cocoa added to tobacco, there is insufficient evidence that adding cocoa to tobacco makes cigarettes more addictive.

The addition of cocoa to tobacco is intended to enhance flavour. More data are needed on the amount of cocoa needed to impart a noticeable flavour.

Priority activities

Based on the available data, cocoa and cocoa products may result in a characterising flavour and increase inhalation and nicotine uptake. The reported percentage of cocoa

used in cigarettes ranges from 0.2% to 0.66%. Taking this information into account, the content of theobromine and caffeine per cigarette seems too low to have a bronchodilating effect on the lungs and thereby increase the absorption of nicotine. Therefore, there is uncertainty with regard to the direct effect of cocoa additives on the bioavailability of nicotine and more studies are required.

Step 1: Additional data should be sought and evaluated to address the above mentioned questions and all the other available information on the additive in the unburnt form.

Step 2: Pyrolysis of cocoa results in the generation of minor amounts of phenol, o-, m-, p-cresol, xylenols, catechol, palmitic acid and stearic acid (<0.001% (w/w) in tobacco) and nitrous gases, carbon monoxide and dioxide. Tryptophan combustion can generate 3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole and 3-amino-1-methyl-5H-pyrido-(4,3-b)indole. Furthermore, tryptophan contains reactive groups and forms reaction products with other compounds during combustion, such as beta-carbolines, including harman (RIVM, 2002). The resulting anti-depressive effects of harman have been suggested to contribute to addiction caused by cigarette smoking. Reaction products of tryptophan, phenylethylamine, tryptamine and tyramine, which are formed during combustion, are thought to exert monoamine oxidase inhibiting properties. Nevertheless, the risk associated with the generation of combustion products produced upon cocoa pyrolysis has not been thoroughly studied and should be carefully evaluated.

Step 3: The exposure to cocoa and cocoa-derived ingredients transferred to cigarette smoke in their pure forms is negligible compared with the exposure to these compounds through food and drinks (RIVM, 2002). However, the consequences of the exposure through inhalation have not been studied. Exposure through smoking should not be neglected as it represents two different types of exposure through inhalation of (1) cocoa itself and (2) combustion products of cocoa and its ingredients (RIVM, 2002).

Several mechanisms of enhancing addictiveness of smoking have been proposed, however, it is unclear whether sufficient amounts of psychoactive compounds are produced to exert psychopharmacological effects that would increase addictiveness. Characterising flavour may make cigarettes more palatable to younger, first-time users and may indirectly facilitate dependence by providing enhanced flavour and mouth sensations, potentially serving as a cue for drug reward. Due to a lack of studies specifically directed to the psychoactive effects of cocoa compounds added to tobacco on addiction, there is insufficient evidence that the addition of cocoa to tobacco contributes to the addictive properties of cigarette smoking.

The addition of cocoa to tobacco is intended to enhance flavour and therefore smoking may result in a characterising flavour. However, although a considerable percentage of cigarette weight could be cocoa additives, it is not known to what degree this influences the flavour of inhaled mainstream or side stream smoke, and especially how this might influence smoking initiation in youths (Fowles, 2001).

3.5.3 Diacetyl

CAS-nr:431-03-8

Synonyms: butanedione, butane-2,3-dione

Rational for inclusion

Diacetyl exposure may lead to serious lung disease after inhalation. For a proper risk assessment, it is necessary to better characterise the concentrations in mainstream smoke. SCOEL accepted that there is uncertainty about the importance of the genotoxicity of diacetyl. There were no data on carcinogenicity. In addition, it can result in a characterising flavour, which can contribute to increasing attractiveness.

Priority activities

Based on the rationale for inclusion, the main open questions concerning diacetyl are:

- Uncertainty concerning the genotoxicity of diacetyl and no data on carcinogenicity.
- No sufficient data was found concerning the burned (pyrolysis) product.
- Exposure may lead to lung disease after inhalation and should be assessed in appropriate tests.
- Due to the typical flavour of diacetyl it is unclear whether the compound can add to the olfactory cue and attractiveness of the smoking product. The question whether this flavour is distinguishable (attractiveness) and/or has a "smoothing" effect on the smoke (attractiveness/addictiveness) remains unclear.

The first activity to be carried out is related to the need to rule out the genotoxicity of the compound. In case of identification of genotoxic potential, the additive will be out according to the TPD provisions; otherwise it should enter the step-wise procedure.

Step 1: Additional data should be sought and evaluated to address the above mentioned questions

Step 2: Pyrolysis products should be studied and evaluated using the available data.

Step 3: In order to fill the gaps identified in Step 1 and 2, toxicity testing for inhalation exposure and then for characterising flavour, inhalation facilitation and addictiveness (considering its potential characterising flavour as well as the "smoothing" effects) for the additive in its unburnt and burnt form.

3.5.4 Fenugreek extract

Synonyms: fenugreek (*trigonella foenum graecum* L.) extract, resin, & absolute

CAS number: 84625-40-1

Physical properties: Complex mixture, dark brown paste

Rationale for inclusion

Natural/botanical concentrates/extracts/resins (e.g. from several fruits - fig, plum, raisins, fenugreek, carob, cocoa, caramel, rum, etc.) form a large number of tobacco additives. They are poorly characterised complexes of several to hundreds of chemicals; the composition further depends upon variable factors influencing botanical source and preparation methods. Although generally recognised as safe as food additives and flavours, this classification is not valid for their inhalation effects and pyrolysis products in tobacco smoke. The combustion/pyrolysis chemistry of each of these additives is not well known in terms of their physiological, toxicological and synergistic additive effects to potentiate the harmful effects of tobacco smoke.

However, many of the botanical extracts have a rich carbohydrate, polysaccharides and sugar content, together with varying amounts of proteins, amino acids and other flavour compounds. Fenugreek seeds contain mucilage (glycoproteins and polysaccharides) and some amount of sugar. The pyrolysis of this class of compounds has been well reported. Upon combustion/pyrolysis at temperatures (up to 900°C) attained during smoking, these compounds, especially the carbohydrates, give rise to a complex mixture of toxic, carcinogenic and mutagenic compounds, as well as aroma/flavour compounds.

Compounds formed include smoothing agents (e.g. organic acids), flavours (e.g. caramel), compounds that facilitate nicotine delivery (e.g. aldehydes) and compounds with CMR properties (e.g. PAHs, formaldehyde). Moreover, pyrazines are important flavour impact compounds that are formed under pyrolytic conditions via reactions between amines and carbonyl compounds, generally sugars. Several pyrazines are also added as additives to cigarettes to impart flavour to low tar cigarette (Alpert *et al.*, 2016). The complex mixtures used as additives cause tremendous harm and contribute to CMR properties, addictiveness and attractiveness of tobacco smoke.

Priority activities

Step 1: Data on the chemical composition and specification of the Fenugreek extract (powder, concentrate) should be provided by industry with emphasis on the concentrations of constituents of relevance, production procedure, maximum levels for microorganisms and possible contaminants. According to available information, *Trigonella foenum-graecum* seeds contain mucilage, trigonelline, 4-hydroxyisoleucine, sotonol, diosgenin, phenolic acids, and protodioscin.

The use of fruit and vegetable extract concentrates are acknowledged to be beneficial to health. Fenugreek extract can thus give an impression of health benefit (*TPD Article 7 6a*) to the consumer. Moreover, as it is also used as a medicinal product, this could also give the impression of health protection.

Step 2: Fenugreek extract does not transfer intact to the mainstream smoke, but undergoes extensive pyrolysis. Based on the available studies (Baker and Bishop 2005), pyrolysis products from fenugreek extract include pyridine, benzene (carcinogen), toluene and furfural. The pyrolysis products, once characterised, should be evaluated according to the procedure.

If the evaluation shows that it is warranted to move on to **Step 3**, the effects which have been considered as matters of concern (e.g. neuropharmacological activities, CNS depressant and stimulant as well as allergic reaction and exacerbation of asthma) should be investigated first. Therefore, the industry should use the proposed step-wise system and the general strategy described to prove that the additive in the unburnt and burnt form does not contribute to toxicity, addictiveness, the characterising flavour or to facilitating inhalation of the tobacco product concerned.

3.5.5 Fig extract

Complex mixture (ficus carica l. extract)

CAS number: 90028-74-3 (any other related one if used)

CoE number: 198

Rationale for inclusion

Natural/botanical concentrates/extracts/resins (e.g. from several fruits - fig, plum, raisins, fenugreek, carob, cocoa, caramel, rum, etc.) form a large number of tobacco additives. They are poorly characterised complexes of several to hundreds of chemicals; the composition further depends upon variable factors influencing botanical source and preparation methods. Although generally recognised as safe as food additives and flavours, this classification is not valid for their inhalation effects and pyrolysis products in tobacco smoke. The combustion/pyrolysis chemistry of each of these additives is not well known in terms of their physiological, toxicological and synergistic additive effects to potentiate the harmful effects of tobacco smoke.

However, many of the botanical extracts have a rich carbohydrate/sugar content, together with varying amounts of proteins, amino acids and other flavour compounds. The pyrolysis of this class of compounds has been well reported. Upon combustion/pyrolysis at temperatures (up to 900°C) attained during smoking, these compounds, especially the carbohydrates, give rise to a complex mixture of toxic, carcinogenic and mutagenic compounds, as well as aroma/flavour compounds.

Compounds formed include smoothing agents (e.g. organic acids), flavours (e.g. caramel), facilitating nicotine delivery (e.g. aldehydes) and with CMR properties (e.g. PAHs, formaldehyde). Moreover, pyrazines are important flavour impacting compounds that are formed under pyrolytic conditions via reactions between amines and carbonyl compounds, generally sugars. Several pyrazines are also added as additives to cigarettes to impart flavour to low tar cigarettes (Alpert *et al.*, 2016). The complex mixtures used as additives cause tremendous harm and contribute to CMR properties, addictiveness and palatability (a key component of attractiveness) of tobacco smoke.

Priority activities

Step 1: Data on the chemical composition of the fig extract should be provided by industry with emphasis on the concentrations of constituents of relevance, production procedure, maximum levels for microorganisms and possible contaminants. The use of fruit and vegetable extract concentrates are acknowledged to be beneficial to the health. Fig extract can thus give an impression of providing a health benefit (*TPD Article 7 6 a*) to the consumer.

Step 2: It does not transfer intact to the mainstream smoke, but undergoes extensive pyrolysis. Information available so far indicates that pyrolysis products include formation of benzene, toluene; in addition the combustion of the sugars lead to the formation of carcinogenic polyaromatic hydrocarbons, a variety of aldehydes, such as acetaldehyde (irritant and possible carcinogen), acrolein (irritant), 2-furfural and a mixture of organic acids. Converging data indicate that MAO (monoamine oxidase) inhibitors contained in tobacco and tobacco smoke act synergistically with nicotine to enhance addiction potential. Smokers have reduced levels of MAO in the brain. Among MAO inhibitors, compounds resulting from sugar combustion, such as acetaldehyde and more complex aldehydes, may play a crucial role in tobacco addiction. MAO inhibitors increase serotonin extracellular levels and desensitize 5-HT1A autoreceptors, thereby allowing nicotine to activate serotonergic neurons and become addictive. As yet, data about the role of acetaldehyde are the only ones available. They are inconclusive and further investigation about other aldehydes is needed before the role of sugars as indirectly addictive compounds can be confirmed (SCENIHR 2010 report). Therefore, any information available on these compounds should also be reported.

Step 3: In order to fill the gaps identified in Step 1 and 2, toxicity testing for inhalation exposure and then for characterizing flavour, inhalation facilitation and addictiveness for the additive in its unburnt and burnt form. Overall, the industry should use the proposed step-wise system and the general strategy described, to prove that the additive does not contribute to the tobacco product toxicity and does not fall into the four categories listed in Art. 6 of the TPD.

3.5.6 Geraniol

CAS number 106-24-1

Rational for inclusion

Geraniol is a known flavouring agent for food and is added to tobacco products for flavouring (one of the factors potentially contributing to attractiveness). More data are needed on the amount of geraniol that imparts a noticeable flavour other than tobacco. No data are available regarding addictiveness.

To perform a toxicity risk evaluation, it is necessary to know the exposure level of geraniol through cigarette smoking. Therefore, research is needed to determine the amount of geraniol in mainstream cigarette smoke. However, considering that the toxicological properties of geraniol are mainly linked to a high potential for skin sensitisation (in addition to skin and eye irritation), no levels considered safe for the majority of consumers could be established from the available data. Geraniol oxidation products (e.g. geranial, epoxy-geraniol, epoxy-geranial) are also potent sensitisers in animals. It could be expected that geraniol would be a respiratory sensitiser (although no information is available on this issue).

It is unknown if geraniol combustion products (about 10-15% of the additive) formed upon smoking a cigarette are toxic or not. Additional pyrolysis experiments are recommended.

Priority activities

Step 1: The chemical characterization of the additive is of paramount importance: indeed, geraniol can contain the relevant impurity methyleugenol, which is a genotoxic carcinogen. Only in the absence of that impurity, proven by specific certificate of analysis, could geraniol be considered as a possible candidate as a tobacco additive.

If it could be demonstrated that geraniol does not contain methyleugenol, the additive can enter the procedure for evaluation.

Step 1: The collection of the available data could be useful anyway, although as already indicated in Tobacco Opinion I, this would lead to confirming that data are available to demonstrate that pure geraniol did not induce gene mutations in *Salmonella typhimurium* and mammalian cells and although equivocal response resulted in an *in vitro* clastogenicity test, its genotoxicity can be reasonably considered eligible. In addition, after long-term studies, no carcinogenicity potential was attributed to food grade geranyl acetate (29 % citronellyl acetate and 71% geranyl acetate). Therefore those end-points are already addressed. Since the oral absorption has been demonstrated to be >80%, the systemic toxicity after inhalation (also assuming a total absorption through the lung (100%)) the effects are not expected to be different. Since

the relevant NOAEL are relatively high (558 mg geraniol/kg bw per day for rats and 279 mg geraniol/kg bw/day for mice), systemic general toxicity is not considered relevant at the doses used as tobacco additive. Therefore data are available to address these end-points. In addition the ECHA REACH registration dossier updated on 18 March 2016 reported a general population inhalation DNEL (Derived No Effect Level) of 47.8 mg/m³ for geraniol.

Step 2: Additional standardised pyrolysis experiments are recommended to identify the products formed other than geraniol, to be then evaluated for their toxicological properties plus addictiveness, characterising flavour and facilitating inhalation.

Step 3: In the case of geraniol, the local toxicity is relevant, as it is a known skin and eye irritant. Furthermore, geraniol and many of its oxidation products (by air oxidation and by metabolic transformation) have already been proven to be skin sensitisers in predictive animal tests. Indeed, geraniol is included among the fragrance substances of clinical importance known to be a prehapten as well as a prohaptens. For skin sensitisation, the SCCS considered that 0.01% could be efficient in limiting elicitation. No data are available for irritation of mucosa in the airways as well as for respiratory sensitisation, but since there is a high potential for inducing that kind of effects, also considering that the few pyrolysis studies available indicate that geraniol is mainly (85-90%) transferred intact to smoke, these should be tested first. In case results would indicate a potential for respiratory irritation sensitisation, the use of geraniol as a tobacco additive should be carefully evaluated.

Characterising flavour should be addressed first, since geraniol is a known flavouring agent for food and is added to tobacco products for flavouring. More data are needed on the amount of geraniol that imparts a noticeable flavour other than tobacco. Geraniol has been demonstrated to have the property to activate cold-menthol "transient receptor potential melastatin 8" (TRPM8). TRPM8 mediates a pleasant cooling sensation in the upper airways that can mask the harsh and irritation effects of tobacco smoke. TRPM8 activation is therefore a suitable physiological mechanism to promote inhalation, especially by unexperienced smokers during the initiation and adoption stages (Behrendt *et al.*, 2004; Lübbert *et al.*, 2013).

3.5.7 Glycerol

CAS number: 56-81-5

Rational for inclusion

Glycerol is added as a humectant to tobacco (to help keep it moist). Its addition is mostly during the "casing" of the tobacco. The amount of glycerol present in cigarettes depends on the cigarette brand. The levels of glycerol added to tobacco in the EU is reported to be on average 1.1 %, with a maximum level comprising 4.5 % of the total weight.

Regarding toxicity, it was reported by the tobacco industry that the transfer rate of glycerol to mainstream smoke is 12 %. A risk assessment procedure using a Margin of Exposure (MOE) analysis concluded that there are risks of effects on the respiratory tract epithelium from glycerol. No thorough assessment on systemic effects was done.

Pyrolysis studies indicate almost 100 % intact transfer of glycerol (Baker & Bishop, 2004; Purkis *et al.*, 2011). However, it was found that less than 0.1 % of the blend glycerol is converted to acrolein in mainstream smoke for different cigarette designs and smoking regimes tested (Yip *et al.*, 2010). Acrolein is a toxic compound that is highly reactive and causes irritation in the respiratory tract. The relationship between added glycerol and acrolein formation is unclear and further research is needed.

Regarding addictiveness, no data were reported to suggest that glycerol plays a role in smokers' addictiveness to cigarettes.

Humectants are added to trap water, thereby keeping the moisture in the tobacco and preventing it from drying out. Glycerol is, therefore, considered to positively influence cigarette smoking, given that humidification improves the palatability of cigarettes. Glycerol does not have a strong flavour, and is, therefore, not expected to impart a noticeable flavour.

Priority activities

Step 1: Additional data should be sought and evaluated to address the issues raised above. This should include evaluating information available on the assessment of the systemic effects of glycerol.

Step 2: Pyrolysis studies have found that a small proportion of glycerol (<0.1%) is converted to acrolein in mainstream smoke and is also generated during the combustion of many other products in tobacco. Both glycerol and acrolein cause irritation to the respiratory tract and acrolein is highly reactive. The relationship between added glycerol and acrolein formation is unclear. If no other information can be retrieved from the available data search, it will be necessary to produce new data (Step 3).

Step 3: Further data is needed to study the additive effects of glycerol or its reactivity with other compounds.

3.5.8 Guaiacol

CAS number 90-05-1

Rational for inclusion

Guaiacol is a known flavouring agent for food and is added to tobacco products for flavouring. More data are needed on the amount of guaiacol that imparts a noticeable flavour other than tobacco.

Its use as a local anaesthetic can enhance smoke inhalation, thus potentially contributing to addictiveness.

To perform a toxicity risk evaluation, it is necessary to know the exposure level of guaiacol through cigarette smoking. Therefore, research is needed to determine the amount of guaiacol in mainstream cigarette smoke.

Guaiacol is a severe eye irritant, a skin irritant and also reported to be a respiratory tract irritant. Other toxicological information on repeated exposure is scant. On the basis of results on structurally related compounds, effects are likely related to the irritation potential at the contact site, generating hyperplasia. Apart from the absence of

mutagenicity tested with the Ames test, the only genotoxicity test on mammalian cells gave positive results (SCE in human lymphocytes). More data are needed for a better evaluation.

Pyrolysis experiments performed with lignin found many guaiacol derivatives besides guaiacol itself and suggest that it transfers largely intact into the smoke.

Priority activities

Since the genotoxic potential of guaiacol is of concern, this is the first issue to be clarified. The SCHEER is aware that negative results have been already published by using the *Ames test*; however, positive results were obtained with human lymphocytes: these data have to be confirmed or denied by means of results coming from appropriate *in silico/in vitro* methods (**Step 3**).

In case of positive results, guaiacol would not meet the TPD requirement (see art.7), no additional testing would be necessary, therefore the procedure can go directly to **Step 4**.

If guaiacol could be proved not to have genotoxic properties, the additive can enter the step-wise procedure for evaluation, starting with:

Step 1: evaluation of available data on the additive in unburnt form

Step 2: Pyrolysis products should be considered

If there are data gaps or uncertainties coming from data collected in Step 1 and 2, further testing would be necessary (proceed to Step 3).

Step 3: Guaiacol is reported to be a respiratory tract irritant: this property should be specifically addressed as a priority. In addition, other toxicological end-point and properties as local anaesthetic, potentially contributing to addictiveness, should be also investigated, together with characterising flavour and inhalation facilitation.

3.5.9 Guar gum

Synonyms: Guaran, Guar Flour, Jaguar

CAS number: 900-30-0 (Guar depolymerised CAS number: 68411-94-9) and others

Rational for inclusion

Guar gum is an extract of the seeds of the guar bean plant. Guar gum consists of high molecular weight polysaccharides and some amount of protein. Reconstituted tobacco is made up of mashed tobacco stems and other parts of the tobacco leaf that would otherwise be discarded. Guar gum (and its derivatives) is added to reconstituted tobacco in cigarettes. Guar gum is also used to prepare the cigarette paper that wraps the tobacco.

The amount of guar gum added to bind the tobacco can make up between 0.6-1.8 % of the total weight of the tobacco used in one cigarette. Guar gum is generally regarded as safe for use in food and cosmetics. However, guar gum does not transfer intact to the mainstream smoke, but undergoes pyrolysis, giving rise to toxic/carcinogenic

(e.g. formaldehyde, benzo(a)pyrene and benzene) compounds. Irritating and toxic fumes, gases and acrid smoke can be formed when the additive is heated to decomposition.

Regarding flavours, it is well known that the thermal degradation of sugars and carbohydrates at lower temperatures as in foods contribute to complex aromas. Several flavour compounds were reported due to pyrolysis reactions of guar gum. These flavour compounds singly or in combination with the thousands of other smoke constituents can act synergistically and contribute to the attractiveness of smoking by improving smoke flavour, thereby masking its bitter taste, reducing the harshness of smoking, creating sensory cues, which all could contribute to the optimisation of nicotine dosing and enhance abuse potential.

Guar gum is hazardous when heated to decomposition, emitting acrid smoke and irritating fumes. Although some information on the effect of pyrolysis is available from the internal industry documents, further chemically defining this additive from the point of view as a tobacco additive and its pyrolysis products would help confirm/facilitate the assessment of the influence on the carob bean extract on toxicity/carcinogenicity, palatability, pro-addictive effect and the interaction/synergistic effect with other additives and tobacco chemicals.

Priority activities

Step 1: Data on the chemical composition of the guar gum should be provided by industry with emphasis on the concentrations of constituents of relevance.

Step 2: Some information on the effect of pyrolysis of guar gum is available, however, it is necessary to:

- further chemically define its pyrolysis products and
- evaluate the CMR and other toxicological properties of its pyrolysis products.

In case of unequivocally positive results for genotoxicity/carcinogenicity of its pyrolysis products the use of guar gum as a tobacco additive should be carefully evaluated. Additional testing would be required for a WoE assessment in case of uncertainties.

Step 3: If CMR properties are not proven by available data, the additive can enter the step-wise procedure for evaluation, analysing data other than those related to CMR properties. The assessment of its pyrolysis product on palatability, pro-addictive effect and the interaction/synergistic effect with other additives and tobacco chemicals should be analysed.

3.5.10 Liquorice

CAS numbers: 1405-86-3 (α -D-Glucopyranosiduronic acid), 103000-77-7 (β -D-Glucopyranosiduronic acid)

Rational for inclusion

Liquorice is a natural extract of the root of the liquorice (*Glycyrrhiza glabra*) plant – logically an incompletely defined complex mixture of compounds. More than 400 compounds were isolated from *Glycyrrhiza* species. Liquorice extracts are used to

improve the organoleptic properties of tobacco smoke, making the harsh cigarette smoke palatable, thereby facilitating inhalation and resulting in characterising flavour. The taste and flavour of tobacco with added liquorice/liquorice root are described as sweet, woody and round. The major active principle of liquorice is the sweet tasting triterpene glycoside glycyrrhizin.

Glycyrrhizin has been hypothesised as a bronchodilator, although not confirmed. It is not clear whether the levels present are sufficient for this effect, although a synergistic effect with other compounds in cigarette smoke maybe expected.

It is expected to pyrolyse extensively, but there is a lack of information on the pyrolysis products formed, which would help facilitate the assessment of the influence on toxicity/carcinogenicity. Additionally, the effect of liquorice on bronchodilation, alone or in combination with other additives and/or tobacco constituents, needs to be ascertained to better understand its effect on the ease of inhalation of nicotine and other alkaloids, thereby potentiating addictiveness.

Priority activities

The potential genotoxic effects of liquorice extract have been postulated but this is controversial: glycyrrhizinic acid and its derivatives have previously been reported to give both positive and negative results in mutagenicity tests.

Starting with **Step 1** and if necessary continuing to **Step 3**, this end-point should be addressed first to identify alert for the genotoxicity and carcinogenicity of the additive.

If results are negative, the additive could enter the procedure.

Step 1: Evaluation of available data on properties other than genotoxicity/carcinogenicity for the additive in its unburnt form

Step 2: Additional standardised pyrolysis experiments are recommended to identify the products formed during the combustion process of liquorice, to be then evaluated for their CMR properties

Step 3: All the testing regarding general systemic toxicity in chronic inhalation exposure and the one regarding characterising flavour should be addressed; since liquorice can mask the undesirable characteristics of tobacco smoke and acts as a bronchodilator, the possibility for facilitating nicotine uptake should be analysed. More data are needed on the amount of liquorice and glycyrrhizic acid that imparts a noticeable flavour other than tobacco. No data are available regarding addictiveness.

The evaluation of the effects of long-term inhalation exposure to liquorice with different content of glycyrrhizic acid should consider that both renal and hepatic 11-beta-hydroxysteroid dehydrogenase (converts cortisol to cortisone) as well as hepatic delta-4-5-beta-steroid-reductase (inactivates glucocorticoids and mineralocorticoids) are inhibited by glycyrrhetic acid, which can lead to pseudohyperaldosteronism and elevated blood pressure. The flavonoids licochalcone A and B inhibit the elevation of calcium ions induced by thrombin, in a dose-dependent manner. They also inhibit thrombin-induced platelet aggregation *in vitro*. Licochalcone A and B were tested with human neutrophils and were found to inhibit the formation of leukotrienes B1 and C4,

cyto B-induced lysosomal enzyme, platelet activating factor, n-formyl-methionyl-leucyl-phenylalanine and calcium ionophore A.

Hypokalemia, hypernatremia, and water retention are primary problems associated with chronic liquorice ingestion. Changes in the sodium/potassium ratios may result in pH changes. Cardiomyopathy, pulmonary edema, myoglobinuria, ptosis, myopathy, tetany, cramping, seizures, and rhabdomyolysis have also been reported in patients following chronic, excessive liquorice ingestion. Only if it could be demonstrated that chronic liquorice inhalation with tobacco smoke has no systemic effects could the additive enter the step-wise procedure for evaluation. The safety evaluation of glycyrrhizic acid should be based on the data from humans. Since the oral absorption has been demonstrated to be high, the systemic toxicity after inhalation (also assuming a total absorption through the lung (100%) the effects are not expected to be different. Since the relevant NOAEL is relatively high (2 mg glycyrrhizic acid / kg bw per day for healthy volunteers) and the blood serum half-life is 5 hours, the risk of systemic general toxicity may not be high at the doses used as tobacco additive.

3.5.11 Maltol

CAS Number: 118-71-8

Synonyms: 3-Hydroxy-2-methyl-4-pyrone, 3-Hydroxy-2-methyl-4H-pyran-4-one, Palatone, Larixinic acid, Talmon.

Rational for inclusion

Following the EFSA report on maltol (FGE19 and FGE213 and FGE213 rev 1 - EFSA, 2008, 2009 and 2014), the concern for genotoxicity could not be excluded. Therefore, maltol will be on the priority list until data on its genotoxicity are clarified. In addition, possible effects on the CNS must be clarified.

Priority activities

The main open questions concerning maltol are therefore uncertainty concerning the genotoxicity.

If the existing information (**Step 1**) does not clarify the uncertainties, some additional testing should be undertaken based on the OECD TG (**Step 3**).

If maltol is proven not to be genotoxic, the additive can enter the step-wise procedure for evaluation.

Step1: Evaluation of available data on the additive in unburnt form

Step 2: Pyrolysis products should be considered

In case there are data gaps or uncertainties coming from data collected in Step 1 and 2, further testing would be necessary (proceed to Step 3).

Step 3: Since an inhibition of the response of the GABAA receptors in the presence of maltol has been reported which may contribute to CNS stimulation/addictiveness, these are the priority effects that should be investigated in Step 3, where all the other end-points should be considered.

In addition to the above, the following issues were identified:

Maltol and other hydroxyl cyclohexanone derivatives (such as ethyl maltol) are used to augment or enhance the taste of consumable materials, with a typical odour of cotton candy and caramel. No information on minimum levels of odour awareness was found. Reports on the health effect of maltol also underline its potential anti-apoptotic effect. It is unclear whether the anti-apoptotic is specific directed to healthy cells, neoplastic cells and/or cells undergoing mutations.

3.5.12 Menthol

CAS numbers: l-Menthol: 2216-51-5; D-Menthol: 15356-70-4; D/L Menthol: 89-78-1; Menthol: 1490-04-6

Rational for inclusion

Menthol is one of the most commonly used tobacco additives worldwide. It is a monocyclic terpene alcohol that is used primarily for its chemosensory effects of creating perceptions of a cooling minty taste and smell. Menthol is added at a continuum of concentrations, from imperceptible amounts to levels imparting different levels of a characterising flavour.

In addition, several additives and formulations are used to simulate menthol effects. Menthol induces anaesthetic and sensory effects, facilitates deeper inhalation and adds to the impact of nicotine.

Menthol is a multifunctional additive. It is an effective anaesthetic, antitussive agent that may increase the sensation of airflow and inhibit respiratory rate, thereby allowing increased lung exposure to nicotine, tar and toxic constituents, while masking reactions like coughing or other early warning signs of respiratory disease. It may increase the absorption and lung permeability of smoke constituents, thereby increasing nicotine and carcinogen uptake. It may also decrease nicotine/cotinine metabolism leading to higher doses of nicotine. It is one of the additives that was originally added to create the impression that a tobacco product has health benefits and/or reduced health risks. It affects multiple sensations including taste, aroma and tactile smoothness, and enhances abuse liability. Its pharmacological actions reduce the harshness of smoke and the irritation from nicotine, and may increase the likelihood of nicotine addiction in adolescents and young adults who experiment with smoking and it may make it more difficult to quit.

In 2011, the FDA Tobacco Products Scientific Advisory Committee (TPSAC, 2011) concluded that menthol 1) impacts youth initiation, 2) contributes to adults continuing to smoke, and 3) has an adverse impact on public health by increasing the numbers of smokers with resulting premature death and avoidable morbidity. Finally, they concluded that the "removal of menthol cigarettes from the marketplace would benefit public health in the United States" (TPSAC, 2011; FDA, 2011).

Independently, the US Food and Drug Administration undertook a thorough review and concluded that the data suggested that menthol use is likely associated with increased smoking initiation by youth and young adults, greater addiction, greater signs of nicotine dependence and less likelihood of successfully quitting smoking. These findings, combined with the evidence indicating that menthol's cooling and anaesthetic properties

may reduce the harshness of cigarette smoke and the evidence indicating that menthol cigarettes are marketed as a smoother alternative to non-menthol cigarettes, make it likely that menthol cigarettes pose a public health risk above that seen with cigarettes without menthol (FDA, 2013). The review concluded that although there is little evidence that menthol cigarettes *per se* are more toxic than menthol-free cigarettes, adequate data indicate that menthol presence is associated with increased smoking initiation and greater addiction, especially among young people, as confirmed later by the studies of Nonnemaker *et al.* (2013) and Brennan *et al.* (2015).

Indeed, smokers usually using menthol cigarettes develop greater nicotine dependence, which is likely associated to the anaesthetic properties that reduce the harshness of smoke. In addition, menthol cigarette smokers are less successful quitting smoking (Smith *et al.*, 2014). Recent perception studies confirm earlier work showing that smokers, especially young adults, perceive menthol cigarettes as less harmful (Brennan *et al.*, 2015; Wackowski and Delnevo, 2016).

With regard to toxicity, Noriyasu *et al.* (2013) exposed cell cultures to menthol and non-menthol smoke and found that cell death was significantly enhanced by mentholated smoke, whereas menthol alone was inert. This suggests a synergistic effect with other smoke-compounds and requires further study. A recent study conducted in mice showed that menthol at low concentration strongly suppressed respiratory irritation due to acrolein and cyclohexane, which are smoke irritants in naïve mice. Additionally, menthol suppressed irritation by tobacco smoke in mice. Menthol increased blood cotinine levels, which is a biomarker of nicotine uptake. Thus, menthol appears to suppress smoke-induced irritation, making it easier to inhale smoke and increasing the dosage of nicotine. Due to the similarities in menthol's pharmacology in humans, experiments in animal models suggest that beginning smokers likely prefer menthol-containing cigarettes because their respiratory tract is less irritated. At the same time, these smokers are exposed to higher levels of nicotine and become addicted faster and are less likely to quit smoking (Ha *et al.*, 2015).

At lower application levels, menthol can be used to increase smoothness and reduce harshness in cigarette smoke. This is likely the main reason for use of menthol as an additive, also in "non" menthol brands. Therefore, research to ascertain the physiological and pharmacological impact of low menthol and its interaction with other chemicals, interaction with nicotine, on palatability and inhalation of smoke/nicotine, etc. is recommended.

Baker and Bishop (2004) and Jenkins (1970) reported that after pyrolysis of menthol, it is transferred intact into smoke (99%). Smoking studies resulted in intact transfer of around 98-99%. There was some formation of menthone, menthene and menthane. In contrast, in earlier pyrolysis experiments (Schmeltz and Schlotzhauer, 1968) 84% of the menthol was pyrolysed and phenol and benzo[a]pyrene were found in the pyrolysate.

Priority activities

Step 1: Additional data should be sought and evaluated to address the above mentioned questions.

Step 2: Based on the available studies, pyrolysis of menthol may result in carcinogenic substances (concern category d). There is uncertainty with regard to the nature of the

pyrolysis products. Pyrolysis studies should be carried out to identify these products and the products should be evaluated.

Step 3: Based on the available data, menthol is concluded to impart a characterising flavour if added in sufficient amounts, facilitate inhalation and addictiveness of tobacco products and increase inhalation and nicotine uptake (concern categories A and C). Uncertainty is low. Further testing to show whether menthol is or is not addictive or does or does not increase attractiveness is not recommended in view of the strength of the data.

Further studies are needed into the suggested synergistic effect of menthol with other smoke compounds. Research to ascertain the physiological and pharmacological impact of low menthol and its interaction with other chemicals, interaction with nicotine, on palatability and inhalation of smoke/nicotine, etc. is recommended.

3.5.13 Propylene glycol

CAS number: 57-55-6

Rational for inclusion

Propylene glycol (PG) is added as humectant to tobacco, rather frequently and in relatively high amounts (1599 counts in NL ingredient lists, 23 in NTM, total number of brand 4265), average (weight %) 1.579 (1.636).

Regarding inhalation facilitation, humectants are added to trap water, thereby keeping the moisture in the tobacco and preventing it from drying out. Internal tobacco industry documents reported that adding 3-7 weight percent of PG increased the mildness and reduced irritation (although this is higher than amounts typically present in tobacco cigarettes). Propylene glycol is, therefore, considered to positively influence the attractiveness of cigarette smoking given that humidification improves palatability of expected to impart a noticeable flavour.

Regarding addictiveness, no data were reported to suggest that propylene glycol plays a role in smokers' addictiveness to cigarettes.

Regarding toxicity, it was reported by tobacco industry that the transfer rate of propylene glycol to mainstream smoke is 10 %. A risk assessment procedure using a Margin of Exposure (MOE) analysis concluded that risks of effects on the respiratory tract epithelium from propylene glycol exist. No thorough assessment on systemic effects was made.

Propylene oxide is regarded as possibly carcinogenic to humans and trace amounts are present in propylene glycol. Additionally, pyrolysis of propylene glycol results in formation of small amounts (<10 %) of 1,3-propylene glycol, acetol or acetic anhydride, and pyruvaldehyde.

Finally and importantly, propylene glycol and/or its combustion products is only one component out of the thousands of compounds contained in cigarette smoke, thus additive effects or reactions with other compounds are likely to occur.

Priority activities

Step 1: Since propylene oxide, which is regarded as possibly carcinogenic to humans (IARC Group 2B carcinogen), is found in trace amounts in industrially-produced propylene glycol, the specification should be provided.

Data available should be collected to prove or disprove whether propylene glycol increases the risks of effects on the respiratory tract epithelium.

Step 2: Pyrolysis products should be better characterised also considering that Propylene oxide has been reported to be generated during cigarette smoking.

Step 3: The effect of propylene glycol on inhalation facilitation to cigarettes at levels found in European cigarettes (range of 0.2 to 2.4%) warrants investigation. The additive effects of propylene glycol and/or its reactivity with other compounds should be further investigated.

No thorough assessment of the systemic effects of propylene glycol has been done, so this should be looked at further.

3.5.14 Sorbitol

CAS number: 50-70-4

Rational for inclusion

Sorbitol is added as a humectant to tobacco (210 times in NL ingredient lists, 30 in NTM, total no of brands 4265), average (weight %) 0.232 (0.458).

Regarding inhalation facilitation, humectants are added to trap water, thereby keeping the moisture in the tobacco and preventing it from drying out. Sorbitol is, therefore, considered to positively influence attractiveness of cigarette smoking given that humidification improves palatability of cigarettes. Sorbitol gives tobacco smoke a slightly bitter taste and a vague odour of cellulose and is, therefore, not expected to impart a noticeable attractive flavour when used in higher amounts.

Regarding addictiveness, no data were reported to suggest that sorbitol plays a role in smokers' addictiveness to cigarettes. However, its combustion products, such as acetaldehyde and formaldehyde, were proposed to increase the addictive effect of nicotine, although data on acetaldehyde produced by pyrolysis entering the brain through the smoke inhaled are inconclusive (SCENIHR 2010).

Regarding toxicity, sorbitol was reported to pyrolyse at 900°C to compounds, such as 2-furfural (31.4 %, see section on furfural), acetaldehyde (irritant and possible human carcinogen), formaldehyde (irritant, carcinogen). Other pyrolysis products of sorbitol include furan, 2-methyltetrahydrofuran, propionaldehyde, acetone, methanol, and carbon monoxide (Baker and Bishop, 2004). Further research is needed to confirm these effects, especially if sorbitol pyrolysis results in carcinogenic compounds.

Finally, it must be borne in mind that sorbitol (and/or its combustion products) is only one component out of the thousands of compounds contained in cigarette smoke, thus additive effects or reactions with other compounds are likely to occur.

Priority activities

Step 2: The main concern for sorbitol to be addressed, before it can enter the evaluation procedure, is the formation of toxic pyrolysis and CMR products. Pyrolysis experiments must be carried out using conditions relevant for cigarette smoking (see section 3.4.1). In case of positive results, sorbitol as a tobacco additive would fall in one of the four categories listed in art. 6 of the TPD and its use as an additive in tobacco product should be carefully evaluated.

If it can be demonstrated that no toxic or carcinogenic pyrolysis products are formed, the additive can enter the step-wise procedure for evaluation.

Step1: Evaluation of available data on the additive in unburnt form

If there are data gaps or uncertainties coming from data collected in Step 1 and 2, further testing would be necessary (proceed to Step 3).

Step 3: In particular, it needs to be assessed whether it increases inhalation facilitation of cigarette smoking. It is not expected that sorbitol will give a characterising flavour but data regarding addictiveness should be produced.

3.5.15 Titanium Dioxide

CAS numbers: 13463-67-7 (mixture of mainly rutile and anatase); 1317-80-2 (rutile); 1317-70-0 (anatase)

Rational for inclusion

The SCCS evaluated its use as cosmetic ingredient (sunscreen). With regard to inhalation toxicity, it was concluded that in subacute repeated dose inhalation toxicity studies, nano-size TiO₂ induce an acute inflammation in the lungs, that may be reversible depending on the dose and the time after exposure. In view of this, acute inflammation (spray) applications, which may result in inhalation exposure, were not recommended by the SCCS. Titanium dioxide was classified by IARC as a Group 2B carcinogen (i.e. possibly carcinogenic to humans) (IARC, 2010).

To perform a risk evaluation, it is necessary to know the exposure level of titanium dioxide through cigarette smoking. Therefore, research is needed to determine the amount of titanium dioxide in mainstream cigarette smoke. Because inhalation toxicity is also related to the size of the particles, a distinction needs to be made between nano and non-nano size.

Priority activities

Step1: Evaluation of available data on the additive in unburnt form

Step 2: Not applicable because titanium is already in its highest oxidised state

Step 3: In subacute repeated dose inhalation toxicity studies, nano-size TiO₂ induces an acute inflammation in the lungs. Based on the available data, titanium dioxide is classified as a IARC Group 2B carcinogen (concern category d).

Within the scope of the EU CLP Regulation, a proposal for harmonised classification of TiO₂ was submitted (ECHA,CLH report, Proposal for Harmonised Classification and Labelling Based on Regulation (EC) No 1272/2008 (CLP Regulation), Annex VI, Part 2,

Substance Name: Titanium dioxide, Version 2, May 2016). It is proposed to reclassify TiO₂ (all forms) specifically by inhalation as Carcinogen Cat 1B. It was concluded that no carcinogenic concern was reported by both oral and dermal routes but that there is sufficient evidence of carcinogenicity in experimental animals after inhalation. Indeed, a causal relationship has been established between TiO₂ and the increase of malignant lung tumours in female rats and benign lung tumours in males and female rats in 2 inhalation and 2 instillation studies. Human data do not suggest an association between occupational exposure to TiO₂ and risk for cancer. However, all these studies have methodological limitations and the level of exposure reported is debatable. Although the full mode of action is still unclear, an inflammatory process and indirect genotoxic effect through ROS production seems to be the major mechanism to explain the effects induced by TiO₂. It is considered that this mode of action is principally due to the biopersistence and poor solubility of the TiO₂ particles.

Evidence may be provided to address the uncertainties with regard to the genotoxicity and carcinogenicity of TiO₂ by inhalation for humans.

4 OPINION

As requested by Article 6 of the Tobacco Products Directive 2014/40/EU (TPD), the Commission has established a priority list of 15 additives contained in cigarettes and roll-your-own tobacco subject to enhanced reporting obligations that is to be updated on a regular basis. SCENIHR Tobacco Opinion 1, provided the scientific basis for the establishment of such priority list.

The TPD prescribes that Member States shall require manufacturers and importers of tobacco products to carry out comprehensive studies on these additives. The SCHEER was requested to provide guidance on the type and criteria for the comprehensive studies, and the most suitable methodologies to be used for the first list of 15 priority additives, as well as for additives on future updated lists.

In the first part of the current Opinion, the SCHEER proposed a step-wise strategy (Section 3.4), as the most pragmatic and efficient way to proceed in the assessment of the toxic and addictive effects as well as characterising flavour properties, and inhalation facilitation as factors potentially contributing to attractiveness, of additives used in cigarettes and roll-your-own tobacco. The tiered approach proposed by DKFZ (DKFZ, 2010) was used as a starting point, but the SCHEER developed its own approach, also including the evaluation of addictive effects, characterising flavour properties and the inhalation facilitation of additives. The proposed strategy ensures that testing is minimised. For this reason the application of grouping different additives with similar chemical structures and of the read-across principle are endorsed.

First, the chemical specification of the additive has to be available (Step 1). Then collection/evaluation of the available open and grey literature needs to be carried out by applying a WoE approach, for the additive in its unburnt form (Step 1) and its pyrolysis products (Step 2). If no data are available on the identity of the pyrolysis products, they need to be generated using relevant test conditions (Step 2). Here, it needs to be noted that no validated methods are available for the pyrolysis of tobacco additives.

In case data retrieved in Step 1 and 2 are not sufficient or robust enough to make the evaluation possible, non-testing methods such as QSAR and read across are proposed, followed by *in vitro* approaches addressing the different endpoints to be considered (Step 3). Regarding types of effects, unless the previous step highlighted some concern for a specific end-point, CMR properties and toxicity are assessed first, as accepted methods and evaluation frameworks are available, followed by characterising flavour, because procedures are available for the assessment of these end-points. Next, addictiveness is assessed, an effect for which no validated tests are currently available, although some mechanisms underlying addictiveness are known. It is strongly advised that *in silico* and *in vitro* test to assess additive-induced addictiveness are developed and validated by independent organisations in the near future.

In line with the provisions of other regulatory contexts, the SCHEER recommends the use of a Quality system (e.g. Good Laboratory Practice or ISO17025) for carrying out the pyrolysis or other physico-chemical studies as well as pre-clinical studies. Human studies should follow the appropriate Quality System.

The issue related to interaction of the additive with other additives/ingredients is also considered. The industry is asked to provide all known information on the interaction of

additives and their pyrolysis products leading to the intended formation of flavours / pH modifiers/ smoothing agents and other important compounds.

In addition to proposing specific steps and tests to be considered by industry, some general criteria were also identified. A pre-ambule here is that additives in tobacco products have no health benefits for the consumer, but rather may promote the use of and addiction to an extremely toxic product. Therefore, a risk-benefit analysis is not the appropriate paradigm for assessing additives.

When comprehensive studies confirm that additives have any of the four properties listed in Article 6 of the TPD, regulatory action should be considered in line with Article 7 of the TPD. If uncertainties cannot be solved by comprehensive studies performed in Step 3, it is a SCHEER recommendation that the assessors consider the worst-case evaluation.

In order to provide a relevant outcome to the question whether an additive contributes to the toxicity, characterising flavour, facilitating inhalation or addictiveness of the tobacco product, the study design must adhere to some methodological criteria. Most importantly, the test outcomes should be relevant for tobacco smoking. This implies that they should be related to actual human exposure and tobacco-induced diseases, and be relevant not only for acute or subchronic, but also for chronic exposure in intermittent use sessions (Johnson *et al.*, 2009).

Furthermore, comparative toxicity testing strategies, where differences in effect of the tobacco product with and without the additive are evaluated, are not considered suitable to address the properties outlined in the Terms of Reference with the currently available methodology. Indeed, due to the high intrinsic toxicity of tobacco products, it is challenging to demonstrate any differences, whether they are increases or decreases, induced by an additive with the currently available tests and methodologies (Kienhuis *et al.*, 2016). Very sensitive tests would be required, with a clear dose-response relationship, in order to show any differences from these high background effects, which can associate assay outcomes to human risk and exposure. In this respect, *in vitro* tests combined with toxicogenomics, using biomarkers of exposure and disease, are the most promising (Kienhuis *et al.*, 2016). However, for the time being, no standardised methods have been validated for this purpose.

As adequately sensitive tests are not currently available, no new comparative studies (tobacco product with and without additives) using the available methodologies of toxicity testing will be considered for the moment, since these studies generally lack discriminative power.

Here, the effects of the pure additive, and its pyrolysis products, are considered in a relevant testing strategy, such as the tiered approach proposed by the SCHEER (Section 3.4) in order to evaluate their contribution to tobacco product toxicity. Studies that are already available could be presented, but the relevance of their results has to be evaluated in a WoE approach based on these considerations.

Comparative studies are also not endorsed for studying the effect of additives on addictiveness, for the same reasons. In human studies, there are two exceptions to this general rule: characterising flavour testing, and facilitating inhalation or nicotine uptake. The former is, by definition, a comparative testing paradigm, as clearly noticeable

flavour is a property of a tobacco product, caused by the addition of flavour additives, and not a property of an additive itself. The latter is related to additives that facilitate inhalation or nicotine uptake, and when large groups of subjects are enrolled, effects on e.g. sensory perception, smoking topography and biomarkers of exposure (e.g. nicotine in blood or cotinine in urine) can be discriminated.

Another problem with comparative testing is that the outcomes would only apply to that specific tobacco test product. The results (e.g. related to toxicity or addictiveness) cannot be generalised to all products and brands, having a different composition with respect to tobacco type, blend and additives. Therefore the obtained results may not lead to general prohibition/acceptance of specific additives but rather to prohibition/acceptance on a product-by-product basis (DKFZ, 2010).

It is ethically questionable to carry out any new animal studies to evaluate the contribution of an additive to the tobacco product toxicity, addictiveness, characterising flavour, and properties that facilitate inhalation or nicotine uptake. Similarly to most cosmetics, it is not necessary to use tobacco products. Moreover, apart from being unnecessary, tobacco products are highly harmful with no benefits to individual or public health. As additives are used for product improvement, often contributing to detrimental effects for the consumers (e.g. addictiveness), there is no health benefit in using tobacco additives. For the hazard assessment of tobacco additives, *in silico* and *in vitro* methods exist. QSAR methodology has been successfully used for decades for predicting toxicological and pharmacological properties of chemicals. The same applies to *in vitro* methods, which were validated, adopted as official protocols (e.g. OECD Test Guidelines) and accepted, also for regulatory purposes. Additionally, many promising *in vitro* methods are currently being developed to assess different adverse outcomes.

Therefore, as a principle, only the use of *in silico*, and *in vitro* methods will be considered suitable for new studies, following the EU policy to ban animal studies for chemicals to be used in voluntary products such as cosmetics (EU Regulation no. 1223/2009). Only already available data obtained with animal models will be evaluated. Human studies are generally discouraged. These may be used (e.g. in case of flavour assessment), but only if the study subjects are informed and not exposed to the harmful smoke emissions of tobacco products.

The data gaps already identified in Tobacco Opinion 1 for the 15 additive included in the EU Commission priority list have been analysed (Section 3.5). Based on the data gaps described in the 'Rationale for inclusion' taken from Opinion 1, the activities to be performed upfront have been described, indicating the most appropriate steps (and end-points) to be carried out and then used for the evaluation, in order to speed up the process making possible testing feasible in the 18-month timeframe.

In general, data gaps for the 15 priority additives are information on addictiveness and characterising flavour or inhalation facilitation, as well as on the identity of the pyrolysis products. In the past, major emphasis was put on toxicity, whereas limited research was carried out on addictiveness (and even less on attractiveness). Regarding toxicity, data were often taken from the food sector, where pyrolysis and inhalation are not an issue.

In conclusion, this Opinion provides general guidance to tobacco industry to conduct studies and prepare reports on the evaluation of Tobacco additives to be sent to the competent authorities. To this purpose, a reporting template is provided as well (see

Annex I). In addition, specific advice is given for priority testing activities to fill the data gaps recognised in Tobacco Additives Opinion 1. In order to limit the testing and administrative burden, the formation of consortia and joint reports by industry is endorsed.

It needs to be noted that there is a lack of validated methods for the pyrolysis of tobacco additives. For the assessment of many toxicological end-points animal-free methodologies are still lacking, especially when the inhalation route is concerned. Similarly, no addictiveness and attractiveness tests (apart from a procedure for characterising flavours) are available, a knowledge gap already noted by the SCHENIHR in 2010 in its report 'Addictiveness and attractiveness of tobacco additives', and the situation has not significantly improved since then. It is advised that independent bodies or organisations conduct relevant research in these fields.

5 MINORITY OPINION

None.

6 CONSIDERATION OF THE RESPONSES RECEIVED DURING THE CONSULTATION PROCESS

A public consultation on this Opinion was opened on the website of the Scientific Committees from 22 July to 22 September 2016. Information about the public consultation was broadly communicated to national authorities, international organisations and other stakeholders.

Twenty-two organisations and individuals participated in the public consultation, providing input to different parts of the Opinion, resulting in 214 contributions and nearly 1000 comments.

Most comments, by far, were from the tobacco industry, which disagreed with some aspects they considered too demanding to implement; on the contrary, other organisations and individual researchers expressed their appreciation to the SCHEER, recognising the difficulties in fulfilling such a complex mandate and positively commenting on the rationale followed by the SCHEER and on the indication that no animal testing should be performed *ex novo*.

The most frequent comments were related to comparative testing, which was not endorsed by the SCHEER in the preliminary Opinion. The claim was that this is the only way to answer to TPD Art 6 (6), according to which TI should assess whether a given additive results in a significant or measureable increase in toxicity, addictiveness or CMR. Similar criticisms were directed toward the indication in the preliminary Opinion to carry out a pyrolysis study instead of smoke chemistry.

Tobacco industry also repeatedly criticised the preliminary Opinion for supposedly going beyond the Terms of References by examining properties such as 'attractiveness' as well as asking for the application of the precautionary principle.

The SCHEER provided an individual reply to each contributor. Each submission was carefully considered by the SCHEER and the preliminary Opinion has been revised in response to relevant comments.

More precisely, in the Final Opinion SCHEER clarified its position about comparative testing, specifying when it can be considered appropriate (e.g. in some human studies), but stating that at present, methodologies are not yet sensitive enough to discriminate between the very high background toxicity associated with tobacco with and without the additive. The SCHEER concludes that testing the effects of inhaling the pure additive and its pyrolysis products is the only meaningful way to comply with art. 6(2) of the TPD, i.e. to assess whether additives contribute to the toxicity or addictiveness of the products concerned.

For consistency with the terms of reference, the wording in the Final Opinion has been aligned with the TPD, avoiding the use of the term 'attractiveness' and replacing it with properties such as characterising flavour, facilitating inhalation and nicotine uptake, which fall under the TPD.

The SCHEER agreed that the reader might associate the precautionary principle with a risk measurement measure, although that was not the SCHEER's intention. For that reason, any reference to the precautionary principle has been deleted and indications

were given for the assessor on the evaluation of the collected available and new data on the additive and its pyrolysis products in case uncertainties could not be clarified by new testing.

The many papers provided by the tobacco industry were checked and the literature has been accordingly updated with relevant publications. However, in most cases they were not considered to have provided any additional information or any information relevant enough to require amending the Opinion.

In the final Opinion, some changes were included to address specific comments and editorial changes were made to address comments pointing out possible misunderstandings.

The SCHEER would like to thank all contributors for their comments and for the references provided during the public consultation.

The text of the comments received and the response provided by the SCHEER are available here:

http://ec.europa.eu/health/scientific_committees/consultations/public_consultations/scheer_consultation_01_en

7 ABBREVIATIONS AND GLOSSARY OF TERMS

AOP	Adverse outcome pathway
ASL	Arterial Spin Labelling
CAS	Chemical Abstracts Service
CLP	Classification, Labelling and Packaging
CMR	Carcinogenic, mutagenic or toxic for reproduction
CNS	Central nervous system
COC	Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment
COM	Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment
COT	Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment
CVD	Cardiovascular disease
CYP	Cytochrome P450 monooxygenase
DA	Dopamine
DKFZ	Deutsches Krebsforschungszentrum (German Cancer Research Center)
EC	European Commission
ECDC	European Centre for Disease prevention and Control
ECHA	European Chemicals Agency
EFSA	European Food Safety Authority
EMA	European Medicines Agency
EPA	Environmental Protection Agency
EU	European Union
FDA	(US) Food and Drug Administration
FEMA	(US) Flavor and Extract Manufacturers Association
FGE	Flavouring Group Evaluation
fMRI	functional magnetic resonance imaging
FTND	Fagerström Test for Nicotine Dependence
GABA	Gamma (γ)-Aminobutyric acid
GABA	γ -aminobutyric acid
GLP	good laboratory practice
IARC	International Agency for Research on Cancer
IC50	The half-maximal inhibitory concentration
IPCS	(WHO) International Programme on Chemical Safety

JECFA	Joint FAO/WHO Expert Committee on Food Additives
JECFA	Joint FAO/WHO Expert Committee on Food Additives
JRC	(EU) Joint Research Centre
MoE	Mode of Exposure
MRI	Magnetic resonance imaging
nACh	nicotinic acetylcholine
NOAEL	No observed adverse effect level
NRC	(US) National Research Council
NTM	Non-tobacco material
OECD	Organisation for Economic Co-operation and Development
PAH	Polycyclic aromatic hydrocarbon
PAH	Polycyclic aromatic hydrocarbon
PBPK	Physiologically based pharmacokinetic
PET	Positron emission tomography
PG	Propylene glycol
pH	Measure of acidity or basicity of a solution
PITOC	EU project "Public Information Tobacco Control"
ppm	Parts per million
QSAR	Quantitative structure--activity relationships
REACH	Registration, Evaluation, Authorisation and Restriction of Chemicals
RIVM	Rijksinstituut voor Volksgezondheid en Milieu (The Netherlands National Institute for Public Health and the Environment)
RYO	Roll-your-own (cigarettes)
SCCP	Scientific Committee on Consumer Products
SCCS	Scientific Committee on Consumer Safety
SCENIHR	Scientific Committee on Emerging and Newly Identified Health Risks
SCHER	Scientific Committee on Health and Environmental and Emerging Risks
SCHER	Scientific Committee on Health and Environmental Risks
SCOEL	Scientific Committee on Occupational Exposure Limits
SPECT	Single-photon emission computed tomography
TG	(OECD) Test Guidelines
TPD	Tobacco products directive
UK	United Kingdom

US(A)	United States (of America)
WHO	World Health Organization
WoE	Weight of evidence

8 REFERENCES

Abreo M.A., Lin N.H., Garvey D.S., Gunn D.E., Hettinger A.M., Wasicak J.T., Pavlik P.A., Martin Y.C., Donnelly-Roberts D.L., Anderson D.J., Sullivan J.P., Williams M., Arneric S.P., Holladay M.W. (1996). Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. *J Med Chem* 39, 817-825.

Ågerstrand M. and Beronius A. Weight of evidence evaluation and systematic review in EU chemical risk assessment: Foundation is laid but guidance is needed. *Environ. Int.* 2015, [Epub ahead of print] doi: 10.1016/j.envint.2015.10.008.

Alpert H.R., Agaku I.T., Connolly G.N. (2016). A study of pyrazines in cigarettes and how additives might be used to enhance tobacco addiction. *Tob Control* 25, 444–50.

Alsharari S.D., Siu E.C., Tyndale R.F., Damaj M.I. (2014). Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor. *Nicotine Tob Res* 16, 18-25.

Alsharari S.D., King J.R., Nordman J.C., Muldoon P.P., Jackson A., Zhu A.Z., Tyndale R.F., Kabbani N., Damaj M.I. (2015). Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice. *PLoS ONE* 10(9): e0137070.

American Psychiatric Association (2013). *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*. 5th ed.

<http://dx.doi.org/10.1176/appi.books.9780890425596>. accessed on 04/05/2015.

Andreoli C., Gigante D., Nunziata A. (2003). A review of in vitro methods to assess the biological activity of tobacco smoke with the aim of reducing the toxicology of smoke. *Toxicology In Vitro*, 17, 587–94.

Ankley G.T., Bennett R.S., Erickson R.J., Hoff D.J., Hornung M.W., Johnson R.D., Mount D.R., Nichols J.W., Russom C.L., Schmieder P.K., Serrano J.A., Tietge J.E., Villeneuve D.L. (2010). Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. *Environ Toxicol Chem* 29 (3), 730 -41.

Antanares project <http://www.antares-life.eu>

ANVISA Working Group on Tobacco Additives (2014). Report of the Working Group on Tobacco Additives.

http://portal.anvisa.gov.br/wps/wcm/connect/5c3e698046be14978161fd2e64280806/Report_Working_Group_Tobacco_Additives_FINAL_26-08-14pdf?MOD=AJPERES.

AOP-Wiki (2014). Users' Handbook Supplement to the Guidance Document for Developing and Assessing AOPs. https://aopkb.org/common/AOP_Handbook.

Arimilli S., Damratoski B.E., Bombick B., Borgerding M.F., Prasad G.L. (2012). Evaluation of cytotoxicity of different tobacco product preparations. *Regul Toxicol Pharm* 64, 350–60.

Asgharian B., Price O., McClellan G., Corley R., Einstein D.R., Jacob R.E., Harkema J., Carey S.A., Schelegle E., Hyde D., Kimbell J.S., Miller F.J. (2012). Development of a rhesus monkey lung geometry model and application to particle deposition in comparison to humans. *Inhal Toxicol* 24, 869-99.

Ashoor A., Nordman J.C., Veltri D., Yang K.H., Al Kury L., Shuba Y., Mahgoub M., Howarth F.C., Sadek B., Shehu A., Kabbani N., Oz M. (2013). Menthol binding and inhibition of alpha7-nicotinic acetylcholine receptors. *PLoS One* 8, e67674.

Aufderheide M., Knebel J.W., Ritter D. (2003). An improved in vitro model for testing the pulmonary toxicity of complex mixtures such as cigarette smoke. *Exp Toxicol Pathol* 55, 51–7.

Aufderheide M., Scheffler S., Möhle N., Halter B. & Hochrainer D. (2011). Analytical in vitro approach for studying cyto- and genotoxic effects of particulate airborne material. *Anal. Bioanal. Chem.* 401, 3213–20.

Bagdas D., Muldoon P.P., Zhu A.Z., Tyndale R.F., Damaj M.I. (2014). Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. *Neuropharmacology* 85, 67-72.

Bakand S., Hayes C. (2010). Troubleshooting methods for toxicity testing of airborne chemicals in vitro. *J Pharmacol Toxicol Methods* 61, 76–85.

Baker R.R., Bishop L.J. (2004). The pyrolysis of tobacco ingredients. *Journal of Analytical and Applied Pyrolysis* 71, 223-311.

Baker R.R., Massey E.D., Smith G. (2004a). An overview of the effects of tobacco ingredients on smoke chemistry and toxicity. *Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association* 42 Suppl, S53-83.

Baker R.R., Pereira da Silva J.R., Smith G. (2004b). The effect of tobacco ingredients on smoke chemistry. Part I: Flavourings and additives. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association* 42 Suppl, S3-37.

Baker R.R., Pereira da Silva J.R., Smith G. (2004c). The effect of tobacco ingredients on smoke chemistry. Part II: casing ingredients. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association* 42 Suppl, S39-52.

Baker T.B., Breslau N., Covey L., Shiffman S. (2012). DSM criteria for tobacco use disorder and tobacco withdrawal: a critique and proposed revisions for DSM-5. *Addiction* 107, 263-75.

Bal-Price A., Crofton K.M., Sachana M., Shafer T.J., Behl M., Forsby A., Hargreaves A., Landesmann B., Lein P.J., Lousse J., Monnet-Tschudi F., Pains A., Rolaki A., Schratzenholz A., Suñol C., van Thriel C., Whelan M., Fritsche E. (2015). Putative adverse outcome pathways (AOP) relevant to neurotoxicity. *Crit Rev Toxicol* 45(1), 83–91.

Bal-Price, A., Crofton, K.M., Leist, M., Allen, S., Arand, M., Buetler, T., Delrue, N., FitzGerald, R.E., Hartung, T., Heinonen, T., Hogberg, H., Bennekou, S.H., Lichtensteiger, W., Oggier, D., Paparella, M., Axelstad, M., Piersma, A., Rached, E., Schilter, B., Schmuck, G., Stoppini, L., Tongiorgi, E., Tiramani, M., Monnet-Tschudi, F., Wilks, M.F., Ylikomi, T. & Fritsche, E. (2015). International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes. *Archives of Toxicology* 89, 269–287.

- Barrett S.P., Boileau I., Okker J., Pihl R.O., Dagher A. (2004). The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [¹¹C]raclopride. *Synapse* 54, 65-71.
- Bates C., Jarvis M., Connolly G. (1999). Tobacco Additives: cigarette engineering and nicotine addiction. London: ASH UK Report; 14 July, 1999.
- Becker R.A., Ankley G.T., Edwards S.W., Kennedy S., Linkov I., Meek B., Sachana M., Segner H., Van Der Berg B., Villeneuve D.L., Watanbe H., Barton- Maclaren T.S. (2015). Increasing scientific confidence in adverse outcome pathways: application of tailored Bradford-Hill considerations for evaluating weight of evidence. *Regul.Toxicol.Pharmacol.*72, 514-37.
- Benowitz N.L., Herrera B., Jacob P., (2004). Mentholated cigarette smoking inhibits nicotine metabolism. *J Pharmacol Exp Ther* 310, 1208-15.
- Berridge K.C., Robinson T.E. (2003). Parsing reward. *Trends in neurosciences* 26, 507-13.
- Berridge M.S., Apana S.M., Nagano K.K., Berridge C.E., Leisure G.P., Boswell M.V. (2010). Smoking produces rapid rise of [¹¹C]nicotine in human brain. *Psychopharmacology (Berl)* 209, 383-94.
- Berube K., Pitt A., Hayden P., Prytherch Z., and Job C. (2010). Filter-well technology for advanced three-dimensional cell culture: perspectives for respiratory research. *Altern Lab Anim* 38 Suppl 1, 49.
- Behrendt *et al.* (2004). *Br J Pharmacol*; 141, 737-45.
- Boyadjieva N.I., Sarkar D.K. (1997). The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. *Life Sci* 61, PL59-66.
- Brennan E., Gibson L., Momjian A., Hornik R.C. (2015). Are Young People's Beliefs About Menthol Cigarettes Associated With Smoking-Related Intentions and Behaviors? *Nicotine Tob Res.* 17(1), 81-90.
- Brody A.L., Olmstead R.E., London E.D., Farahi J., Meyer J.H., Grossman P., Lee G.S., Huang J., Hahn E.L., Mandelkern M.A. (2004). Smoking-induced ventral striatum dopamine release. *Am J Psychiatry* 161, 1211-8.
- Brody A.L., Mandelkern M.A., London E.D., Olmstead R.E., Farahi J., Scheibal D., Jou J., Allen V., Tiongson E., Chefer S.I., Koren A.O., Mukhin A.G. (2006a). Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. *Arch Gen Psychiatry* 63, 907-15.
- Brody A.L., Mandelkern M.A., Olmstead R.E., Scheibal D., Hahn E., Shiraga S., Zamora-Paja E., Farahi J., Saxena S., London E.D., McCracken J.T. (2006b). Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. *Arch Gen Psychiatry* 63, 808-16.
- Brody A.L., Mandelkern M.A., Costello M.R., Abrams A.L., Scheibal D., Farahi J., London E.D., Olmstead R.E., Rose J.E., Mukhin A.G. (2009). Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. *Int J Neuropsychopharmacol* 12, 305-16.

Brody A.L., Mandelkern M.A., London E.D., Khan A., Kozman D., Costello M.R., Vellios E.E., Archie M.M., Bascom R., Mukhin A.G. (2011). Effect of secondhand smoke on occupancy of nicotinic acetylcholine receptors in brain. *Arch Gen Psychiatry* 68, 953-60.

Brody A.L., Mukhin A.G., La Charite J., Ta K., Farahi J., Sugar C.A., Mamoun M.S., Vellios E., Archie M., Kozman M., Phuong J., Arlorio F., Mandelkern M.A. (2013). Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers. *Int J Neuropsychopharmacol* 16, 957-66.

Brody A.L., Mukhin A.G., Mamoun M.S., Luu T., Neary M., Liang L., Shieh J., Sugar C.A., Rose J.E., Mandelkern M.A. (2014). Brain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment: A Randomized Trial. *JAMA Psychiatry*. 71(7), 797-805.

Brust P., Patt J.T., Deuther-Conrad W., Becker G., Patt M., Schildan A., Sorger D., Kendziorra K., Meyer P., Steinbach J., Sabri O. (2008). In vivo measurement of nicotinic acetylcholine receptors with [¹⁸F]norchloro-fluoro-homoepibatidine. *Synapse* 62, 205-18.

Busch C., Streibel T., Liu C., McAdam K.G., Zimmermann R. (2012). Pyrolysis and combustion of tobacco in a cigarette smoking simulator under air and nitrogen atmosphere. *Anal Bioanal Chem*, 419-30.

Caille S., Clemens K., Stinus L., Cador M. (2012). Modelling nicotine addiction in rats. *Methods Mol Biol* 829, 243-56.

Camlin N.J., McLaughlin E.A., Holt J.E. (2014). Through the smoke: use of in vivo and in vitro cigarette smoking models to elucidate its effect on female fertility. *Toxicol Appl Pharmacol*. 281(3), 266-75.

Carmines E.L. (2002). Evaluation of the potential effects of ingredients added to cigarettes. Part 1: cigarette design, testing approach, and review of results. *Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association* 40, 77-91.

Carpenter C.M., Wayne G.F., Connolly G.N. (2005a). Designing cigarettes for women: new findings from the tobacco industry documents. *Addiction* 100, 837-51.

Carpenter C.M., Wayne G.F., Pauly J.L., Koh H.K., Connolly G.N. (2005b). New cigarette brands with flavors that appeal to youth: Tobacco marketing strategies. *Health Aff (Millwood)* 24, 1601-10.

Carpenter C.M., Wayne G.F., Connolly G.N. (2007). The role of sensory perception in the development and targeting of tobacco products. *Addiction* 102, 136-47.

Cavallo D., Ursini C.L., Fresegna A.M., Maiello R., Ciervo A., Ferrante R., Buresti G., Iavicoli S. (2013). Cyto-genotoxic effects of smoke from commercial filter and non-filter cigarettes on human bronchial and pulmonary cells. *Mutat Res*. 750(1-2), 1-11.

Cervellati F., Muresan X.M., Sticozzi C., Gambari R., Montagner G., Forman H.J., Torricelli C., Maioli E., Valacchi G. (2014). Comparative effects between electronic and cigarette smoke in human keratinocytes and epithelial lung cells. *Toxicology in Vitro* 28, 999-1005.

Chen H., Cui L., Jiang X.Y., Pang Y.Q. Tang, G.L. Hou, H.W. Jiang J.H., Hu, Q.Y. (2012). Evaluation of the cytotoxicity of cigarette smoke condensate by a cellular impedance biosensor. *Food & Chemical Toxicology* 50, 612-18.

- COC (2009). Annual report 2009. <https://cotfoodgovuk/sites/default/files/cot/cocsection2009pdf>.
- Collins C.C., Moolchan E.T. (2006). Shorter time to first cigarette of the day in menthol adolescent cigarette smokers. *Addict Behav* 31, 1460-4.
- Commission Implementing Regulation (EU) 2016/779 of 18 May 2016 laying down uniform rules as regards the procedures for determining whether a tobacco product has a characterising flavour: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2016.131.01.0048.01.ENG&toc=OJ:L:2016:131:TOC
- Commission Implementing Decision (EU) 2016/786 of 18 May 2016 laying down the procedure for the establishment and operation of an independent advisory panel assisting Member States and the Commission in determining whether tobacco products have a characterising flavour: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2016.131.01.0079.01.ENG&toc=OJ:L:2016:131:TOC
- Combes R., Scott K., Dillon D., Meredith C., McAdam K., Proctor, C. (2012). The effect of a novel tobacco process on the in vitro cytotoxicity and genotoxicity of cigarette smoke particulate matter. *Toxicology in Vitro* 26, 1022-9.
- Combes R., Scott K., Crooks I., Dillon D., Meredith C., McAdam K., Proctor, C. (2013). The in vitro cytotoxicity and genotoxicity of cigarette smoke particulate matter with reduced toxicant yields. *Toxicology in Vitro* 27, 1533-41.
- Connolly G.N., Wayne G.D., Lymperis D., Doherty M.C. (2000). How cigarette additives are used to mask environmental tobacco smoke. *Tob Control* 9, 283-91.
- Connolly G.N. (2004). Sweet and spicy flavours: new brands for minorities and youth. *Tob Control* 13, 211-2.
- CORESTA in vitro toxicology task force. (2004). THE RATIONALE AND STRATEGY FOR CONDUCTING IN VITRO TOXICOLOGY TESTING OF TOBACCO SMOKE (May 2004): https://www.coresta.org/sites/default/files/technical_documents/main/IVT_TF_Rationale-IVT-Testing-Tob.-Smoke_Report_Jun04.pdf.
- CORESTA in vitro toxicology task force report. (2006). In vitro exposure of cells to smoke at the air liquid interface: https://www.coresta.org/sites/default/files/technical_documents/main/IVT_TF_Report_Smoke_Air_Liquid_Interface.pdf.
- Cosgrove K.P., Batis J., Bois F., Maciejewski P.K., Esterlis I., Kloczynski T., Stiklus S., Krishnan-Sarin S., O'Malley S., Perry E., Tamagnan G., Seibyl J.P., Staley J.K. (2009). beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. *Arch Gen Psychiatry* 66, 666-76.
- Cosgrove K.P., Esterlis I., Sandiego C., Petrulli R., Morris E.D. (2015). Imaging Tobacco Smoking with PET and SPECT. *Curr Top Behav Neurosci* 24, 1-17.
- COT/COM/COT (2009). Carcinogenicity testing of tobacco products. Annual report. Committees on toxicity (COT), mutagenicity (COM), carcinogenicity (COC) of chemicals in food, consumer products and the environment, London.
- Counts M.E., Morton M.J., Laffoon S.W., Cox R.H., Lipowicz P.J. (2005). Smoke composition and predicting relationships for international commercial cigarettes smoked with three machine-smoking conditions. *Regul Toxicol Pharm*, 41(3), 185-227.

- Costigan S., Meredith C. (2015) An approach to ingredient screening and toxicological risk assessment of flavours in e-liquids. *Regul Toxicol Pharmacol.* 72(2), 361-9.
- Cramer R.D., Patterson D.E., Bunce J.D. (1988). Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. *J Am Chem Soc* 110, 5959-67.
- Crooks I., Dillon D., Scott K., Ballantyne M., Meredith C. (2013). The effect of long term storage on tobacco smoke particulate matter in in vitro genotoxicity and cytotoxicity assays. *Regul Toxicol Pharm* 65, 196–200.
- Crooks, I., Scott, K., Dalrymple, A., Dillon, D., Meredith, C. (2015). The combination of two novel tobacco blends and filter technologies to reduce the in vitro genotoxicity and cytotoxicity of prototype cigarettes. *Regul Toxicol Pharmacol.* 71(3), 507-14.
- Cummings KM, Morley CP, Horan JK, Steger C, Leawell NR. (2002). Marketing to America's youth: evidence from corporate document. *Tob Control* 11, 15-17.
- Damaj M.I., Meyer E.M., Martin B.R. (2000). The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. *Neuropharmacology* 39, 2785-91.
- Dani J.A., De Biasi M. (2001). Cellular mechanisms of nicotine addiction. *Pharmacol Biochem Behav* 70, 439-46.
- Davenport K.E., Houdi A.A., Van Loon G.R. (1990). Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. *Neurosci Lett* 113, 40-6.
- de Jong P.M., van Sterkenburg M.A., Hesseling S.C., Kempenaar J.A., Mulder A.A., Mommaas A.M., Dijkman J.H., and Ponc M. (1994). Ciliogenesis in human bronchial epithelial cells cultured at the air-liquid interface. *Am J Respir Cell Mol Biol* 10, 271.
- DKFZ (2010). Strategy for Toxicity Evaluation of Tobacco Additives and their Regulation. Deutsches Krebsforschungszentrum (DKFZ), Heidelberg.
- Domino E.F., Hirasawa-Fujita M., Ni L., Guthrie S.K., Zubieta J.K. (2015). Regional brain [(11)C]carfentanil binding following tobacco smoking. *Prog Neuropsychopharmacol Biol Psychiatry* 59, 100-4.
- EFSA (2010). Application of Systematic Review Methodology to Food and Feed Safety Assessments to Support Decision Making. <http://www.efsa.europa.eu/en/search/doc/1637.pdf>
- EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) (2012). Scientific European Food Safety Authority (EFSA), Parma, Italy. Opinion, Guidance for submission for food additive evaluations, *EFSA Journal* 10(7), 2760.
- EFSA (2013). International Frameworks Dealing with Human Risk Assessment of Combined Exposure to Multiple Chemicals, *EFSA Journal* 2013; 11(7):3313 [69 pp.]. http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/3313.pdf
- Egger M., Smith D.G. (1997). Meta-analysis: Potentials and promise. *BMJ* 315, 1371–4. [PubMed: 9432250]
- Esfahani A., Wong J.M., Truan J., Villa C.R., Mirrahimi A., Srichaikul K., Kendall C.W. (2011). Health effects of mixed fruit and vegetable concentrates: a systematic review of the clinical interventions. *J Am Coll Nutr.* 30(5), 285-94.

Eskes C., Sullivan K., Aardema M., Spielmann H., Hill E., Schoeters G., Curren R., Vinken M., Blaauboer B. (2012). Comparing the challenges in developing and implementing 3Rs alternative methods in Europe and United States: Industrial and academic perspectives. ALTEX 1/12, WC8 Proceedings, 205–9.

Etter J.F., Le Houezec J., Perneger T.V. (2003). A self-administered questionnaire to measure dependence on cigarettes: the cigarette dependence scale. *Neuropsychopharmacology* 28, 359-70.

Etter J.F. (2005). A self-administered questionnaire to measure cigarette withdrawal symptoms: the Cigarette Withdrawal Scale. *Nicotine Tob Res* 7, 47-57.

EU Scientific Committees on Health and Environmental Risks (SCHER), on Emerging and Newly Identified Health Risks (SCENIHR) and Consumer Safety (SCCS) opinion on Toxicity and Assessment of Chemical Mixtures in 2011, supported the use of a tiered approach, such as that presented in the WHO Framework. http://ec.europa.eu/health/scientific_committees/environmental_risks/docs/scher_o_155.pdf

EuroMix project: <https://www.euromixproject.eu>.

European Union (2014). Directive 2014/40/EU of the European Parliament. In: Union, E. (Ed.). Official Journal of the European Union.

Fagerstrom K. (2012). Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. *Nicotine Tob Res* 14, 75-8.

Farsalinos K.E., Romagna G., Alliffranchini E., Ripamonti E., Bocchietto E., Todeschi S., Tsiapras D., Kyrzopoulos S., Voudris, V. (2013). Comparison of the cytotoxic potential of cigarette smoke and electronic cigarette vapour extract on cultured myocardial cells. *Int J Environ Res Public Health* 10, 5146–62.

Fearon I.M., Gaca M.D., Nordskog B.K. (2013). In vitro models for assessing the potential cardiovascular disease risk associated with cigarette smoking. *Toxicology in vitro* 27, 513-22.

Ferreira C.G., Silveira D., Hatsukami D.K., Paumgarten F.J., Fong G.T., Gloria M.B., Toledo M.C., Talhout R. (2015). The effect of tobacco additives on smoking initiation and maintenance. *Cadernos de saude publica* 31, 223-5.

Forbes, B., and Ehrhardt, C. (2005). Human respiratory epithelial cell culture for drug delivery applications. *Eur J Pharm Biopharm* 60, 193.

Forster M., Liu C., Duke M.G., McAdam K.G., Proctor C.J. (2015). An experimental method to study emissions from heated tobacco between 100-200 degrees C. *Chem Cent J* 9, 20.

Fowler J.S., Logan J., Wang G.J., Volkow N.D. (2003). Monoamine oxidase and cigarette smoking. *Neurotoxicology* 24, 75-82.

Fowler P., Smith K., Young J., Jeffrey L., Kirkland D., Pfuhler S., Carmichael P. (2012) Reduction of misleading (“false”) positive results in mammalian cell genotoxicity assays. I. Choice of cell type *Mutation Research* 742, 11–25.

Fowles, J. (2001). Chemical factors influencing the addictiveness and attractiveness of cigarettes in New Zealand. New Zealand Ministry of Health

- Fowles J., Dybing E. (2003). Application of toxicological risk assessment principles to the chemical toxicants of cigarette smoke. *Tobacco Control* 12, 424–30.
- Fukano Y., Ogura M., Eguchi K., Shibagaki M., Suzuki M. (2004). Modified procedure of a direct in vitro exposure system for mammalian cells to whole cigarette smoke. *Experimental and Toxicologic Pathology* 55, 317–23.
- Gao H., Prasad G.L., Zacharias W. (2013). Differential cell-specific cytotoxic responses of oral cavity cells to tobacco preparations. *Toxicology in Vitro* 27, 282–91.
- Garcia-Canton C., Errington G., Anadon A., Meredith, C. (2014). Characterisation of an aerosol exposure system to evaluate the genotoxicity of whole mainstream cigarette smoke using the in vitro γ H2AX assay by high content screening. *BMC Pharmacology & Toxicology* 23, 15–41.
- Gaworski C.L., Schramke H., Diekmann J., Meisgen T.J., Tewes F.J., Veltel D.J., Vanscheeuwijck P.M., Rajendran N., Muzzio M., Hausmann H.J. (2009). Effect of filtration by activated charcoal on the toxicological activity of cigarette mainstream smoke from experimental cigarettes. *Inhal Toxicol* 21, 688–704.
- Gaworski C.L., Wagner K.A., Morton M.J., Oldham M.J. (2011). Insights from a multi-year program designed to test the impact of ingredients on mainstream cigarette smoke toxicity. *Inhal Toxicol Suppl* 1, 172-83.
- Gee D. (2008). Establishing evidence for early action: the prevention of reproductive and developmental harm. *Basic Clin Pharmacol Toxicol*. 102, 71-2.
- Ghallab A. (2013). In vitro test systems and their limitations EXCLI J. 12, 1024–6. Published online 2013 Dec 12. PMID: PMC4803002.
- Gnerre C., Catto M., Leonetti F., Weber P., Carrupt P.A., Altomare C., Carotti A., Testa B. (2000). Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. *J Med Chem*. 43, 4747-58.
- Godoy P., Hengstler J.G., Ilkavets I., Meyer C., Bachmann A., Müller A., *et al.* (2009). Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. *Hepatology* 49, 2031–43.
- Godoy P., Lakkapamu S., Schug M., Bauer A., Stewart J.D., Bedawi E., *et al.* (2010). Dexamethasone-dependent versus -independent markers of epithelial to mesenchymal transition in primary hepatocytes. *Biol Chem*. 391, 73–83.
- Godoy P., Schug M., Bauer A., Hengstler J.G. (2010). Reversible manipulation of apoptosis sensitivity in cultured hepatocytes by matrix-mediated manipulation of signaling activities. *Methods Mol Biol*. 640, 139–55.
- Gotti C., Zoli M., Clementi F. (2006). Brain nicotinic acetylcholine receptors: native subtypes and their relevance. *Trends Pharmacol Sci*. 27, 482-91.
- Grainger C.I., Greenwell L.L., Lockley D.J., Martin G.P., and Forbes B. (2006). Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. *Pharm Res*. 23, 1482.
- Guo X., Verkler T.L., Chen Y., Richter P.A., Polzin G.M., Moore M.M., Mei N. (2011). Mutagenicity of 11 cigarette smoke condensates in two versions of the mouse lymphoma assay. *Mutagenesis* 26, 273–81.

Ha, M.A., Smith, G.J., Cichocki, J.A., Fan, L., Liu, Y.S., Caceres, A.I., Jordt, S.E., Morris, J.B. (2015). Menthol attenuates respiratory irritation and elevates blood cotinine in cigarette smoke exposed mice. *PLoS One*. 2015 Feb 13; 10(2):e0117128. doi: 10.1371/journal.pone.0117128. PMID: 25679525.

Haddadian E.J., Cheng M.H., Coalson R.D., Xu Y., Tang P. (2008). In silico models for the human alpha4beta2 nicotinic acetylcholine receptor. *J Phys Chem B* 112, 13981-90.

Hans M., Wilhelm M., Swandulla D. (2012). Menthol suppresses nicotinic acetylcholine receptor functioning in sensory neurons via allosteric modulation. *Chem Senses* 37, 463-9.

Hart A., Roelofs W., Hardy A.R., Macleod A. (2007). Comparative review of risk terminology. A comparative review of terminology and expressions used by the three scientific committees established by Commission Decision 2004/210/EC and by their predecessors established by Commission Decision 97/579/EC (repealed by Commission Decision 2004/210/EC). Report No. S12.454739. The Central Science Laboratory, DEFRA, Sand Hutton, York, UK.

He X., Chen Y.Y., Shi J.B., Tang W.J., Pan Z.X., Dong Z.Q., Song B.A., Li J., Liu X.H. (2014). New coumarin derivatives: Design, synthesis and use as inhibitors of hMAO. *Bioorg Med Chem*. 22(14), 3732-8.

Henningfield J.E., Hatsukami D.K., Zeller M., Peters E. (2011). Conference on abuse liability and appeal of tobacco products: conclusions and recommendations. *Drug Alcohol Depend* 116, 1-7.

Herraiz T., Chaparro C. (2005). Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. *Biochem Biophys Res Commun* 326, 378-86.

Herraiz T., Chaparro C. (2006). Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee. *Life Sci* 78, 795-802.

Hertz-Schunemann R., Ehlert S., Streibel T., Liu C., McAdam K., Baker R.R., Zimmermann R. (2015). High-resolution time and spatial imaging of tobacco and its pyrolysis products during a cigarette puff by microprobe sampling photoionisation mass spectrometry. *Anal Bioanal Chem*. 407, 2293-9.

Herzog F., Clift M.J., Piccapietra F., Behra R., Schmid O., Petri-Fink A., and Rothen-Rutishauser B. (2013). Exposure of silver-nanoparticles and silver-ions to lung cells in vitro at the air-liquid interface. *Part Fibre Toxicol* 10, 11.

Hillmer A.T., Wooten D.W., Moirano J.M., Slesarev M., Barnhart T.E., Engle J.W., Nickles R.J., Murali D., Schneider M.L., Mukherjee J., Christian B.T. (2011). Specific alpha4beta2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey. *Synapse* 65, 1309-18.

Hockley B.G., Stewart M.N., Sherman P., Quesada C., Kilbourn M.R., Albin R.L., Scott P.J. (2013). (-)-[(18) F]Flubatine: evaluation in rhesus monkeys and a report of the first fully automated radiosynthesis validated for clinical use. *J Labelled Comp Radiopharm* 56, 595-9.

Hoffman A.C., Simmons D. (2011). Menthol cigarette smoking and nicotine dependence. *Tob Induc Dis* 9 Suppl 1, S5.

Hoffman A.C., Evans S.E. (2013). Abuse potential of non-nicotine tobacco smoke components: acetaldehyde, nor nicotine, cotinine, and anabasine. *Nicotine Tob Res* 15, 622-32.

Holma B., Hegg P.O. (1989). pH- and protein-dependent buffer capacity and viscosity of respiratory mucus. Their interrelationships and influence on health. *Sci Total Environ* 84, 71-82.

Horvath A.R., Pewsner D. (2004). Systematic reviews in laboratory medicine: principles, processes and practical considerations. *Clinica Chimica Acta* 342, 23–39.

<http://cactus.nci.nih.gov>

http://echa.europa.eu/documents/10162/13632/information_requirements_r7a_en.pdf

http://ihcp.jrc.ec.europa.eu/our_databases/jrc-qsarinventory

http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/qsar_tools/QRF

<http://qsar.food.dtu.dk>

<http://www.oecd.org/chemicalsafety/risk-assessment/introductiontoquantitativestructureactivityrelationships.htm>

<http://www.qsartoolbox.org>

<https://eurl-ecvam.jrc.ec.europa.eu/databases/jrc-qsar-model-database>

https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive_toxicology/qsar_tools/qsar-tools

https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive_toxicology/qsar_tools/toxtree

https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive_toxicology/qsar_tools/DART

https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive_toxicology/qsar_tools/toxmatch

https://eurl-ecvam.jrc.ec.europa.eu/laboratories-research/predictive_toxicology/qsar_tools/stat4tox

[http://www.comcarelink.health.gov.au/internet/main/publishing.nsf/Content/14F3E74C2B8CFB98CA257BF0001DE830/\\$File/pmorris.pdf](http://www.comcarelink.health.gov.au/internet/main/publishing.nsf/Content/14F3E74C2B8CFB98CA257BF0001DE830/$File/pmorris.pdf)

<http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm>

http://www.hc-sc.gc.ca/hl-vs/tobac-tabac/legislation/reg/indust/constitu_e.html

<http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/legislation/reg/indust/method/index-eng.php#main>

Hukkanen J., Jacob P. 3rd, Benowitz N.L. (2005). Metabolism and disposition kinetics of nicotine. *Pharmacol Rev* 57, 79-115.

Hurt R.D., Robertson C.R. (1998). Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial. *JAMA* 280, 1173-81.

IARC (2006). Monographs on the Evaluation of Carcinogenic Risks to Humans. Preamble (<http://monographs.iarc.fr/ENG/Preamble/CurrentPreamble.pdf>).

- Jaffe A.J., Glaros A.G. (1986). Taste dimensions in cigarette discrimination: a multidimensional scaling approach. *Addict Behav* 11, 407-13.
- Jasinska A.J., Zorick T., Brody A.L., Stein E.A. (2014). Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans. *Neuropharmacology* 84, 111-22.
- Jenkins C.R., Boham N., Burden A.J., Dixon M., Dowle M., Fiebelkorn R.T., Ferris R.P., Hemsley S.R., Maswood M.R., Mooney P.J., O'Reilly R., Stephenson A.G., Wagner C., Walshe P.W.D., White P.R. (1997). British American Tobacco Company Limited Product Seminar. Tobacco documents 760076123-760076408, 760076123-760076408.
- Jenkins R.W., Newman R.H., Chavis M.K. (1970). Cigarette smoke formation studies. Smoke distribution and mainstream pyrolytic composition of added ¹⁴C-menthol. *Beitrag zur Tabakforschung* 5, December.
- Jennings P. (2015). The future of in vitro toxicology. *Toxicol In Vitro*. 29(6), 1217-21.
- Jensen A.A., Frolund B., Liljefors T., Krogsgaard-Larsen P. (2005). Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. *Journal of Medical Chemistry* 48, 4705-45.
- Jianlin, L., Guohai, C., Guojun, Z., Jian, J., Fangfang, H., Juanjuan, X., Shu, Z., Zhijian, C., Wei, J., Yezhen, L., Xiaoxue, L. & Jiliang, H. (2009). Assessing cytogenotoxicity of cigarette smoke condensates using three in vitro assays. *Mutation Research* 677, 21–26.
- Jianlin, L., Guohai, C., Guojun, Z., Jian, J., Fangfang, H., Juanjuan, X., Shu, Z., Zhijian, C., Wei, J., Yezhen, L., Xiaoxue, L., Jiliang, H. (2009). Studying the impact of S9 on cytogenotoxicity of cigarette smoke in human peripheral blood lymphocytes in vitro. *Environmental Toxicology & Pharmacology* 28, 275–79.
- Jianlin L., Guohai C, Guojun Z, Jian J, Fangfang H, Juanjuan X, Shu Z, Wei J, Yezhen L, Xiaoxue L, Zhijian C, Jiliang H. (2010). Comparison between two kinds of cigarette smoke condensates (CSCs) of the cytogenotoxicity and protein expression in a human B-cell lymphoblastoid cell line using CCK-8 assay, Comet assay and protein microarray. *Mutation Research* 697, 55–9.
- Johnson C.L. (1976). Quantitative structure-activity studies on monoamine oxidase inhibitors. *J Med Chem* 19, 600-5.
- Johnson M.D., Schilz J., Djordjevic M.V., Rice J.R. & Shields P.G. (2009). Evaluation of in vitro assays for assessing the toxicity of cigarette smoke and smokeless tobacco. *Cancer Epidemiol Biomarkers Prev* 18, 3263–304.
- Kabbani N. (2013). Not so Cool? Menthol's discovered actions on the nicotinic receptor and its implications for nicotine addiction. *Front Pharmacol*. 4, 95.
- Kanebratt K.P., Andersson T.B. (2008). HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. *Drug Metab Dispos*. 36, 137–45.
- Katrak P., Bialocerkowski A., Massy-Westropp N., Kumar V.S., Grimmer K. (2004). A systematic review of the content of critical appraisal tools. *BMC Medical Research Methodology* 4, 22.
- Keiser M.J., Roth B.L., Armbruster B.N., Ernsberger P., Irwin J.J., Shoichet B.K. (2007). Relating protein pharmacology by ligand chemistry. *Nat Biotechnol*. 25, 197-206.

- Keithly L, Ferris Wayne G., Cullen D.M., Connolly G.N. (2005). Industry research on the use and effects of levulinic acid: A case study in cigarette additives. *Nicotine Tob Res.* 7, 761-71.
- Kienhuis A.S., Soeteman-Hernández L.G., Staal Y.C.M., van de Nobelen S., Talhout R. (2016). A test strategy for the assessment of additive attributed toxicity of tobacco products. Available online. doi:10.1016/j.fct.2016.05.002.
- Kilford J., Thorne D., Payne R., Dalrymple A., Clements J., Meredith C., Dillon D. (2014). A method for assessment of the genotoxicity of mainstream cigarette-smoke by use of the bacterial reverse-mutation assay and an aerosol-based exposure system. *Mutat Res.* 769: 20-8.
- Klus H., Scherer G., Muller L. (2012). Influence of additives on cigarette related health risks. *Contributions to Tobacco Research* 25 (3), 412–93.
- Kober H., Deleone C.M. (2011). Smoking and Neuroimaging: A Review. *Curr Cardiovasc Risk Rep.* 5, 484-91.
- Kochhar N., Warburton D.M. (1990). Puff-by-puff sensory evaluation of a low to middle tar medium nicotine cigarette designed to maintain nicotine delivery to the smoker. *Psychopharmacology (Berl)* 102, 343-9.
- Koren A.O., Horti A.G., Mukhin A.G., Gundisch D., Kimes A.S., Dannals R.F., London E.D. (1998). 2-, 5-, and 6-Halo-3-(2(S)-azetidylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. *J Med Chem.* 41, 3690-8.
- Kosmider B., Messier E.M., Chu H.W., Mason R.J. (2011). Human alveolar epithelial cell injury induced by cigarette smoke. *PLoS One* 6, e26059.
- Koustaas E., Lam J., Sutton P., Johnson P.I., Atchley D.S., Sen S., Robinson K.A., Axelrad D.A., Woodruff T.J. (2014). The navigation guide—evidence-based medicine meets environmental health: systematic review of nonhuman evidence for PFOA effects on fetal growth. *Environ Health Perspect.* 122 (10), 1015-27.
- Kramlinger V.M., von Weymarn L.B., Murphy S.E. (2012). Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, beta-nicotyrine and menthol. *Chem Biol Interact* 197, 87-92.
- Kuwabara H., Wong D.F., Gao Y., Valentine H., Holt D.P., Ravert H.T., Dannals R.F., Horti A.G. (2012). PET Imaging of nicotinic acetylcholine receptors in baboons with 18F-AZAN, a radioligand with improved brain kinetics. *J Nucl Med.* 53, 121-9.
- Kuwabara H., Heishman S.J., Brasic J.R., Contoreggi C., Cascella N., Mackowick K.M., Taylor R., Rousset O., Willis W., Huestis M.A., Concheiro M., Wand G., Wong D.F., Volkow N.D. (2014). Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers. *PLoS One* 9, e113694.
- Landesmann, B., Mennecozzi, M., Berggren, E., Whelan, M. (2013). Adverse outcome pathway-based screening strategies for an animal-free safety assessment of chemicals. *ATLA* 41, 461–71.
- Langer T., Hoffmann R.D. (2006). Pharmacophore modelling: applications in drug discovery. *Expert Opin Drug Discov.* 1, 261-7.
- Laruelle M. (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. *J Cereb Blood Flow Metab.* 20, 423-51.

- Lawrence D., Cadman B., Hoffman A.C. (2011). Sensory properties of menthol and smoking topography. *Tob Induc Dis* 9 Suppl. 1, S3.
- Le Foll B., Guranda M., Wilson A.A., Houle S., Rusjan P.M., Wing V.C., Zawertailo L., Busto U., Selby P., Brody A.L., George T.P., Boileau I. (2014). Elevation of dopamine induced by cigarette smoking: novel insights from a [¹¹C]-++-PHNO PET study in humans. *Neuropsychopharmacology* 39, 415-24.
- Lee J.G., Lee C.G., Kwag J.J., Rhee M.S., Buglass A.J., Lee G.H. (2007). Fast analysis of nicotine in tobacco using double-shot pyrolysis--gas chromatography--mass spectrometry. *J Agric Food Chem.* 55, 1097-102.
- Levin E.D., Simon B.B. (1998). Nicotinic acetylcholine involvement in cognitive function in animals. *Psychopharmacology (Berl)*. 138, 217-30.
- Levin R., Jansson S.O., Rudén C. (2004). Indicators of uncertainty in chemical risk assessments. *Regul Toxicol Pharm.* 39, 33-43.
- Lewis A., Miller J.H., Lea R.A. (2007). Monoamine oxidase and tobacco dependence. *Neurotoxicology* 28, 182-95.
- Li X., Shang P., Peng B., Nie C., Zhao L., Liu H., Xie J. (2012). Effects of smoking regimens and test material format on the cytotoxicity of mainstream cigarette smoke. *Food Chem Toxicol.* 50(3-4), 545-51.
- Li X., Peng B., Nie C., Shang P., Liu H. (2013). Evaluation of the cytotoxicity of cigarette smoke total particulate matter using three in vitro assays and two types of cells. *Toxicol Mech Methods.* 23(4), 240-6.
- Li X., Nie C., Shang P., Xie F., Liu H., Xie J. (2014). Evaluation method for the cytotoxicity of cigarette smoke by in vitro whole smoke exposure. *Exp Toxicol Pathol.* 66, 27-33.
- Li X., Lin B., Zhang H., Xie F., Ta N., Tian L., Liu H., Xi Z. (2016). Cytotoxicity and mutagenicity of sidestream cigarette smoke particulate matter of different particle sizes. *Environ Sci Pollut Res Int.* 23(3), 2588-94.
- Lin B., Li X., Zhang H., Lin Z., Tian L., Nie C., Fang Y., Xi Z. (2014). Comparison of in vitro toxicity of mainstream cigarette smoke particulate matter from nano- to micro-size. *Food Chem Toxicol.* 64, 353-60.
- Lin J.C., Roy J.P., Verreault J., Talbot S., Côté F., Couture R., Morin A. (2012). An ex vivo approach to the differential parenchymal responses induced by cigarette whole smoke and its vapor phase. *Toxicology.* 293(1-3), 125-31.
- Ling P.M., Glantz S.A. (2005). Tobacco industry consumer research on socially acceptable cigarettes. *Tobacco Control.* 14(5), e3.
- Lotfipour S., Mandelkern M., Brody A.L. (2011). Quantitative Molecular Imaging of Neuronal Nicotinic Acetylcholine Receptors in the Human Brain with A-85380 Radiotracers. *Curr Med Imaging Rev* 7, 107-12.
- Lou J., Zhou G., Chu G., Jiang J., Huang F., Zheng S., Lu Y., Li X., He, J. (2010). Studying the cyto-genotoxic effects of 12 cigarette smoke condensates on human lymphoblastoid cell line in vitro. *Mutation Research* 696, 48-54.

Lübbert M., Kyereme J., Schöbel N., Beltrán L., Wetzels C.H., Hatt H. (2013). Transient receptor potential channels encode volatile chemicals sensed by rat trigeminal ganglion neurons. *PLoS One* 8, e77998.

Lundström J.N., Boesveldt S., Albrecht J. (2011). Central Processing of the Chemical Senses: an Overview. *ACS chemical neuroscience* 2, 5-16.

Mamede M., Ishizu K., Ueda M., Mukai T., Iida Y., Kawashima H., Fukuyama H., Togashi K., Saji H. (2007). Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. *J Nucl Med.* 48, 1829-35.

Manupallo J.R., Sullivan K.M. (2015). Toxicity assessment of tobacco products in vitro. *ATLA* 43, 39-67.

Mathis C., Poussin C., Weisensee D., Gebel S., Hengstermann A., Sewer A., Belcastro V., Xiang Y., Ansari S., Wagner S., Hoeng J., Peitsch M.C. (2013). Human bronchial epithelial cells exposed in vitro to cigarette smoke at the air-liquid interface resemble bronchial epithelium from human smokers. *American Journal of Physiology: Lung Cellular & Molecular Physiology.* 304, L489-L503.

McAdam K.G., Gregg E.O., Liu C., Dittrich D.J., Duke M.G., Proctor C.J. (2011). The use of a novel tobacco-substitute sheet and smoke dilution to reduce toxicant yields in cigarette smoke. *Food & Chemical Toxicology.* 49, 1684-96.

McKinney D.L., Gogova M., Davies B.D., Ramakrishnan V., Fisher K., Carter W.H., Karnes H.T., Garnett W.R., Iyer S.S., Somani A.A., Kobal G., Barr W.H. (2012). Evaluation of the effect of ammonia on nicotine pharmacokinetics using rapid arterial sampling. *Nicotine Tob Res.* 14, 586-95.

Meek (Bette) M.E., Boobis A.R., Crofton K.M., Heinemeyer G., Van Raaij M., Vickers C. (2011). Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. *Regul Toxicol Pharm.* 60, S1-S14.

Menossi H.S., Goudriaan A.E., de Azevedo-Marques Perico C., Nicastri S., de Andrade A.G., D'Elia G., Li C.S., Castaldelli-Maia J.M. (2013). Neural bases of pharmacological treatment of nicotine dependence - insights from functional brain imaging: a systematic review. *CNS Drugs* 27, 921-41.

Messner, B., Frotschnig, S., Steinacher-Nigisch, A., Winter, B., Eichmair, E., Gebetsberger, J., Schwaiger, S., Ploner, C., Laufer, G. & Bernhard, D. (2012). Apoptosis and necrosis: Two different outcomes of cigarette smoke condensate-induced endothelial cell death. *Cell Death & Disease.* 3, e424.

Mitsui K., David F., Tienpont B., Sandra K., Ochiai N., Tamura H., Sandra P. (2015). Analysis of the reaction products from micro-vial pyrolysis of the mixture glucose/proline and of a tobacco leaf extract: Search for Amadori intermediates. *Journal of chromatography A* 1422, 27-33.

Montgomery A.J., Lingford-Hughes A.R., Egerton A., Nutt D.J., Grasby P.M. (2007). The effect of nicotine on striatal dopamine release in man: A [¹¹C]raclopride PET study. *Synapse* 61, 637-45.

Mukhin A.G., Kimes A.S., Chefer S.I., Matochik J.A., Contoreggi C.S., Horti A.G., Vaupel D.B., Pavlova O., Stein E.A. (2008). Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. *J Nucl Med.* 49, 1628-35.

Nara H., Fukano Y., Nishino T., Aufderheide M. (2013). Detection of the cytotoxicity of water-insoluble fraction of cigarette smoke by direct exposure to cultured cells at an air-liquid interface. *Exp Toxicol Pathol.* 65(5), 683-8.

National Institute for Public Health and the Environment (2012). Tobacco additives; Information for Professionals. <http://www.rivm.nl/dsresource?objectid=rivmp:185755&type=org&disposition=inline>.

Naven R.T., Greene N., Williams R.V. (2012). Latest advances in computational 1 genotoxicity prediction. *Expert Opin Drug Metab Toxicol.* 8, 1579-87.

Nichols J.E., Niles J.A., Vega S.P., Cortiella J. (2013). Novel in vitro respiratory models to study lung development, physiology, pathology and toxicology. *Stem Cell Res Ther.* 4 Suppl 1, S7.

Nichols J.E., Niles J.A., Vega S.P., Argueta L.B., Eastaway A., Cortiella J. (2014). Modelling the lung: Design and development of tissue engineered macro- and micro-physiologic lung models for research use. *Exp Biol Med* (Maywood). 239, 1135-69.

NIEHS (National Institute of Environmental Health Sciences). 2012. Tox21: Transforming Environmental Health. Available: http://www.niehs.nih.gov/health/assets/docs_p_z/tox21_transforming_environmental_health_508.pdf

NIST Standard Reference Database 1A: NIST/EPA/NIH Mass Spectral Library with Search Program. Including a tool for GC/MS deconvolution: AMDIS version 2.72. Data Version: NIST 14. Software Version: 2.2g. The NIST Mass Spectrometry Data Center, National Institute of Standards and Technology. Gaithersburg. Retrieved from <http://www.nist.gov/srd/nist1a.cfm>.

Nonnemaker J., Hersey J., Homsy G., Busey A., Allen J., Vallone D. (2013). Initiation with menthol cigarettes and youth smoking uptake. *Addiction* 108, 171-8.

Noriyasu A., Konishi T., Mochizuki S., Sakurai K., Tanaike Y., Matsuyama K., Uezu K., Kawano T. (2013). Menthol-enhanced cytotoxicity of cigarette smoke demonstrated in two bioassay models. *Tob Induc Dis.* 11(1), 18.

NRC (National Research Council). 2007 Toxicity Testing in the 21st Century: A Vision and A Strategy. Washington, DC: National Academies Press. Available: http://www.nap.edu/openbook.php?record_id=11970.

Nuechterlein E.B., Ni L., Domino E.F., Zubieta J.K. (2016). Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms. *Prog Neuropsychopharmacol Biol Psychiatry* 69, 69-77.

OECD (2013). Guidance Document on Developing and Assessing Adverse Outcome Pathways. OECD Environment, Health and Safety Publications Series on Testing and Assessment. No. 184, ENV/JM/MONO(2013)6.

Okuwa K., Tanaka M., Fukano Y., Nara H., Nishijima Y., Nishino, T. (2010). In vitro micronucleus assay for cigarette smoke using a whole smoke exposure system: A comparison of smoking regimens. *Experimental & Toxicologic Pathology* 62, 433-40.

Oldham M.J., Haussmann H.-J., Gomm W., Rimmer L.T., Morton M.J., McKinney W.J., Jr. (2012). Discriminatory power of standard toxicity assays used to evaluate ingredients added to cigarettes. *Regul Toxicol Pharmacol* 62, 49-61.

O'Leary C., Gilbert J.L., O'Dea S., O'Brien F.J., Cryan S.-A. (2015). Respiratory Tissue Engineering: Current Status and Opportunities for the Future. *Tissue Engineering Part B: Reviews*, 4, 323-44.

O'Leary C., Cavanagh B., Unger R.E., Kirkpatrick C.J., O'Dea S., O'Brien F.J., Cryan S.-A. (2016). The development of a tissue-engineered tracheobronchial epithelial model using a bilayered collagen-hyaluronate scaffold *Biomaterials* 85, 111127.

Park K., Kim D. (2008). Binding similarity network of ligand. *Proteins* 71, 960-71.

Pavlovicz R.E., Henderson B.J., Bonnell A.B., Boyd R.T., McKay D.B., Li C. (2011). Identification of a negative allosteric site on human alpha4beta2 and alpha3beta4 neuronal nicotinic acetylcholine receptors. *PLoS One* 6, e24949.

Pecina, M., Bohnert, A.S., Sikora, M., Avery, E.T., Langenecker, S.A., Mickey, B.J., Zubieta, J.K. (2015). Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression. *JAMA Psychiatry* 72, 1087-1094.

Pennings J., Kienhuis A., Schenk E., van de Nobelen S., Visser W., Talhout R. (2016). Additives in Dutch tobacco products; RIVM letter rapport 2015-0201 (in Dutch). http://www.rivm.nl/Documenten_en_publicaties/Wetenschappelijk/Rapporten/2016/maart/Additieven_in_Nederlandse_tabaksproducten_Trendanalyse_gegevens_2010_2014.

Philip Morris. Citric acid. Tobacco Industry Documents: Philip Morris; Bates Number: 2028670128-0129, 1989. Available from: URL: http://tobaccodocuments.org/product_design/2028670128-0129.html.

Purkis S.W., Mueller C., Intorp M. (2011). The fate of ingredients in and impact on cigarette smoke. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association* 49, 3238-48.

Rabinoff M.D., Caskey N., Rissling A., Park C. (2007). Pharmacological and Chemical Effects of Cigarette Additives. *American Journal of Public Health* 97(11), 1981-91.

Rach J., Budde J., Möhle N., Aufderheide M. (2014). Direct exposure at the air-liquid interface: evaluation of an in vitro approach for simulating inhalation of airborne substances. *J Appl Toxicol.*34(5), 506-15.

Rahnasto M., Raunio H., Poso A., Juvonen R.O. (2003). More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde. *Xenobiotica* 33, 529-39.

Rahnasto M., Wittekindt C., Juvonen R.O., Turpeinen M., Petsalo A., Pelkonen O., Poso A., Stahl G., Holtje H.D., Raunio H. (2008). Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach. *Pharmacogenomics J* 8, 328-38.

Ray R., Ruparel K., Newberg A., Wileyto E.P., Loughhead J.W., Divgi C., Blendy J.A., Logan J., Zubieta J.K., Lerman C. (2011). Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. *Proc Natl Acad Sci U S A* 108, 9268-73.

Reichl F.X., Schwenk M., (Herausgeber) (2004). *Regulatorische Toxikologie*. Springer Verlag, Heidelberg.

Renne R. (1992). 2-week and 13-week inhalation studies of aerosolized glycerol in rats, *Inhal Toxicol* 4, 95-111.

Richter P.A., Li A.P., Polzin G., Roy S.K. (2010). Cytotoxicity of eight cigarette smoke condensates in three test systems: comparisons between assays and condensates. *Regul Toxicol Pharmacol.* 58(3), 428-36.

Rodgman A., Perfetti T.A. (2013). *The Chemical Components of Tobacco and Tobacco Smoke*, Second Edition, 2013 by CRC Press Reference - 2332 Pages - 3091 B/W Illustrations ISBN 9781466515482 - CAT# K15040.

Rooney A.A., Boyles A.L., Wolfe M.S., Bucher J.R., Thayer K.A. (2014). Systematic review and evidence integration for literature-based environmental health science assessments. *Environ. Health Perspect.* <http://dx.doi.org/10.1289/ehp.1307972>.

Rose J.E., Mukhin A.G., Lokitz S.J., Turkington T.G., Herskovic J., Behm F.M., Garg S., Garg P.K. (2010). Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing ¹¹C-nicotine. *Proc Natl Acad Sci U S A* 107, 5190-5.

Rothen-Rutishauser B.M., Kiama S.G., Gehr, P. (2005). A three-dimensional cellular model of the human respiratory tract to study the interaction with particles. *Am J Respir Cell Mol Biol* 32, 28.

Rustemeier K., Stabbert R., Haussmann H.J., Roemer E., Carmines E.L. (2002). Evaluation of the potential effects of ingredients added to cigarettes. Part 2: chemical composition of mainstream smoke. *Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association* 40, 93-104.

Sabri O., Becker G.A., Meyer P.M., Hesse S., Wilke S., Graef S., Patt M., Luthardt J., Wagenknecht G., Hoepping A., Smits R., Franke A., Sattler B., Habermann B., Neuhaus P., Fischer S., Tiepolt S., Deuther-Conrad W., Barthel H., Schonknecht P., Brust P. (2015). First-in-human PET quantification study of cerebral alpha4beta2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine. *Neuroimage* 118, 199-208.

SCENIHR (2010a). Addictiveness and attractiveness of tobacco additives. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_029.pdf. accessed on 10/09/2015.

SCENIHR (2010b). Addictiveness and Attractiveness of Tobacco Additives. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_031.pdf. accessed on.

SCENIHR (2012). Memorandum on the use of the scientific literature for human health risk assessment purposes – weighing of evidence and expression of uncertainty. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_s_001.pdf.

SCHER, SSCS, SCENIHR (2012). Opinion on the Toxicity Assessment of Chemical Mixtures.

http://ec.europa.eu/health/scientific_committees/environmental_risks/docs/scher_o_155.pdf.

Schmeltz I. Schlotzhauer W.S. (1968). Benzo[a]pyrene, phenols and other products from pyrolysis of the cigarette additive, (d,l)-Menthol. *Nature* 219, 370-1.

Scott D.J., Domino E.F., Heitzeg M.M., Koeppe R.A., Ni, L., Guthrie S., Zubieta J.K. (2007). Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. *Neuropsychopharmacology* 32, 450-7.

- Scott D.J., Stohler C.S., Egnatuk C.M., Wang H., Koeppe R.A., Zubieta J.K. (2008). Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. *Arch Gen Psychiatry* 65, 220-31.
- Shelke S.M., Bhosale S.H., Dash R.C., Suryawanshi M.R., Mahadik K.R. (2011). Exploration of new scaffolds as potential MAO-A inhibitors using pharmacophore and 3D-QSAR based in silico screening. *Bioorg Med Chem Lett* 21, 2419-24.
- Small D.M. (2012). Flavor is in the brain. *Physiology & behavior* 107, 540-52.
- Smith, S.S., Fiore, M.C., Baker, T.B. (2014). Smoking cessation in smokers who smoke menthol and non-menthol cigarettes. *Addiction*. 109(12), 2107-17.
- Sokol N.A., Kennedy R.D., Connolly G.N. (2014). The role of cocoa as a cigarette additive: opportunities for product regulation. *Nicotine & tobacco research: official journal of the Society for Research on Nicotine and Tobacco* 16, 984-91.
- Staley J.K., Krishnan-Sarin S., Cosgrove K.P., Krantzler E., Frohlich E., Perry E., Dubin J.A., Estok K., Brenner E., Baldwin R.M., Tamagnan G.D., Seibyl J.P., Jatlow P., Picciotto M.R., London E.D., O'Malley S., van Dyck C.H. (2006). Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. *J Neurosci* 26, 8707-14.
- Stein E.A., Pankiewicz J., Harsch H.H., Cho J.K., Fuller S.A., Hoffmann R.G., Hawkins M., Rao S.M., Bandettini P.A., Bloom A.S. (1998). Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. *Am J Psychiatry* 155, 1009-15.
- Stotesbury S., Digard H., Willoughby L., Couch A. (1999). The pyrolysis of tobacco additives as a means of predicting their behaviour in a burning cigarette. *Beitr Tabakforsch Int* 18, 147-63.
- Sullivan J.M., Kim S.J., Cosgrove K.P., Morris E.D. (2013). Limitations of SRTM, Logan graphical method, and equilibrium analysis for measuring transient dopamine release with [(11)C]raclopride PET. *Am J Nucl Med Mol Imaging* 3, 247-60.
- Takahashi H., Fujimura Y., Hayashi M., Takano H., Kato M., Okubo Y., Kanno I., Ito H., Suhara T. (2008). Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. *Int J Neuropsychopharmacol* 11, 413-7.
- Talhout R., Schulz T., Florek E., van Benthem J., Wester P., Opperhuizen A. (2011). Hazardous Compounds in Tobacco Smoke. *Int J Environ Res Public Health*. 8(2), 613-28.
- Talhout R., Opperhuizen A., van Amsterdam J.G. (2006). Sugars as tobacco ingredient: Effects on mainstream smoke composition. *Food Chem Toxicol* 44, 1789-98.
- Talhout R., Opperhuizen A., van Amsterdam J.G. (2007). Role of acetaldehyde in tobacco smoke addiction. *Eur Neuropsychopharmacol* 17, 627-36.
- Talhout R., van de Nobelen S., Kienhuis A.S. (2016). An inventory of methods suitable to assess additive-induced characterising flavours of tobacco products. *Drug Alcohol Depend* 161, 9-14.
- Tapper A.R., McKinney S.L., Nashmi R., Schwarz J., Deshpande P., Labarca C., Whiteaker P., Marks M.J., Collins A.C., Lester H.A. (2004). Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. *Science* 306, 1029-32.

- Thielen A., Klus H., Lutz Müller L. (2008). Tobacco smoke: Unraveling a controversial subject. *Experimental and Toxicologic Pathology* 60 (2–3), 141–56.
- Thorne D., Adamson J. (2013). A review of in vitro cigarette smoke exposure systems *Experimental and Toxicologic Pathology* 65, 1183 – 93.
- Thorne D., Payne R., Haswell L., Dalrymple A., Meredith C., Dillon, D. (2014). Development of a BALB/c 3T3 Neutral Red Uptake cytotoxicity test using a mainstream cigarette smoke exposure system. *BMC Research Notes* 7, 367.
- Thorne D., Dalrymple A., Dillon D., Duke M., Meredith, C. (2015). A comparative assessment of cigarette smoke aerosols using an in vitro air-liquid interface cytotoxicity test. *Inhal. Toxicol.* 27(12), 629-40.
- Tice R.R., Austin C.P., Kavlock R.J., Bucher J.R. (2013). Improving the human hazard characterization of chemicals: a Tox21 update. *Environ Health Perspect.* 121, 756–65.
- Tomar S.L., Henningfield J.E. (1997). Review of the evidence that pH is a determinant of nicotine dosage from oral use of smokeless tobacco. *Tob Control* 6, 219-25.
- Torikai K., Yoshida S., Takahashi H. (2004). Effects of temperature, atmosphere and pH on the generation of smoke compounds during tobacco pyrolysis. *Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association* 42, 1409-17.
- Torikai K., Uwano Y., Nakamori T., Tarora W., Takahashi H. (2005). Study on tobacco components involved in the pyrolytic generation of selected smoke constituents. *Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association* 43, 559-68.
- U.S. Dept. of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER). (2010). Guidance for Industry Assessment of Abuse Potential of Drugs. <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm198650.pdf>. accessed on 18/12/2015.
- U.S. Dept. of Health and Human Services, F.a.D.A., Center for Drug Evaluation and Research (CDER). (2015). Abuse-Deterrent Opioids — Evaluation and Labeling Guidance for Industry.
- US EPA (2000, 2007): <https://www.epa.gov/risk/guidelines-health-risk-assessment-chemical-mixtures>.
- Usmani O.S., Belvisi M.G., Patel H.J., Crispino N., Birrell M.A., Korbonits M., Korbonits D., Barnes P.J. (2005). Theobromine inhibits sensory nerve activation and cough. *Faseb j* 19, 231-3.
- van Amsterdam J., Sleijffers A., van Spiegel P., Blom R., Witte M., van de Kassteele J., Blokland M., Steerenberg P., Opperhuizen A. (2011). Effect of ammonia in cigarette tobacco on nicotine absorption in human smokers. *Food Chem Toxicol* 49, 3025-30.
- van de Nobelen S., Kienhuis A.S., Talhout R. (2016). An Inventory of Methods for the Assessment of Additive Increased Addictiveness of Tobacco Products. *Nicotine Tob Res.* 1–10.
- Vilar S., Cozza G., Moro S. (2008). Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. *Curr Top Med Chem* 8, 1555-72.

Vilar S., Ferino G., Quezada E., Santana L., Friedman C. (2012). Predicting monoamine oxidase inhibitory activity through ligand-based models. *Curr Top Med Chem* 12, 2258-74.

Villeneuve D.L., Garcia-Reyero N. (2011). Vision & strategy: predictive ecotoxicology in the 21st century. *Environ. Toxicol. Chem.* 30 (1), 1e8.

Volkow N.D., Fowler J.S., Ding Y.S., Wang G.J., Gatley S.J. (1999). Imaging the neurochemistry of nicotine actions: studies with positron emission tomography. *Nicotine Tob Res* 1 Suppl 2, S127-132; discussion S139-140.

Wackowski, O.A., Delnevo, C.D. (2016). Young Adults' Risk Perceptions of Various Tobacco Products Relative to Cigarettes: Results From the National Young Adult Health Survey. *Health Educ. Behav.* 43(3), 328-36.

Wang H., Word B., Lyn-Cook L. Jr, Yang M., Hammons G., Lyn-Cook B. (2015). Cytotoxicity of chronic exposure to 4 cigarette smoke condensates in 2 cell lines. *Int J Toxicol.* 34(2), 182-94.

Wang T., Wang B., Chen H. (2014). Menthol facilitates the intravenous self-administration of nicotine in rats. *Front Behav Neurosci* 8, 437.

Wayne G., Connolly G. (2002). How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983-93. *Tob Control* 11 (Suppl 1), i32-39.

Wayne G.F., Henningfield J.E. (2008). Tobacco product attractiveness as a contributor to tobacco addiction and disease. Report to Health Canada, 1-37.

Wayne G.F., Carpenter, C.M. (2009). Tobacco industry manipulation of nicotine dosing. *Handb Exp Pharmacol*, 457-85.

Weber S., Hebestreit M., Wilms T., Conroy L.L., Rodrigo G. (2013). Comet assay and air-liquid interface exposure system: A new combination to evaluate genotoxic effects of cigarette whole smoke in human lung cell lines. *Toxicology in Vitro* 27, 1987-91.

Weed D.L. (2005). Weight of evidence: a review of concept and methods. *Risk Anal.* 25(6), 1545-57.

Weisensee D., Poth A., Roemer E., Conroy L.L., Schlage W.K. (2013). Cigarette smoke-induced morphological transformation of Bhas 42 cells in vitro. *Altern Lab Anim.* 41(2), 181-9.

WHO (2007). The Scientific Basis of Tobacco Product Regulation. Geneva, Switzerland. pp. 1 -112.

WHO OECD ILSI/HESI (2011). International Workshop on Risk Assessment of Combined Exposures to Multiple Chemicals Workshop Report <http://www.oecd.org/env/ehs/testing/seriesontestingandassessmentworkshopreportsmeetingreports.htm>.

WHO (2012). Partial guidelines for implementation of Articles 9 and 10. http://www.who.int/fctc/guidelines/adopted/article_9and10/en/. Accessed on 06/08/2015

WHO Study Group on Tobacco Product Regulation (2012). Report on the Scientific Basis of Tobacco Product Regulation, WHO Technical Report Series, no. 967. http://www.who.int/tobacco/publications/prod_regulation/trs_967/en/

Wilkinson J.L., Bevins R.A. (2008). Intravenous nicotine conditions a place preference in rats using an unbiased design. *Pharmacol Biochem Behav* 88, 256-64.

Winkler D.A. (2002). The role of quantitative structure--activity relationships (QSAR) in biomolecular discovery. *Brief Bioinform* 3, 73-86.

Wong D.F., Kuwabara H., Kim J., Brasic J.R., Chamroonrat W., Gao Y., Valentine H., Willis W., Mathur A., McCaul M.E., Wand G., Gean E.G., Dannals R.F., Horti A.G. (2013). PET imaging of high-affinity alpha4beta2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics. *J Nucl Med* 54, 1308-14.

Working Group on Tobacco Additives 2014. Report of the Working Group on Tobacco Additives.

http://portal.anvis.gov.br/wps/wcm/connect/5c3e698046be14978161fd2e64280806/Report_Working_Group_Tobacco_Additives_FINAL_26-08-14pdf?MOD=AJPERES.

Wullner U., Gundisch D., Herzog H., Minnerop M., Joe A., Warnecke M., Jessen F., Schutz C., Reinhardt M., Eschner W., Klockgether T., Schmaljohann J. (2008). Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. *Neurosci Lett* 430, 34-7.

Yang G.Y., Zhang C.L., Liu X.C., Qian G., Deng, D.Q. (2013). Effects of cigarette smoke extracts on the growth and senescence of skin fibroblasts in vitro. *International Journal of Biological Sciences* 9, 613-23.

Yao J., Gao Q., Mi Q., Li X., Miao M., Cheng P., Luo Y. (2013). In vitro micronucleus assay for the analysis of total particulate matter in cigarette smoke: comparison of flow cytometry and laser scanning cytometry with microscopy. *Mutat Res.* 755(2), 120-5.

Yararbas G., Keser A., Kanit L., Pogun S. (2010). Nicotine-induced conditioned place preference in rats: sex differences and the role of mGluR5 receptors. *Neuropharmacology* 58, 374-82.

Yauk C.L., Williams A., Buick J.K., Chen G., Maertens R.M., Halappanavar S., White P.A. (2012). Genetic toxicology and toxicogenomic analysis of three cigarette smoke condensates in vitro reveals few differences among full-flavor, blonde, and light products. *Environmental & Molecular Mutagenesis* 53, 281-96.

Zellmer S., Schmidt-Heck W., Godoy P., Weng H., Meyer C., Lehmann T., *et al.* (2010). Transcription factors ETF, E2F, and SP-1 are involved in cytokine-independent proliferation of murine hepatocytes. *Hepatology* 52, 2127-36.

Zenzen V., Diekmann J., Gerstenberg B., Weber S., Wittke S., Schorp, M.K. (2012). Reduced exposure evaluation of an electrically heated cigarette smoking system. Part 2: Smoke chemistry and in vitro toxicological evaluation using smoking regimens reflecting human puffing behavior. *Regul Toxicol Pharm* 64, S11-S34.

Zhang L., Tsai K.C., Du L., Fang H., Li M., Xu W. (2011). How to generate reliable and predictive CoMFA models. *Curr Med Chem* 18, 923-30.

Zhou S., Xu Y., Wang C., Tian Z. (2011). Pyrolysis behavior of pectin under the conditions that simulate cigarette smoking. *Journal of Analytical and Applied Pyrolysis* 91, 232-40.

Zubieta J.K., Bueller J.A., Jackson L.R., Scott D.J., Xu Y., Koeppe R.A., Nichols T.E., Stohler C.S. (2005). Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. *J Neurosci* 25, 7754-62.

Zuo Y., Mukhin A.G., Garg S., Nazih R., Behm F.M., Garg P.K., Rose J.E. (2015). Sex-Specific Effects of Cigarette Mentholation on Brain Nicotine Accumulation and Smoking Behavior. *Neuropsychopharmacology* 40(4), 884-92.

9 Annex I

GUIDANCE AND TEMPLATE

A. GENERAL ISSUES

This brief guidance intends to support the understanding of “what was done”. Authors should take responsibility to be clear of the definitions and provide proper citations for any terms/data they use.

1. TITLE PAGE

The title page should contain the following information:

Identification of the additive

Abstract and keywords, if applicable

Name of sponsor (and bodies that fund or commission the analysis)

Name and affiliation of person or persons responsible for producing and signing off the report

Date and version of report.

2. SUMMARY

The summary is intended to provide a concise description of the key elements.

3. REPORTING SOURCES OF INFORMATION

This section should describe any data source or sources that were used (e.g. existing data and/or databases, *in silico* techniques/models used, experimental studies).

This section addresses the key features of the design.

The rationale for the overall study design should be documented

If needed also ethical approval (approval number – approved by ...- date) for *in vivo* experiments (animals or humans) should be given.

4. REPORTING DATA QUALITY / DATA COLLECTION QUALITY ASSURANCE

This section addresses the reporting of the elements of data collection and pre-processing that could influence data quality.

- How was the literature search conducted and which quality controls were in place and used

- In own experimental studies, were quality controls in place:

In silico

In vitro

In vivo

5. PUBLIC SUMMARY OF THE DOSSIER

The target group of a public summary is the non-professional public. The structure and content of the public summary shall be elaborated accordingly. The document should be less extensive compared to the *summary*. A scientific/professional terminology shall be avoided if possible.

6. CD/DVD

The applicant shall submit a dossier with the full information on standard electronic media such as CD ROMs or DVDs. Two or three CD ROMs or DVDs shall be submitted.

Common electronic formats should be used (e.g. MS Office, Adobe Acrobat Reader) allowing content copying and printing (no content copy protection). The text of the files should be searchable using the search facilities of standard software packages. The CD or DVD shall be structured in folders that reflect the structure of the submission.

Also a full paper copy of the dossier is requested, it has to be declared by the applicant on a separate sheet or in the accompanying letter that the electronic and the paper versions are identical.

7. LIST OF PARTS OF THE DOSSIER REQUESTED TO BE TREATED AS CONFIDENTIAL

Applicants have the right to request a confidential treatment of certain information. They shall indicate which sections and data they wish to be treated as confidential (and give verifiable justification for each part for which a confidential treatment is required).

Furthermore, the applicant shall provide the Commission with two electronic versions of the dossier, namely the complete dossier and a second version of the complete dossier without confidential information.

B. SPECIFIC ISSUES – GENERAL LAYOUT

1. CHEMICAL AND PHYSICAL SPECIFICATIONS OF ADDITIVE

A. Chemical identity

Primary name and/or INCI name

Chemical names

Trade names and abbreviations

CAS / EC number

Structural formula

Empirical formula

B. Physical form

Molecular weight

Purity, composition and substance codes

Impurities / accompanying contaminants

Solubility

Partition coefficient (Log Pow)

Additional physical and chemical specifications

Where relevant:

- organoleptic properties (colour, odour, taste if relevant)

- vapour pressure (include also temperature used for the assessment)

- pKa

- ...

C. Function and use of the additive

2. (Each identified) PYROLYSIS PRODUCTS

Chemical identity

Molecular weight

% formed (at specific temperature)

Solubility

Partition coefficient (Log Pow)

Additional physical and chemical specifications

Where relevant:

- organoleptic properties (colour, odour, taste if relevant)

- vapour pressure (include also temperature used for the assessment)

- density

-- pKa

- ...

3. TOXICOLOGICAL EVALUATION

For each study, regardless of whether it is an own study or data were assessed from literature, a full study report should be given:

- If data is derived from an original (own) study, all original (rough) data should be submitted
- If data is derived from literature, the full paper/report should be submitted.

Next to the full report a study summary should be submitted, including, if applicable, the following (the summary reports should usually only be 1 page long):

Guideline:

GLP/quality control measure:

Test system: (in silico/in vitro/in vivo/human):

N° independent assessments – group size:

Test substance:

Batch:

Purity:

Vehicle:

Dose level:

Route of exposure:

Exposure duration:

Exposure duration & observation period:

Study date/period:

Specific methodological issues:

Brief summary of the results: (summary):

Brief conclusion:

If more studies were reported for one toxicological endpoint, a final conclusion should be formulated, taking into account the data of the different related studies.

Summary: Finally, at the end of the Toxicology section, a brief general conclusion should be formulated.

4. ADDICTIVENESS ASSESSMENT

For each study, regardless of whether it is an own study or data were assessed from literature, a full study report should be given:

- If data is derived from an original (own) study, all original (rough) data should be submitted
- If data is derived from literature, the full paper/report should be submitted.

Next to the full report a study summary should be submitted, including, if applicable, the following (the summary reports should not usually exceed 1 page):

*Guideline:**GLP/quality control measure:**Test system: (in silico/in vitro/in vivo/human):**N° independent assessments – group size:**Test substance:**Batch:**Purity:**Vehicle:**Dose level:**Route of exposure:**Exposure duration:**Exposure duration & observation period:**Study date/period:**Specific methodological issues:**Brief summary of the results: (summary):**Brief conclusion:*

If more studies were reported for one addictiveness endpoint, a final conclusion should be formulated, taking into account the data of the different related studies.

Summary: Finally, at the end of the section addictiveness assessments, a brief general conclusion should be formulated.

5. CHARACTERISING FLAVOUR AND INHALATION FACILITATION PROPERTIES ASSESSMENT

For each study, regardless of whether it is an own study or data were assessed from literature, a full study report should be given:

- If data is derived from an original study, all original (rough) data should be submitted
- If data is derived from literature, the full paper/report should be submitted.

Next to the full report, a study summary should be submitted, including the following (the summary reports should usually only be 1 page in length):

*Guideline:**GLP/quality control measure:*

Test system: (in silico/in vitro/in vivo/human):

N° independent assessments – group size:

Test substance:

Batch:

Purity:

Vehicle:

Dose level:

Route of exposure:

Exposure duration:

Exposure duration & observation period:

Study date/period:

Specific methodological issues:

Brief summary of the results: (summary):

Brief conclusion:

If more studies were reported for one attractiveness endpoint, a final conclusion should be formulated, taking into account the data of the different related studies.

Summary: Finally, at the end of the section attractiveness assessments a brief general conclusion should be formulated.

6. ASSESSMENT OF INTERACTION OF ADDITIVES WITH OTHER ADDITIVES/INGREDIENTS

For each study, regardless of whether it is an own study or data were assessed from literature, a full study report should be given:

- If data is derived from an original study, all original (rough) data should be submitted
- If data is derived from literature, the full paper/report should be submitted.

Next to the full report, a study summary should be submitted, including the following (the summary reports should usually only be 1 page):

Guideline:

GLP/quality control measure:

Test system: (in silico/in vitro/in vivo/human):

N° independent assessments – group size:

Test substance:

Batch:

Purity:

Vehicle:

Dose level:

Route of exposure:

Exposure duration:

Exposure duration & observation period:

Study date/period:

Specific methodological issues:

Brief summary of the results: (summary):

Brief conclusion:

If more studies were reported for one endpoint, a final conclusion should be formulated, taking into account the data of the different related studies.

Summary: Finally, at the end of the section, a brief general conclusion should be formulated on the Interactions with other additives/ingredients.

SUMMARY / OVERALL CONCLUSIONS

In the final section, a summary and an overall conclusion shall be formulated covering all issues discussed above (chemical and physical specifications, use, toxicity, addictiveness, attractiveness and interactions with other ingredients).